Use these links to rapidly review the documentTABLE OF CONTENTS Index to Financial Statements

Table of Contents



UNITED STATES
SECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549



FORM 10-K

(Mark One)ý

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the Fiscal Year Ended December 31, 2010oro

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934Commission File Number: 001-34973


ANACOR PHARMACEUTICALS, INC.(Exact name of registrant as specified in its charter)

Delaware(State or other jurisdiction of
incorporation or organization)

2834(Primary Standard Industrial
Classification Code Number)

25-1854385(I.R.S. Employer
Identification No.)1020 East Meadow Circle
Palo Alto, CA 94303-4230(Address of Principal Executive Offices) (Zip Code)(650) 543-7500(Registrant's Telephone Number, Including Area Code)


Securities
registered pursuant to Section 12(b) of the Act:

Title of Each Class:

Name of Each Exchange on which RegisteredCommon Stock, par value $0.001 per share

The NASDAQ Global Market


Securities
registered pursuant to Section 12(g) of the Act: None

Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities
Act.    Yes o    No ý

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the
Act.    Yes o    No ý

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing requirements for the past
90 days.    Yes ý    No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be
submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and
post such files).    Yes o    No o

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be
contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to
this Form 10-K.    ý

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting
company. See definitions of "large accelerated filer," "accelerated filer," and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer o

Accelerated filer o

Non-accelerated filer ý (Do not check if a
smaller reporting company)

Smaller reporting company o


Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the
Act).    Yes o    No ý

The registrant's common stock was not publicly traded as of the last business day of the registrant's most recently completed second fiscal quarter. The number of
outstanding shares of the registrant's common stock on February 28, 2011 was 27,996,928.

DOCUMENTS INCORPORATED BY REFERENCE

Part III
incorporates information by reference to the definitive proxy statement for the Company's Annual Meeting of Stockholders to be held on or about May 26, 2011, to be
filed within 120 days of the registrant's fiscal year ended December 31, 2010.



---





Table of Contents



TABLE OF CONTENTS

Anacor Pharmaceuticals, Inc.
Form 10-K
Index



PagePart IItem 1.

Business

1Item 1A.

Risk Factors

32Item 1B.

Unresolved Staff Comments

58Item 2.

Properties

58Item 3.

Legal Proceedings

58Item 4.

Reserved

58Part IIItem 5.

Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

59Item 6.

Selected Financial Data

62Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

63Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

77Item 8.

Financial Statements and Supplementary Data

78Item 9.

Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

114Item 9A.

Controls and Procedures

114Item 9B.

Other Information

114Part IIIItem 10.

Directors, Executive Officers and Corporate Governance

115Item 11.

Executive Compensation

115Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

115Item 13.

Certain Relationships and Related Transactions, and Director Independence

115Item 14.

Principal Accountant Fees and Services

115Part IVItem 15.

Exhibits and Financial Statement Schedules

116Signatures

117Exhibit Index

119


i

---





Table of Contents

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This report contains forward-looking statements, including statements regarding the progress and timing of clinical trials, the safety
and efficacy of our product candidates, actions to be taken by our partner, GlaxoSmithKline LLC, or GSK, our ability to enter into and maintain additional collaborations, our ability to scale
and support commercial activities, the goals of our research and development activities, estimates of the potential markets for our product candidates, availability of drug product, our expected
future revenues, operations and expenditures and projected cash needs. The forward-looking statements are contained principally in the sections entitled "Business," "Risk Factors" and "Management's
Discussion and Analysis of Financial Condition and Results of Operations." These statements relate to future events or our future financial performance and involve known and unknown risks,
uncertainties and other factors that could cause our actual results, levels of activity, performance or achievement to differ materially from those expressed or implied by these forward-looking
statements.

Forward-looking
statements include all statements that are not historical facts. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should,"
"could," "would," "expects," "plans," "anticipates," "believes," "estimates," "projects," "predicts," "potential," or the negative of those terms, and similar expressions and comparable terminology
intended to identify forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given
these uncertainties, you should not place undue reliance on these forward-looking statements. These forward-looking statements represent our estimates and assumptions only as of the date of this
Annual Report on Form 10-K and, except as required by law, we undertake no obligation to update or
revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this Annual Report on Form 10-K.

---





Table of Contents

PART I

ITEM 1.    BUSINESS

Overview

We are a biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapeutics derived
from our boron chemistry platform. We have demonstrated that our organization, utilizing our boron chemistry platform, is highly productive and efficient at creating novel clinical product candidates.
We have discovered, synthesized and developed five molecules that are currently in clinical development, and we believe that our organization and boron chemistry platform have the potential to
continue to yield clinical candidates at a similar pace and efficiency in the future. While drug development is often uncertain and occasionally uneven, our current portfolio of product candidates and
our ability to efficiently fill our own pipeline provide us with a unique opportunity to create a valuable and sustainable biopharmaceutical company.

We
believe that our expertise in boron chemistry enables us to identify compounds that interact with known drug targets in novel ways and also inhibit drug targets that have been
historically difficult to inhibit with traditional chemistry. We have applied this expertise across a range of fungal, inflammatory, bacterial and parasitic diseases that represent significant unmet
medical needs. We have discovered and advanced into clinical development multiple differentiated product candidates that we believe have significant disease-modifying potential and attractive
pharmaceutical properties. We believe that our product candidates may offer significant improvements over the standard of care for diseases that represent large, well-defined commercial
opportunities.

The
productivity of our internal discovery capability has enabled us to generate a pipeline of both topical and systemic boron-based compounds. We currently have five product candidates
in clinical development. Our three lead product candidates include two topically administered dermatologic compoundsAN2690, an antifungal for the treatment of onychomycosis, and AN2728,
an anti-inflammatory for the treatment of psoriasis and atopic dermatitis, as well as a systemic antibiotic for the treatment of infections caused by Gram-negative
bacteriaGSK2251052, or GSK '052 (formerly referred to as AN3365). In addition, we are developing AN2718 as a topical antifungal product candidate for the treatment of onychomycosis
and skin fungal infections and AN2898 as a topical anti-inflammatory product candidate for the treatment of psoriasis and atopic dermatitis.

We
have entered into and are seeking partnerships to expand the therapeutic application and commercial value of our boron chemistry platform. In October 2007, we entered into a research
and development collaboration, option and license agreement with GlaxoSmithKline LLC, or GSK, for the discovery, development and worldwide commercialization of boron-based systemic
anti-infectives. In July 2010, GSK exercised its option to license GSK '052, and we are actively conducting research to discover additional systemic anti-infectives with
GSK. In August 2010, we entered into a collaboration with Eli Lilly and Company, or Lilly, under which we are collaborating to discover products for a variety of animal health applications. In
February 2011, we entered into a research and development option and license agreement with Medicis Pharmaceutical Corporation, or Medicis, to discover and develop compounds directed against a target
for the potential treatment of acne. In addition, we are applying our boron chemistry platform to the development of treatments for various neglected diseases in collaboration with leading
not-for-profit organizations, including the Drugs for Neglected Diseases initiative, Medicines for Malaria Ventures, Sandler Center for Basic Research in Parasitic Diseases and
the Institute for OneWorld Health.

1

---



Table of Contents



The following table summarizes the current status and the anticipated next steps in the development plans for our clinical-stage
product candidates:

CHART

AN2690
is our lead topical antifungal product candidate for the treatment of onychomycosis, a fungal infection of the nail and nail bed. Onychomycosis affects approximately
35 million people in the United States, and new prescriptions to treat this disease continue to grow. Lamisil (terbinafine), a systemic drug approved for onychomycosis, had worldwide peak sales
of $1.2 billion in 2004, before generic entry. According to IMS Health, for the 12-month period ending June 30, 2010, 1.4 million new prescriptions were filled in the
United States for both branded and generic versions of terbinafine. Despite its high labeled efficacy (38%), we believe the usage of branded and generic terbinafine has been limited due to safety
concerns related to liver toxicity. The leading topical drug for onychomycosis, Penlac Nail Lacquer (ciclopirox), had U.S. sales of $125.0 million in 2002, before generic entry. According to
IMS Health, for the 12-month period ending June 30, 2010, over 350,000 new prescriptions were filled in the United States for branded or generic ciclopirox. While ciclopirox has
been shown to be safe due in part to its topical administration, we believe the usage of branded and generic ciclopirox has been limited due to its low labeled efficacy (5.5%-8.5%).

We
believe AN2690 can potentially offer significant improvements over the standards of care for onychomycosis by combining the safety of a topical drug with significant efficacy. Due to
its unique boron chemistry, AN2690 has demonstrated enhanced nail penetration properties, a novel mechanism

2

---



Table of Contents

of
action with potent antifungal activity and, due in part to its topical administration, no observed systemic side effects in human dosing. AN2690 inhibits an essential fungal enzyme, leucyl-transfer
RNA synthetase, or LeuRS, required for protein synthesis. The inhibition of protein synthesis leads to termination of cell growth and cell death, eliminating the fungal infection. We reported positive
results from three Phase 2 clinical trials and held an end-of-Phase 2 meeting with the United States Food and Drug Administration, or FDA. In August 2010, we
filed a Special Protocol Assessment, or SPA, request with the FDA in order to reach agreement on key endpoint measures and trial design to be used in our first of two identical planned Phase 3
clinical trials of AN2690. We have received the FDA's agreement on what we believe are the major parameters associated with the design and conduct of our first Phase 3 trial for AN2690. We
initiated the Phase 3 clinical trial in onychomycosis in the fourth quarter of 2010. We are currently enrolling patients at clinical sites in the United States and also plan to enroll patients
at clinical sites in Canada and Mexico in 2011.

AN2728
is our lead topical anti-inflammatory product candidate for the treatment of psoriasis, a chronic inflammatory skin disease that affects approximately
7.5 million people in the United States and over 100 million people worldwide. Approximately 80% of psoriasis patients have mild-to-moderate disease, which is
mainly treated with topical corticosteroids and vitamin D analogs. However, topical corticosteroids and vitamin D analogs are limited in their use by patients due to their
long-term safety and/or their tolerability profile. In spite of these limitations, according to IMS Health, approximately 3.9 million prescriptions were filled for these topical
therapies to treat psoriasis in the United States in 2009.

We
believe that AN2728 has the potential to be an effective psoriasis treatment with an attractive safety profile in a topical application, and thus provide an alternative to treatment
with topical corticosteroids and vitamin D analogs. Due to its boron-based structure, AN2728 binds with the active site of the enzyme phosphodiesterase-4 (PDE4) in a novel manner,
thus inhibiting its activity. This mechanism subsequently reduces the production of TNF-alpha, IL-12, IL-23 and other pro-inflammatory cytokines that
are precursors of the inflammation associated with psoriasis. In June 2010, we successfully completed a Phase 2b dose-ranging trial to evaluate the safety and efficacy of AN2728. We
have initiated a final Phase 2b trial for AN2728 in psoriasis that matches the anticipated design of our planned Phase 3 trials in which patients will be randomized to receive either
AN2728 or vehicle. Following the completion of this Phase 2b trial, we plan to initiate a Phase 3 trial in the second half of 2011. We are also exploring the activity of AN2728 for the
treatment of atopic dermatitis, and plan to initiate a Phase 2 trial in this indication in the first half of 2011. This Phase 2 clinical trial will be designed as a two-arm
trial evaluating the efficacy and safety of AN2728 and AN2898 compared to vehicle.

GSK '052
is our lead systemic antibiotic for the treatment of infections caused by Gram-negative bacteria. Gram-negative bacterial infections are
increasing in prevalence, especially in hospitals, and represent a serious public health challenge due to their growing resistance to currently available drug therapies. According to the New England Journal of
Medicine, it is estimated that there were 1.7 million hospital-acquired Gram-negative and
Gram-positive infections and approximately 100,000 associated deaths in the United States alone in 2002. TheNew England Journal of Medicinealso indicates that Gram-negative bacteria are responsible for more than 30.0% of hospital-acquired infections and account for approximately 70.0% of hospital-acquired infections in the
intensive care unit. IMS Health estimates there were 40 million days of Gram-negative therapy administered in the United States in 2009. Gram-negative bacterial
infections are becoming a major global health issue where their growing resistance to currently available drug therapies is rapidly increasing. Furthermore, recently approved Gram-negative
antibiotics have been limited to new versions of existing antibiotics, which carry the risk of rapid resistance development from pre-existing mechanisms of resistance. Preclinical studies
suggest that GSK '052 could be a novel approach for the treatment of infections caused by a broad range of

3

---



Table of Contents

Gram-negative
bacteria, includingE. coli,Klebsiella pneumoniae, Citrobacter spp.,S. marcescens, P. vulgaris,Providentia spp.,Pseudomonas
aeruginosaandEnterobacter spp.

Due
to its unique boron-based chemical structure, GSK '052 specifically targets the bacterial enzyme leucyl-transfer RNA synthetase, or LeuRS, which is required for protein
synthesis. The inhibition of protein synthesis leads to termination of cell growth and cell death, eliminating the bacterial infection. Since GSK '052 is the first antibiotic to target LeuRS,
bacteria have not developed resistance to it. In preclinical safety, pharmacology and toxicology studies, GSK '052 showed robust activity against multi-resistant Gram-negative
bacteria with no cross resistance to existing classes of antibiotics. In a Phase 1 proof-of-concept trial, GSK '052 demonstrated a promising safety profile and
linear dose-proportional pharmacokinetic properties, reaching blood levels that were many times higher than the anticipated efficacious dose. If approved, we believe GSK '052 would
be the first new class of antibacterial agents to treat serious hospital-acquired Gram-negative infections in thirty years. In addition, we believe GSK '052 has the potential to be
the first antibiotic specifically targeting infections caused by Gram-negative bacteria that can be administered by both IV and oral routes, which would allow patients to continue on the
same antibiotic therapy they received in the hospital once they are discharged.

Following
the completion of the Phase 1 trial, GSK exercised its option to obtain an exclusive license to develop and commercialize GSK '052 and has assumed responsibility
for further development of the product candidate and any resulting commercialization. Following the exercise of the option in July 2010, we received a fee of $15.0 million. We are eligible to
receive further development milestones up to $69.0 million, commercial milestones up to $175.0 million and double-digit tiered royalties with the potential to reach the
mid-teens on annual net sales. We believe GSK currently plans to develop GSK '052 as a potential treatment for complicated urinary tract infections, or cUTI, complicated
intra-abdominal infections, or cIAI, and other Gram-negative bacterial infections, such as hospital-acquired and ventilator-associated pneumonia, or HAP/VAP. We anticipate that GSK will
initiate Phase 2 trials of GSK '052 in patients with cUTI and cIAI in 2011.

Our
clinical pipeline also includes two additional product candidates that may extend and expand the market opportunity of our dermatology portfolio. AN2718, our second topical
antifungal product candidate, has the potential to treat onychomycosis and fungal infections of the skin. We expect to initiate a Phase 2 trial of AN2718 in onychomycosis after we have
completed Phase 3 trials with AN2690. AN2898, our second topical anti-inflammatory product candidate, has the potential to treat psoriasis and atopic dermatitis. We expect to
initiate a two-arm Phase 2 trial with AN2898 and AN2728 compared to vehicle in atopic dermatitis in the first half of 2011.

Boron Chemistry Platform

All of our current research and development programs, including our five clinical product candidates, are based on compounds that have
been internally discovered using our boron chemistry platform. Boron is a naturally occurring element that is ingested frequently through consumption of fruits, vegetables, milk and coffee. Boron has
two attributes that we believe confer compounds with drug-like properties. First, boron-based compounds have a unique geometry that allows them to have two distinct shapes, giving
boron-based drugs the ability to interact with biological targets in novel ways and to address targets not amenable to intervention by traditional carbon-based compounds. Second, boron's enhanced
reactivity as compared to carbon allows us to design molecules that can hit targets that are difficult to inhibit with carbon chemistry.

Despite
the ubiquity of boron in the environment, researchers have faced challenges in evaluating boron-based compounds as product candidates due to previously limited understanding of
the physical properties necessary to provide boron-based compounds with the chemical and biological attributes required of pharmaceutical therapies as well as difficulty in chemical synthesis.

4

---



Table of Contents

We
have developed expertise and an understanding of the interactions of boron-based compounds with key biological targets relevant to treating disease. This know-how is
primarily related to methods for modulating boron's reactivity to optimize reactions with the target and minimize unwanted chemical reactivity. Our advances have enabled the efficient optimization of
disease-modifying properties for our lead compounds and their rapid progression from the research stage into clinical trials.

Additionally,
we have discovered new methods of synthesis of boron compounds, allowing for the creation of new compound families with broad chemical diversity and retention of
drug-like properties. These new compound families expand the universe of biological targets that can be addressed by small-molecule, boron-based compounds. We have been in operation since
2002 and began generating clinical candidates in our second year. Since that time, we have discovered and synthesized thousands of boron-containing molecules, and of these, five are currently in
clinical development. The rate of discovery of molecules and promotion to clinical development has occurred at a relatively constant rate.

We
believe our focus on boron-based chemistry provides us with multiple advantages in the small-molecule drug discovery process. These advantages include:



Our Strategy

Our objective is to discover, develop and commercialize proprietary boron-based drug compounds with superior efficacy, safety and
convenience for the treatment of a variety of diseases. The key elements of our strategy to achieve this objective are to:



5

---



Table of Contents



Our Product Candidates

Our Topical Antifungal Programs



Our most advanced product candidate is AN2690, a topical treatment for onychomycosis, which is a fungal infection of the nail and nail
bed. We reported positive results from three Phase 2 clinical trials, have completed an end-of-Phase 2 meeting with the FDA, and filed a Special Protocol
Assessment request with the FDA in order to reach agreement on key endpoint measures and trial design to be used in our planned Phase 3 clinical trials of AN2690 in onychomycosis. We initiated
Phase 3 trials in the fourth quarter of 2010, at clinical sites in the United States and are enrolling at clinical sites in Canada and Mexico in 2011.



Onychomycosis is primarily caused by dermatophytes, which are fungi that infect the skin, hair or nails. The infection involves the
nail plate, the nail bed and, in some cases, the skin surrounding the nail plate. Onychomycosis causes nails to deform, discolor, thicken, become brittle and split and separate from the nail bed.
Toenails affected by onychomycosis can become so thick that routine trimming of the nails becomes difficult. The condition can also cause pain when individuals wear shoes, leading to difficulties
walking. Onychomycosis can also lead to social embarrassment due to the unsightly appearance of the infected nails and because it may be perceived to be an active infection and contagious.

According
toPodiatry Today, 35 to 36 million people in the United States have onychomycosis. Over 95% of onychomycosis infections
are infections of the toenail, according to a report inU.S. Dermatology Review. According to the manufacturer of Lamisil, 47% of those affected by
onychomycosis are not receiving treatment. For those who do seek treatment, options include debridement, oral or topical drugs or a combination of debridement and drug therapies. Debridement consists
of scraping, cutting away or removal of the affected nail. Onychomycosis may persist or worsen if not treated. Onychomycosis often recurs in susceptible individuals because the fungi that cause
onychomycosis are present in many common locations such as floors, the soil, socks and shoes. Consequently, the nail can

6

---



Table of Contents

be
reinfected, and additional courses of treatment are frequently required even after successful treatment.

Lamisil
(terbinafine), a systemic drug approved for onychomycosis, had worldwide peak sales of $1.2 billion in 2004, before generic entry. According to IMS Health, for the
12-month period ending June 30, 2010, 1.4 million new prescriptions were filled in the United States for both branded and generic versions of terbinafine. Despite its high
labeled efficacy (38%), we believe the usage of branded and generic terbinafine has been limited due to safety concerns related to liver toxicity. Penlac Nail Lacquer (ciclopirox), the only U.S.
approved topical agent for onychomycosis, had U.S. sales of $125.0 million in 2002, before generic entry. According to IMS Health, for the 12-month period ending June 30,
2010, over 350,000 new prescriptions were filled in the United States for branded or generic ciclopirox. While ciclopirox has been shown to be safe due in part to its topical administration, we
believe the usage of branded and generic ciclopirox has been limited due to its low labeled efficacy (5.5%-8.5%).



Current therapies for onychomycosis include debridement and drug therapies. Debridement is time consuming and only marginally effective
in eliminating the fungal infection. Drug therapies are available in two types, either oral therapies such as Lamisil, or topical therapies such as Penlac. According to the Lamisil product label, 38%
of patients treated in clinical trials with a 12-week course of therapy achieved 100% clear nail and mycological cure. However, Lamisil has been associated with rare cases of liver
failure, some leading to death or liver transplant. We believe this risk of liver failure limits acceptance of this therapy by both physicians and patients. Patients are recommended to undergo liver
function tests prior to initiating Lamisil treatment and those patients with pre-existing liver disease cannot be treated with it.

Penlac
is approved for use in onychomycosis in conjunction with frequent debridement. In the two clinical trials cited on Penlac's product label, even with frequent debridement, only
5.5% and 8.5% of patients treated with Penlac achieved 100% clear nail and mycological cure, respectively. We believe that a significant barrier to effective treatment by current topical therapies is
the difficulty of formulating the drug product to penetrate through the nail plate and reach the site of infection.



By addressing the limitations of current therapies, we believe AN2690 has a potential safety and efficacy profile that can make it a
best-in-class therapy for the treatment of onychomycosis. We have completed three Phase 2 clinical trials in which AN2690 had no observed systemic side effects. We
believe that the clinical data that we have generated to date demonstrates the potential advantages of AN2690 relative to Lamisil and Penlac.

We
have designed AN2690, our topical antifungal, with three distinguishing characteristics:



7

---



Table of Contents



We
have completed three Phase 2 clinical trials which demonstrated that AN2690 is efficacious as defined by the percentage of patients achieving clear nail growth and negative
fungal culture. We believe that these data have demonstrated that AN2690's efficacy should be in a range that is at least twice that of Penlac and may approach that of Lamisil. In addition, in our
Phase 1 and Phase 2 clinical trials, we have shown that AN2690 achieves significant nail penetration, results in little or no systemic exposure and is well-tolerated across a
range of doses.



In the fourth quarter of 2010, we initiated Phase 3 clinical trials for AN2690 in onychomycosis in the United States. The AN2690
Phase 3 program consists of two double-blind, vehicle-controlled trials enrolling approximately 600 patients each. Vehicle refers to the formulation without the active ingredient.
Two-thirds of the patients are randomized to receive AN2690 at the 5.0% concentration, or dose, compared to one-third who receive vehicle once daily for 48 weeks. The
primary efficacy endpoint is a composite endpoint measuring complete cure of the great toenail at week 52, which is consistent with the FDA requirement for Lamisil. Complete cure requires both
a mycologic cure and a completely clear nail. Mycologic cure is achieved when the fungus present in the nail plate is killed by treatment. Achieving a clear nail
requires a complete elimination of the diseased portion of the nail by replacement with a new healthy growing nail and nail bed. Given the slow rate of nail growth, which is approximately one to two
millimeters per month, the industry standard for conducting Phase 3 clinical trials of onychomycosis is to evaluate the nails over a 12-month period, in order to allow sufficient
time for patients to grow a new nail. An end-of-Phase 2 meeting with the FDA was completed, and in August 2010 we filed an SPA request with the FDA in order to reach
agreement on key endpoint measures and trial design to be used in our planned Phase 3 trials of AN2690 in onychomycosis. We have received the FDA's agreement on what we believe are the major
parameters associated with the design and conduct of our Phase 3 trials for AN2690. We initiated Phase 3 trials in the fourth quarter of 2010 at clinical sites in the United States, and
we also plan to enroll patients at clinical sites in Canada and Mexico in 2011. Guidance meetings have also been completed with the European Medicines Agency and regulatory authorities in Japan. Based
upon these discussions, we anticipate that our Phase 3 development program will help support approval in these regions, although an additional comparator trial will likely be required in these
regions.



Our Phase 2 clinical trials of AN2690 have enabled us to define multiple well-tolerated, efficacious doses and a
dose-response relationship. We have also demonstrated that topical application to the toenails has led to little or no detectable systemic drug exposure in blood or urine. Results from
these trials support the selection of the 5.0% dose of AN2690 for the Phase 3 clinical trials and have enabled appropriate statistical calculations for the design of those trials.

8

---



Table of Contents

The following chart summarizes our Phase 2 clinical trials:

Study Number

Type

Dosing

Patients

Trial Objectives

Completed200/200a

Double-blind

Vehicle; 2.5%; 5.0%; 7.5%

187

Evaluate safety and efficacy compared to vehicle

August 2007201
(first and second cohorts)

Open-label

5.0%; 7.5%

60

Evaluate safety and efficacy

February 2007201
(third cohort)

Open-label

5.0%

29

Evaluate safety and efficacy of longer treatment period

July 2008203

Open-label

1.0%; 5.0%

60

Evaluate efficacy of lower doses and less frequent dosing

August 2007


In our Phase 2 clinical trials, we enrolled onychomycosis patients representative of a wide clinical spectrum of the disease. We believe
that the results of these trials indicate that AN2690 may effectively treat patients who are representative of the population that would seek treatment for onychomycosis and collectively support
Phase 3 clinical trial initiation.



The primary objectives of Study 200/200a were to demonstrate that the efficacy of AN2690 could be differentiated from vehicle, and to
select the appropriate dose of AN2690 for Phase 3 clinical trials. A total of 187 patients were enrolled at multiple sites in Mexico and the United States. Enrolled patients were randomly
assigned to be dosed with the vehicle or one of the following concentrations of AN2690 solution: 2.5%, 5.0% or 7.5%. The double-blind nature of the trial ensured that neither the patients nor the
investigators were aware of which of the four treatment options was being applied. Patients dosed themselves daily for the first three months and three times per week for the remaining three months of
the six-month treatment period. After an additional six months of follow-up, complete and partial responders were identified and post-treatment effects were
assessed.

The
study's primary endpoint was the number of patients with at least two millimeters of clear nail growth and negative fungal culture at the end of the six-month treatment
period. At this time point, 27% of patients receiving the 2.5% dose, 26% of patients receiving the 5.0% dose and 32% of patients receiving the 7.5% dose were observed to achieve the trial's primary
endpoint, compared to 14% of patients receiving the vehicle. Overall, significantly more patients treated with AN2690 achieved the primary endpoint, compared with the vehicle (P-value of
0.03). Of 187 enrolled patients, four subjects experienced five episodes of skin irritation, and four of these episodes were observed in patients receiving AN2690 at the highest dose level. Based upon
these results, we believe the 5% dose will offer patients the best combination of efficacy and tolerability and therefore, we selected this dose for advancement into our Phase 3 clinical
trials.



The objective of Study 201 was to determine the safety and efficacy of 5.0% and 7.5% topical solutions of AN2690 in treating
onychomycosis. A total of 60 patients were
enrolled at multiple sites in Mexico in the first two cohorts. Half received a 5.0% daily dose and the other half received a 7.5% daily dose for a period of six months, with a subset of patients
receiving an additional six months of follow-up assessment. The trial was open-label, such that both investigators and the patients knew which dose was being administered. The
study's primary endpoint was the number of patients with at least two millimeters of clear nail growth at six months and a negative fungal culture. At the end of the six-month treatment
period, 43% of patients receiving the 5.0% dose and 53% of patients receiving the 7.5% dose were observed to have achieved the trial's primary endpoint.

9

---



Table of Contents

The
primary objective of the third cohort of Study 201 was to evaluate the safety of a longer treatment period of AN2690 in onychomycosis. In this open-label trial, patients
received a 5.0% dose once daily for up to 360 days. A total of 29 patients were enrolled in this cohort, which indicated that 5.0% AN2690 solution applied daily for 360 days was
well-tolerated by most subjects. At the end of the 12-month period, tolerability was shown to be similar to what was previously seen with 24 weeks of treatment. In
addition, 14% and 24% of the patients treated in the third cohort reached the endpoint of at least two millimeters of clear nail growth and negative fungal culture at six months and twelve months,
respectively. Seven percent of the third cohort patients demonstrated a completely clear nail and negative fungal culture after twelve months of dosing. The percentage of patients reaching the primary
endpoint at six months in the third cohort was significantly lower than the percentage of patients reaching the primary endpoint in the first and second cohorts.



The objective of Study 203 was to determine safety and efficacy of lower dosing and less frequent dosing of AN2690 in treating
onychomycosis. Two groups of 30 patients were enrolled at multiple sites in the United States. Half applied a 1.0% daily dose for six months and the other half applied a 5.0% daily dose for the first
month, then three times per week for the remaining five months of treatment. A subset of each treatment group was followed for an additional six months after the end of treatment. The study's primary
endpoint was the number of patients with at least two millimeters of clear nail growth at six months and a negative fungal culture. At the end of the six-month treatment period, 30% of
patients receiving the 1.0% dose and 50% of patients receiving the 5.0% dose achieved the primary endpoint.



We believe we have completed all of the preclinical toxicology studies required for marketing approval, including a chronic
(nine-month) dermal minipig study, two-year mouse and rat carcinogenicity studies and definitive characterization of ADME (absorption, distribution, metabolism, and excretion)
in animals.



In February 2007, we entered into an exclusive license, development and commercialization agreement with Schering-Plough Corporation,
or Schering, for the development and worldwide commercialization of AN2690. Under the agreement, Schering paid us a $40.0 million upfront fee and $9.5 million for our development-related
transition activities and assumed sole responsibility for development and commercialization of AN2690. In addition, Schering invested $10.0 million in a preferred stock financing completed in
December 2008. In October 2009, the end-of-Phase 2 meeting with the FDA was completed. In November 2009, Schering merged with Merck & Co., Inc., or
Merck, and in May 2010, pursuant to a mutual termination and release agreement, we regained the exclusive worldwide rights to AN2690. Merck did not retain any rights to this compound. Since regaining
rights to AN2690 in May 2010, Merck has transferred back to us all materials and documents relating to AN2690 and has paid us $5.8 million.



AN2718 is our second topical antifungal in clinical development for onychomycosis and fungal infections of the skin and utilizes the
same mechanism as AN2690. AN2718 appears to be well-suited to target organisms that cause common skin and topical fungal infections, including TrichophytonandCandidafungi. Based on preclinical studies and in comparison to AN2690, we believe
that AN2718 has greater potency against the dermatophytesT. mentagrophytesandT. rubrumand results in
similar nail

10

---



Table of Contents

penetration.
These studies suggest that, like AN2690, AN2718 also has significantly greater nail penetration than Penlac.

Our
Phase 1 data for AN2718 has also indicated that AN2718 has a low skin irritation profile across multiple doses and that it would thus be suitable for the treatment of skin
fungal infection. This Phase 1 data, which we announced in March 2009, was from a 21-day skin irritation trial. In the trial, we compared AN2718 gel at 1.5%, 2.5%, 5.0% and 7.5%,
and AN2718 cream at 0.3% and 1.0% to their respective vehicles. All doses of AN2718 gel, cream and vehicle were applied to the skin of normal volunteers for 21 days using
semi-occlusive, or semi-air and water-tight, adhesive patches. Application sites were then evaluated daily for signs of irritation. The irritation indices for all AN2718 doses
were very low and comparable to vehicle. We currently intend to initiate a Phase 2 trial of AN2718 for onychomycosis following the completion of Phase 3 trials of AN2690.

Our Topical Anti-Inflammatory Programs



AN2728 is our lead topical anti-inflammatory product candidate for the treatment of psoriasis and atopic dermatitis,
chronic inflammatory diseases that affect millions of people worldwide. We have achieved positive results from three Phase 1b, one Phase 2a, one Phase 2 and one Phase 2b
clinical trials. In February 2011, we initiated a final Phase 2b trial to evaluate the safety and efficacy of AN2728 in patients with mild-to-moderate psoriasis. We
anticipate that the design of this trial will be similar to that of our planned Phase 3 trials in which patients will be randomized to receive either AN2728 or vehicle. The objective of this
Phase 2b trial is to demonstrate efficacy in a patient-to-patient trial design using the anticipated FDA-required endpoints and to inform the design and
powering of our planned two Phase 3 trials for AN2728. Following the completion of this Phase 2b trial, we plan to have an end-of-Phase 2 meeting with the
FDA and subsequently advance AN2728 into Phase 3 development in the second half of 2011.

In
addition, in the first half of 2011, we expect to initiate a Phase 2 trial of AN2898 outside of the United States in patients with atopic dermatitis, which will be designed as
a two-arm trial evaluating the efficacy and safety of AN2898 and AN2728 compared to vehicle. Prior to initiation of clinical trials of AN2898 in the United States, we will file an
investigational new drug application, or IND, with the FDA for AN2898 for psoriasis and/or atopic dermatitis.



Psoriasis is a chronic inflammatory skin disease that affects approximately 7.5 million people in the U.S and over
100 million people worldwide. Patients can be categorized as mild, moderate or severe, with approximately 80% of patients having mild to moderate forms of the disease. Psoriasis is
characterized by thickened patches of inflamed, red skin covered with thick, silvery scales typically found at the elbows, knees, scalp and genital area. The disorder ranges from a single, small,
localized lesion in some patients to a severe generalized eruption. Patients with mild-to-moderate psoriasis are typically treated with a combination of topical therapies,
while patients with moderate-to-severe psoriasis are typically treated with a combination of topical and systemic therapies. The recent introductions of new systemic biologic
therapies have provided new treatment options for patients with moderate to severe disease and have greatly expanded amounts spent on drugs to treat psoriasis. According to LeadDiscovery, sales of
psoriasis drugs in the seven major pharmaceutical markets (United States, Japan, France, Germany, Italy, Spain and the United Kingdom) were $2.5 billion in 2008. In 2009, over
4.5 million prescriptions were written for patients with psoriasis in the United States, with approximately 3.9 million of these prescriptions written for topical therapies.

11

---



Table of Contents



Most psoriasis patients use more than one type of treatment at any given time and may rotate treatments over time as their disease
severity changes or they develop complications. Although current treatments attempt to decrease the severity of the disease, none of them cures the disease. Currently available treatments can be
classified as topical, oral, injectable or phototherapy. According to IMS Health, 84% of all prescriptions for psoriasis within the United States in 2009 were for topical treatments. The most common
topical treatments are corticosteroids, vitamin D derivatives, such as Dovonex (calcipotriene), topical retinoids, such as Tazorac (tazarotene), and crude coal tar preparations. Taclonex is
also a treatment for psoriasis and is a combination of calcipotriene and the high potency corticosteroid betamethasone dipropionate. The most common oral treatments are the immunosuppressive drug
methotrexate and the oral retinoid acetretin. A number of injectable biologic drugs in the market include Amevive, Enbrel, Humira, Remicade and Stelara. The majority of these drugs are monoclonal
antibodies, complex protein molecules, some of which act by the inhibition of TNF-alpha. In addition to topicals, orals and injectables, psoriasis is also treated with ultraviolet light
exposure. Typically, physicians initiate treatment by prescribing topical therapies to treat mild or moderate forms of psoriasis, followed by light therapy or oral treatments if the patient's disease
does not improve. For patients who do not respond to oral treatments or light therapy, or for those
who have moderate-to-severe psoriasis, physicians will prescribe injectable biologic treatments.

Current
topical therapies have demonstrated varying levels of efficacy. However, their use has been limited due to issues of safety and tolerability. Long-term use of topical
corticosteroids is associated with atrophy, or thinning, of the skin and has the potential to suppress the body's ability to make normal amounts of endogenous corticosteroids, which limit the duration
of safe treatment with these therapies. Vitamin D derivatives can cause skin irritation, and some patients report burning sensations associated with their use. Topical retinoids can also cause skin
irritation and have been shown to cause birth defects. Thus, their use must be avoided during pregnancy. Oral and injectable drugs have greater activity than topical therapies, but also have
well-documented and significant systemic side effects, such as liver toxicity, increase in blood fats and suppression of the immune system. In addition, injectable biologic drugs are very
expensive, costing tens of thousands of dollars annually. Ultraviolet light treatments can be effective, but require multiple visits to the doctor's office each week and may increase patients' risk of
developing skin cancer.



Atopic dermatitis is a chronic rash characterized by inflammation and itchiness. In 2007, Datamonitor reported that atopic dermatitis
affected approximately 40 million people across the seven major pharmaceutical markets. The condition most commonly appears in childhood, with 20% of children in the United States affected, and
it can persist into adulthood. Skin that is broken and chafed from itching allows bacterial or viral access, which leads to secondary infections.



Current atopic dermatitis treatments attempt to reduce inflammation and itchiness to maintain the protective integrity of the skin.
Combinations of antibiotics, antihistamines, topical corticosteroids and topical immunomodulators, such as Elidel and Protopic, are the current standard of care. However, these have limited utility
because of lack of efficacy and side effects. While not approved by the FDA for treatment of atopic dermatitis, ultraviolet light has been used to treat this disease.



We believe that AN2728 will have comparable efficacy to that of topical corticosteroids and vitamin D analogs in treating
psoriasis, but with a better safety and tolerability profile thus allowing for

12

---



Table of Contents

longer
duration of treatment. AN2728 is a novel boron-containing small molecule that inhibits PDE4 and reduces the production of TNF-alpha, a precursor of the inflammation associated with
psoriasis, as well as other cytokines, including IL-12 and IL-23, which are proteins believed to be involved in the inflammation process and immune responses. If approved,
AN2728 would be the first topical non-steroidal treatment that inhibits TNF-alpha release. Because AN2728 has a novel mechanism of action, it can potentially be combined with
topical corticosteroids and vitamin D analogs for patients with mild-to-moderate psoriasis. In addition, patients with severe psoriasis who combine topical and systemic
therapies may use AN2728. We believe the anti-inflammatory characteristics of AN2728 may also prove effective for the treatment of patients with atopic dermatitis.



In February 2011, we initiated a final Phase 2b trial to evaluate the safety and efficacy of AN2728 in patients with
mild-to-moderate psoriasis. We anticipate that the design of this trial will be similar to that of our planned Phase 3 trials in which patients will be randomized to
receive either AN2728 or vehicle. The objective of this Phase 2b trial is to demonstrate efficacy in a patient-to-patient trial design using the anticipated
FDA-required endpoints and to inform the design and powering of our planned two Phase 3 trials for AN2728. Following the completion of this Phase 2b trial, we plan to have an
end-of-Phase 2 meeting with the FDA and subsequently advance AN2728 into Phase 3 development with the first of two planned Phase 3 trials anticipated to
commence in the second half of 2011. We anticipate that we will have data from at least one of our two Phase 3 trials for AN2728 by the second half of 2012.



AN2728 has demonstrated initial tolerability and activity against psoriatic lesions in three Phase 1b, one Phase 2a, one
Phase 2 and one Phase 2b clinical trials. For AN2728, all three of our completed Phase 1b microplaque trials showed significant activity over vehicle. Subsequently, our three
completed Phase 2 trials confirmed the results of the microplaque studies when applied by the patient.

The
following chart summarizes our AN2728 clinical trials to date which compared AN2728 to existing topical treatments for psoriasis or vehicle:

Study Number

Type

Dosing

Patients

Trial
Duration

Trial
Objectives

CompletedMicroplaque Phase 1b

Open-label

5.0% Betnesol-V, Protopic, Vehicles

12

12 days

Evaluate safety and efficacy compared to Betnesol-V, Protopic and vehicles

March 2007Microplaque Phase 1b

Open-label

0.5%, 2.0%, 5.0%, Betnesol-V, Protopic, Vehicle

12

12 days

Evaluate safety and efficacy of multiple doses compared to Betnesol-V, Protopic and vehicle

December 2007Microplaque Phase 1b

Open-label

0.3%, 1.0%, 2.0%, Betnesol-V, Vehicle

12

12 days

Evaluate safety and efficacy of multiple doses compared to Betnesol-V and vehicle

March 2008Phase 2a

Double-blind

Vehicle; 5.0%

35

4 weeks

Evaluate safety and efficacy compared to vehicle

March 2008Phase 2

Double-blind

Vehicle; 5.0%

30

12 weeks

Evaluate optimal duration of therapy

December 2008Phase 2b dose-ranging

Double-blind

Vehicle; 0.5%, 2.0% once and twice daily

145

12 weeks

Evaluate optimal dose and duration of therapy

June 2010


13

---



Table of Contents



We have completed three Phase 1b clinical trials of AN2728. These trials utilized a microplaque design in which each patient had
small areas of a large psoriatic lesion treated with various medications for 12 days. Each of the treatment areas was evaluated at days one, eight and twelve. The primary endpoint for each of
these trials was the change in thickness of the psoriatic lesion as measured by sonography, and the secondary endpoint was improvement based on clinical score as evaluated by a physician. No
treatment-related adverse events were observed in these trials.

In
March 2007, we completed our first Phase 1b microplaque clinical trial of AN2728 in patients with psoriasis. The study enrolled 12 patients for a 12-day treatment
and compared AN2728 5.0% ointment, AN2728 5.0% cream, Betnesol-V cream (betamethasone vallerate, a mid potency corticosteroid) and Protopic ointment (tacrolimus, an immunomodulator),
vehicle cream and vehicle ointment. This study demonstrated that AN2728 caused a significant reduction in the thickness of psoriatic lesions compared to both vehicles, at a P-value of
0.025. The mean percent reduction in infiltrate thickness for AN2728 was 54%, as compared to 48% for Protopic and 72% for Betnesol-V. The results of the secondary endpoint paralleled the
results of the primary endpoint.

In
December 2007, we completed our second Phase 1b microplaque clinical trial of AN2728 in patients with psoriasis. This study was a dose-ranging study designed to
compare 0.5%, 2.0% and 5.0% AN2728 ointment, Betnesol-V cream, Protopic, and the ointment vehicle. Based on the primary endpoint, which was the change in the thickness of the inflammatory
infiltrate, all three concentrations were significantly better than the ointment vehicle (P-values less than 0.003). The mean percent reductions for 5.0%, 2.0% and 0.5% AN2728 ointment
were 36%, 35%, and 26%, respectively. The percent reductions for Betnesol-V and Protopic were 59% and 34%, respectively.

In
March 2008, we completed our third Phase 1b microplaque trial in patients with psoriasis. This was a study designed to compare 0.3%, 1% and 2% AN2728, Betnesol-V
and vehicle. The study enrolled 12 patients for a 12-day treatment. In the study, 1% and 2% AN2728 demonstrated significant improvement over vehicle and 0.3% AN2728 demonstrated a strong
trend in superiority over vehicle.



Psoriasis is often bilateral and symmetrical, meaning that patients with psoriasis commonly have similar areas of psoriasis on opposing
sides of their body. Each of our Phase 2
studies of AN2728 for the treatment of psoriasis were designed as a bilateral study in which patients treat one of their plaques with one treatment and a similar plaque or the other side of the body
with a comparison treatment. This allowed patients to serve as their own control.

In
March 2008, we completed a Phase 2a bilateral trial of AN2728 to characterize the safety profile and to assess efficacy. In this trial, patients, in a double-blinded fashion,
treated one of their areas of psoriasis with AN2728 5.0% ointment and a matching area on the opposite side of the body with the vehicle alone. The trial treated 35 patients with
mild-to-moderate psoriasis. The primary endpoint was the proportion of patients in whom the AN2728-treated area improved more than the vehicle-treated area based on
the overall target plaque severity score, or OTPSS. The OTPSS is a scoring system used by investigators that characterizes severity of disease, which ranges from zero (no evidence of disease) to eight
(very severe). Based on the OTPSS after four weeks, the trial achieved its primary endpoint, with 69% of the AN2728 treated plaques demonstrating a lower score than the vehicle treated plaques as
compared to 6% of the vehicle treated plaques (P-value less than 0.001). Significant differences were also noted after two weeks and three weeks and in all secondary endpoints, including
scaling, erythema and plaque elevation. In addition to no serious adverse events, there were no treatment-related adverse reactions or application site reactions.

14

---



Table of Contents

In
December 2008, we completed a Phase 2 double-blind bilateral trial comparing 5.0% AN2728 ointment and vehicle using a design similar to our Phase 2a study but using a
longer treatment duration. In this Phase 2 study, patients with mild-to-moderate psoriasis applied AN2728 and vehicle twice daily for 12 weeks in order to define
the optimal duration of therapy. Results showed statistically significant reductions in the OTPSS, as well as in the individual signs of psoriasis, such as erythema, scale and plaque thickness at
several time points. Compared to those treated with vehicle, psoriasis plaques treated with AN2728 achieved a lower OTPSS in a significantly greater proportion of patients after as few as two weeks of
treatment, with optimal responses seen at six and eight weeks (P-value less than 0.001 and 0.01, respectively). Thirteen percent of the treated plaques cleared completely and 43% of the
plaques achieved clear or almost clear with a two-grade improvement from baseline. Treatments were generally well-tolerated with the most common side effect being irritation at
the application site. During the course of the trial, one serious adverse event was reported in a patient who developed a rash after receiving an injection of penicillin outside of the trial for a
sore throat and needed to be hospitalized for this non-life threatening reaction.

In
June 2010, we completed a 145-patient randomized, double-blind, vehicle-controlled, multicenter, Phase 2b bilateral dose-ranging trial to evaluate the
safety and efficacy of 0.5% and 2.0% AN2728 ointment, applied either once or twice daily for 12 weeks for the treatment of mild-to-moderate psoriasis. Compared to those
treated with vehicle, psoriasis plaques treated with AN2728 achieved greater improvement in the OTPSS in a significantly higher proportion of patients after six weeks in the 2.0% AN2728 twice daily
dosing group
(P-value less than 0.001), which was the primary endpoint of the trial. A dose response was also observed across the four dosing groups for this outcome. Additionally, of those plaques
treated for 12 weeks with 2.0% AN2728 twice daily, 54% achieved complete or near complete clearance with at least a two-grade improvement from their baseline severity score.

Based
on these results, we initiated and have completed enrollment in a double-blind, Phase 2b trial for AN2728 in February 2011. The Phase 2b trial is designed to evaluate
the safety and efficacy of AN2728 in patients with mild to moderate plaque-type psoriasis and is being conducted under anticipated Phase 3 conditions. This double-blind, randomized,
vehicle-controlled trial has enrolled 68 patients with mild to moderate plaque-type psoriasis at ten centers in the United States. Patients have been randomized to 2% AN2728 topical
ointment or vehicle in a 2:1 ratio and will apply the ointment twice daily for 12 weeks. Given its size, the trial is not designed to demonstrate statistical differentiation of AN2728 from
vehicle, but to inform the size and design of the two planned pivotal Phase 3 trials for AN2728. Following the completion of this Phase 2b trial, we plan to have an
end-of-Phase 2 meeting with the FDA and subsequently advance AN2728 into Phase 3 development with the first of two planned Phase 3 trials anticipated to
commence in the second half of 2011. We anticipate that we will have data from at least one of our two Phase 3 trials for AN2728 by the second half of 2012.



AN2898 is our second anti-inflammatory product candidate for psoriasis and atopic dermatitis. Like AN2728, AN2898 is a
novel boron-containing small molecule that inhibits PDE4 and reduces the production of both TNF-alpha, a precursor of the inflammation associated with psoriasis, and other cytokines,
including IL-12 and IL-23. AN2898 has a similar mechanism of action to that of AN2728 and appears to have activity in a larger set of animal models, which may predict greater
clinical efficacy than AN2728 in atopic dermatitis.

In
February 2009, we initiated a Phase 1b study evaluating AN2898 in 12 patients with plaque-type psoriasis for 12 days. This was a microplaque study conducted
in a similar fashion as the AN2728 microplaque trials. Achieving its primary endpoint, this study demonstrated that AN2898 caused a significant reduction in the thickness of psoriatic lesions compared
to vehicle, at a P-value less than

15

---



Table of Contents

0.0001.
The mean percent reduction in infiltrate thickness on day 12 for AN2898 was 39%, as compared to 60% for Betnesol-V, the positive control. The results relative to the secondary
endpoint (clinical response) paralleled those of the primary endpoint.

In
a cumulative irritation trial completed in the first quarter of 2009, AN2898 ointment at 5.0% and its vehicle were applied daily to the skin of normal volunteers under occlusive,
adhesive patches for four consecutive days. Application sites were evaluated daily for signs of irritation. No irritation potential was seen for 5.0% AN2898 ointment or the vehicle.

In
the first half of 2011, we expect to initiate a Phase 2 trial of AN2898 outside of the United States in patients with atopic dermatitis, which will be designed as a
two-arm trial evaluating AN2898 and AN2728 compared to vehicle. Prior to initiation of clinical trials of AN2898 in the United States, we will file an IND with the FDA for AN2898 for
psoriasis and/or atopic dermatitis. We are also evaluating AN2898 for the treatment of psoriasis. However, we expect AN2728 to remain our lead product candidate in psoriasis since it has reached a
more advanced stage of clinical development.

Our Systemic Antibiotic Program



GSK '052 (formerly AN3365) is our lead systemic antibiotic product candidate for the treatment of infections caused by
Gram-negative bacteria. In July 2010, GSK exercised its option to obtain an exclusive license to develop and commercialize GSK '052. GSK has assumed responsibility for further development
of the product candidate and any resulting commercialization. We anticipate that GSK will initiate Phase 2 trials of GSK '052 in patients with cUTI and cIAI in 2011.



Gram-negative infections are a type of bacterial infection caused by a broad class of bacteria called
Gram-negative bacteria and are most commonly acquired and treated in the hospital setting. Many commonly used antibiotics do not work against Gram-negative bacteria and
resistance to existing therapies continues to be a growing problem. According to theNew England Journal of Medicine, it is estimated that there were
1.7 million hospital-acquired Gram-negative and Gram-positive infections and approximately 100,000 associated deaths in the United States alone in 2002. The New England
Journal of Medicinealso indicates that Gram-negative bacteria are responsible for more than 30.0% of hospital-acquired infections and account for approximately
70.0% of hospital-acquired infections in the intensive care unit. IMS Health estimates that there were 40 million days of Gram-negative therapy administered in the United States in
2009. According to theArchives of Internal Medicine, hospital-acquired infections related to sepsis and pneumonia alone caused $8.1 billion in
additional hospital costs in 2006.



Traditionally, Gram-negative infections have been treated with antibiotics, particularly beta-lactams,
including penicillins, cephalosporins and carbapenems, and quinolones, including flouroquinolones. However, the effectiveness of existing antibiotics has been declining due to increasingly prevalent
drug resistance. Bacteria develop resistance to drugs through genetic mutations or by acquiring genes from other bacteria that have become resistant. For example, in a recent survey of resistance
rates of Gram-negative bacteria to current therapies in the United States, the resistance ofE. colito fluoroquinolones has been
dramatically increasing. For example, resistance ofE. colito ciprofloxacin increased from 4% in 1999 to 30% in 2008 and resistance of E. colito
levofloxacin increased from 10% in 2003 to 30% in 2008. Over the same period, resistance of another Gram-negative bacteria, Klebsiella pneumoniae, to third generation cephalosporins, such as ceftriaxone
and ceftazidime, increased from virtually no resistance to 15%. The same
survey also showed that by 2008, 17%-19% ofPseudomonas aeruginosawere resistant to fluoroquinolones, 10%-70% were resistant to
third generation

16

---



Table of Contents

cephalosporins
and 7%-15% were resistant to carbapenems, such as meropenem and imipenem. Therefore, there is an ongoing need for novel antibiotics to combat the widespread proliferation of
antibiotic resistance, particularly for Gram-negative bacteria. Additionally, currently marketed products have side effect profiles that can include nausea, diarrhea, vomiting, rash,
insomnia, and potential liver toxicity. Also, currently approved antibiotics specifically targeting infections caused by Gram-negative bacteria are only available in either IV or oral
formulations, but not both, so patients cannot continue on the same antibiotic therapy they received in the hospital once they are discharged.



GSK '052 is a novel boron-based, small molecule product candidate that targets the bacterial enzyme leucyl tRNA synthetase. The
inhibition of protein synthesis leads to termination of cell growth and cell death, eliminating the bacterial infection. Since GSK '052 is the first
antibiotic to target LeuRS, bacteria have not developed resistance to it. Preclinical studies suggest that GSK '052 could be a novel approach for the treatment of infections caused by
Gram-negative bacteria, includingE. coli,Klebsiella pneumoniae, Citrobacter spp.,S. marcescens,P. vulgaris, Providentia spp.,Pseudomonas aeruginosaandEnterobacter
spp.GSK '052 has demonstrated a favorable profile in preclinical safety and toxicology studies. Results from a Phase 1 proof-of-concept trial
showed that GSK '052 demonstrated a promising safety profile and linear dose-proportional pharmacokinetic properties, reaching blood levels that were multiple times higher than the
anticipated efficacious dose. We believe, if approved, GSK '052 would be the first new class antibacterial to treat serious hospital-acquired Gram-negative infections in thirty years. In
addition, we believe GSK '052 has the potential to be the first antibiotic specifically targeting infections caused by Gram-negative bacteria that can be administered by both IV and oral
routes, which, for the first time, would allow patients to continue on the same antibiotic therapy they received in the hospital once they are discharged.



In November 2009, we initiated a Phase 1 dose-escalating clinical study for GSK '052, to evaluate the safety,
tolerability and pharmacokinetics of GSK '052 in healthy volunteers. The randomized, double-blind, placebo-controlled, dose-escalation study enrolled 72 subjects. Participants in this
study received GSK '052 in single or multiple doses for treatment durations of up to 14 days and included doses that achieve blood levels that are approximately four times the expected
efficacious blood levels based on our preclinical studies. In June 2010, we reported Phase 1 results showing that GSK '052 appeared to be safe and well-tolerated. In July 2010, GSK
exercised its option to obtain an exclusive license to develop and commercialize GSK '052. Upon exercise of the option, we received a fee of $15.0 million. We are eligible to receive further
development milestones up to $69.0 million, commercial milestones up to $175.0 million and double-digit tiered royalties with the potential to reach the mid-teens on annual
net sales. GSK has assumed responsibility for further development of the product candidate and any resulting commercialization. We believe GSK currently plans to develop GSK '052 as a potential
treatment for cUTI, cIAI, and other Gram-negative bacterial infections, such as HAP/VAP. We anticipate that GSK will initiate Phase 2 trials of GSK '052 in patients with cUTI and
cIAI in 2011.

Research Activities



Under our collaboration with GSK, we are conducting research on additional systemic anti-infectives in three target-based
project areas in addition to GSK '052. The collaborative research term of the agreement is six years, subject to a two-year extension if agreed to by both parties.

17

---



Table of Contents



Our internal research activities include follow-on research to our existing compounds as well as investigation of novel
activity of our boron chemistry platform in multiple therapeutic applications. Key efforts currently include the further development of topical and systemic PDE4 inhibitors for the treatment of
inflammatory diseases, the development of novel anti-infectives against targets not covered in our existing GSK collaboration, and work on novel kinase inhibitors.



Neglected diseases are defined as diseases that disproportionately affect the world's poorest people, including tuberculosis, or TB,
malaria, visceral leishmaniasis, Chagas disease, human African trypanosomiasis, or African sleeping sickness, and filarial worms. Despite the fact that these diseases cause significant morbidity and
mortality worldwide, and that the current standards of care are difficult to administer, have significant toxicities and are increasingly becoming
less effective due to resistance, there has been little investment in developing new therapies for these diseases due to the absence of a reasonable expectation of a financial return.

Our
boron chemistry platform appears to be particularly well suited for the treatment of these types of infectious diseases, and we feel a responsibility to apply our technology to the
development of new treatments. Until such time as we are profitable, however, we are committed to doing that research only when we can use grants and other non-dilutive sources of funding
in a cash-neutral manner.

In
recent years, a number of foundations and governments have created public-private partnerships to address this gap by funding promising technologies that may result in new drugs. In
December 2007, we established a partnership with the Drugs for Neglected Diseases initiative, or DNDi, to develop new therapeutics for African sleeping sickness, visceral leishmaniasis and Chagas
disease. In May 2009, we established a collaboration with the Global Alliance for TB Drug Development. In April 2010, we entered into a research collaboration with the Medicines for Malaria Venture,
or MMV, to identify lead compounds for the treatment of prophylaxis of malaria and in March 2011 we also entered into a development agreement with MMV to develop our compound AN3661 for the treatment
of malaria. In December 2010, we entered into a collaboration with the Sandler Center for Drug Discovery at the University of California at San Francisco to discover new drug therapies for the
treatment of river blindness, a parasitic disease that is the second leading cause of infectious blindness worldwide. In March 2011, we announced the establishment of our joint research agreement with
the Institute for OneWorld Health to discover antibacterial compounds for treating diarrheal diseases.

Our
work in this area also allows us the potential benefits of expanding the chemical diversity of our boron compounds, understanding new properties of our boron compounds, receiving
future incentives, such as the potential grant of a priority review voucher by the FDA, and, ultimately if a drug is approved, potential revenue in some regions.

Collaboration with GSK

In October 2007, we entered into a research and development collaboration, option and license agreement with GSK for the discovery,
development and worldwide commercialization of boron-based systemic anti-infectives. Under the agreement, we are currently working to identify and develop multiple product candidates in
three target-based project areas. The collaborative research term of the agreement is six years, subject to an extension of up to two years if agreed to by both parties.

In
each project, GSK has the option to obtain an exclusive license to develop, commercialize and market worldwide certain product candidates once they have achieved certain
proof-of-concept criteria. We will be primarily responsible for the discovery and development of each product candidate from the

18

---



Table of Contents

research
stage until GSK exercises an option for such product candidate, at which point GSK will assume sole responsibility for the further development and commercialization of such product candidate
on a worldwide basis, including the responsibility to obtain regulatory approvals on a country-by-country basis. During the research term, we are committed to use diligent
efforts to discover and optimize compounds pursuant to agreed research plans and to provide specified resources, including certain numbers of full-time equivalent scientists, on a
project-by-project basis. Each party is responsible for its own research and development costs.

Pursuant
to the agreement, GSK paid us a $12.0 million non-refundable, non-creditable upfront fee in October 2007. In addition, GSK invested
$30.0 million in a preferred stock financing completed in December 2008.

In
July 2010, GSK exercised its option to obtain an exclusive license to develop and commercialize GSK '052 (formerly AN3365), our lead systemic antibiotic for the treatment of
infections caused by Gram-negative bacteria. We believe GSK currently plans to develop GSK '052 as a potential treatment for cUTI, cIAIs and other Gram-negative bacterial
infections, such as HAP/VAP. Upon exercise of the option, we received a licensing fee of $15.0 million. We are eligible to receive further development milestones up to $69.0 million,
commercial milestones up to $175.0 million and double-digit tiered royalties with the potential to reach the mid-teens on annual net sales. GSK has assumed responsibility for
further development of the product candidate and any resulting commercialization.

In
addition to assuming sole responsibility for the costs of further development and commercialization of the compounds for which it exercises an option to license, GSK is obligated to
make payments to us if certain development, regulatory and commercial milestones are met on a compound-by-compound basis. In addition, GSK is obligated to make payments to us
if certain milestones are met, which range from up to $252.8 million to $330.5 million in the aggregate per product candidate. Milestone payments may be lower for designated programs
depending upon: whether GSK makes the selection of the product candidate before or after initiation of Phase I clinical trial dosing (10%-15% reduction if selected before such
dosing); if certain target product profile characteristics are not achieved (20%-40% reduction); and whether the product candidate is designated after the initial two product candidate
designations in a program (50% reduction). GSK is further obligated to pay us double-digit tiered royalties with the potential to reach the mid-teens on annual net sales of products
containing optioned compounds in jurisdictions where there is a valid patent claim covering composition of matter or method of use of the product and lesser royalties for sales in jurisdictions where
there is no such valid patent claim. Such royalties shall continue until the later of expiration of such valid patent claims or ten years from the first commercial sale on a
product-by-product and
country-by-country basis. To date, in addition to the $12.0 million upfront payment and $15.0 million option exercise fee, we have received $10.1 million
for achievement of performance milestones, including GSK '052 milestones for lead declaration, candidate selection and first patient dosing in a Phase 1 clinical trial. We have also received
milestone payments for lead declarations in two other GSK programs.

The
agreement provides for a joint research committee to oversee the research collaboration, and a joint patent subcommittee responsible for coordination of intellectual property
developed by the collaboration, including patent application filing. We and GSK have appointed an equal number of members to each such committee and decisions are made on a consensus basis, except
that ultimate decision-making authority with respect to the establishment of proof-of-concept criteria, the design of proof-of-concept trials for each
research compound and determining whether proof-of-concept criteria have been met, is vested in GSK. Unless earlier terminated, the agreement will continue in effect until
expiration of all payment obligations under the agreement. GSK retains the unilateral right to terminate the agreement in its entirety upon six months prior written notice to us and immediately with
respect to any project. Either party may also terminate the agreement, on a project-by-project basis or in its entirety, for any uncured material breach of the agreement by the
other party. Either party may

19

---



Table of Contents

also
terminate the agreement upon specified actions relating to insolvency of the other party. In the event of unilateral termination by GSK, all rights granted by us to GSK with respect to the
project to which such termination applies would terminate and we would retain the rights to any compounds relating to such project. In the event of termination by GSK for cause, GSK would have a
perpetual exclusive license under our intellectual property to develop and commercialize any project compounds to which such termination applies, subject to GSK's payment to us of specified royalties
on sales of such compounds. In the event of termination by us for cause, we would have a perpetual exclusive license under GSK's intellectual property to develop and commercialize any project compound
to which such termination applies, subject to payment by us to GSK of specified royalties on sales of such compounds.

For
nine years following the effective date of the agreement, subject to certain exceptions, we may not research, optimize, develop or commercialize outside of the collaboration any
compounds that we progressed through the project, or any other compounds directed against the same target, unless GSK's option to such compound terminated without being exercised or GSK later
terminates its license to such compound after exercising such option. If we choose to develop such compounds after expiration of GSK's option or termination of GSK's license, we may be required under
certain circumstances to make certain regulatory milestone and royalty payments to GSK for such compounds.

Upon
a change of control of either party, the agreement would remain in effect. Upon a change of control of Anacor, GSK has the right to elect to exercise any remaining options to
license and commercialize compounds then under development pursuant to the research collaboration. Depending upon the status of compound development and the project under which the compound is being
developed, the exercise by GSK of its license options in connection with a change of control of Anacor could result in lower milestone payments and royalty rates being payable by GSK upon
commercialization of such compound.

Collaboration with Eli Lilly and Company

In August 2010, we entered into a research agreement with Eli Lilly and Company, or Lilly, under which we will collaborate to discover
products for a variety of animal health applications and Lilly will be responsible for worldwide development and commercialization of compounds advancing from these efforts. The collaboration combines
our boron-based technology platform and drug research capabilities with Lilly's expertise in the area of animal health. We received an upfront payment of $3.5 million and we will receive a
minimum of $6.0 million in research funding with the potential of up to $12.0 million in research funding, if successful. In addition, we will be eligible to receive payments upon the
achievement of development and regulatory milestones, as well as tiered royalties escalating from high single digit to in the tens commercial royalties on sales depending in part upon the mix of
products sold. Such royalties continue through the later of expiration of our patent rights or six years from the first commercial sale on a product-by-product and
country-by-country basis.

Unless
earlier terminated, the agreement continues in effect until the termination of royalty payment obligations. The agreement allows for termination by Lilly upon written notice, with
certain additional payments to us and a notice period that has a duration dependent on whether the notice is delivered prior to the first regulatory approval of a product under the agreement or
thereafter. In addition, either party may terminate for the other party's uncured material breach of the agreement. In the event of termination by us for material breach by Lilly or termination upon
written notice by Lilly, Lilly would assign to us certain trademarks and regulatory materials used in connection with the products under the agreement and grant to us an exclusive license under
Lilly's patent rights covering such products, and we would pay to Lilly a reasonable royalty on sales of such products should we desire an exclusive license. In the event of termination for material
breach by us, Lilly will be entitled to a return of all research funding payments for expenses we have not incurred or irrevocably committed.

20

---



Table of Contents

Collaboration with Medicis

In February 2011, we entered into a research and development option and license agreement with Medicis to discover and develop
boron-based small molecule compounds directed against a target for the potential treatment of acne.

Under
the terms of the agreement, we received a $7.0 million upfront payment from Medicis and will be primarily responsible, during a defined research collaboration term, for
discovering and conducting early development of product candidates which utilize our proprietary boron chemistry platform. Medicis will have an option to obtain an exclusive license for products
covered by the agreement. We will be eligible for future research, development, regulatory and sales milestones of up to $153.0 million, as well as high single-digit to in the tens royalties on
sales of products that Medicis licenses pursuant to its option. Following option exercise, Medicis will be responsible for further development and commercialization of the licensed products on a
worldwide basis.

If
Medicis exercises its option for a product candidate, the agreement will continue in effect until the expiration of royalty payment obligations, which obligations will run through the
later of patent or regulatory exclusivity and 7 years from first commercial sale, on a product-by-product basis. Upon the expiration of such payment obligations for a
product under the agreement, Medicis will retain an exclusive, fully paid and royalty-free right and license in such product. The agreement allows for at-will termination by
Medicis upon written notice, and either party may terminate for the other party's uncured material breach of the agreement or specified activities related to insolvency. In the event of
at-will termination by Medicis or termination by us for material breach or insolvency activities by Medicis, all rights granted by us to Medicis would revert to us, and Medicis would be
required to grant to us a non-exclusive license under its patent rights covering products under the agreement. If we materially breach the agreement prior to the completion of the research
collaboration term and exercise of the option, Medicis would be entitled to either terminate the agreement or continue with the agreement and terminate the research collaboration term, in which case
Medicis would have a right to reduce its financial obligations to us or recover its costs to mitigate the damages resulting from such breach.

We
have agreed not to research or develop, with respect to the target that is the subject of the agreement, any small molecule products in a specified field for use in humans for a
period of 11 years. Medicis has agreed not to research or develop with respect to the target that is the subject of the agreement any boron-containing compound for 9 years from the date
of the agreement or, if a certain milestone is not met, for 4 years from the date of the agreement.

Sales and Marketing

Our strategy is to develop a sales force targeting dermatologists and other specialty markets in the United States and to collaborate
with other companies for sales into primary care markets. In addition, we plan to enter into agreements with third parties to commercialize our products outside of the United States.

We
expect that if AN2690 and AN2718 are approved, primary care physicians will write the majority of prescriptions for these compounds in the United States, and we expect half of overall
sales will be within the United States. Accordingly, we plan to enter into a partnership for AN2690 after the completion of Phase 3 clinical trials. We also anticipate that, if AN2690, AN2718,
AN2728 and AN2898 are approved, dermatologists will write a significant number of AN2690 and AN2718 prescriptions, as well as the majority of prescriptions for AN2728 and AN2898, which we expect to
address with our own sales force in the United States. If AN2728 and AN2898 are approved, we intend to sell these products for psoriasis and atopic dermatitis to dermatologists in the United States,
and license commercialization rights to these product candidates to third parties for sales outside of the United States.

21

---



Table of Contents

Intellectual Property

Previous efforts to produce boron-based drugs have been centered largely on boronic acids as serine protease inhibitors, such as the
oncology treatment Velcade. Our research concentrates on different biological targets and uses novel boron-based compounds where we believe there is little existing intellectual property held by
others. All of our intellectual property related to our product candidates was initially developed by us or our subcontractors. In the course of our development and commercialization collaborations,
additional intellectual property relating to our product candidates may be developed by us and our collaborators, such as GSK.

As
of February 15, 2011, we were the owner of record of 8 issued U.S. patents (U.S. Pat. No. 7,390,806; U.S. Pat. No. 7,888,356; U.S. Pat. No. 7,465,836; U.S.
Pat. No. 7,393,856; U.S. Pat. No. 7,652,000; U.S. Pat. No. 7,582,621; U.S. Pat. No. 7,767,657; and U.S. Pat. No. 7,816,344) and 4 non-U.S. patents (2
South African patents, 1 Australian patent and 1 New Zealand patent). We are actively pursuing, either solely or with a collaborator, 28 U.S. patent applications (10 provisional and 18
non-provisional), 16 international (PCT) patent applications and 103
non-U.S. patent applications in at least 39 jurisdictions, including Australia, Brazil, Canada, China, Europe, Hong Kong, India, Israel, Japan, Mexico, New Zealand, Russia, South Africa,
and South Korea. Of these actively pursued applications, 3 U.S. patent applications (2 provisional and 1 non-provisional) and 1 international (PCT) patent application are solely owned by a
collaborator as of February 15, 2011.

Our
patent filings seek to protect innovations created by us, such as composition of matter (compound or pharmaceutical formulation), method of use, and process of production. As of
February 15, 2011, claims have issued in the United States (U.S. Pat. No. 7,582,621 and 7,767,657), Australia, New Zealand, and South Africa which cover, among other embodiments, methods
of using AN2690 to treat onychomycosis as well as pharmaceutical formulations containing AN2690. As of February 15, 2011, claims have issued in Australia and South Africa which cover, among
other embodiments, methods of using AN2718 to treat onychomycosis as well as pharmaceutical formulations containing AN2718. Due to the existence of an expired U.S. patent relating to a
non-pharmaceutical use of the compounds, we are not pursuing a claim solely covering AN2690 or AN2718 as a compound. U.S. Pat. No. 7,816,344 claims GSK '052 as a compound as well as
part of a pharmaceutical formulation. U.S. Pat. No. 7,390,806 and U.S. Pat. No. 7,465,836 claim compounds which do not relate to our current product candidates. U.S. Pat.
No. 7,465,836 and U.S. Pat. No. 7,888,356 claim pharmaceutical formulations which do not relate to our current product candidates. U.S. Pat. No. 7,465,836, U.S. Pat.
No. 7,393,856, U.S. Pat. No. 7,652,000 and U.S. Pat. No. 7,888,356 claim methods of using compounds which do not relate to our current product candidates.

In
2011, we are electing to allow certain non-U.S. patents and non-U.S. patent applications that do not relate to our current product candidates to expire or
become abandoned. In 2011, we estimate that we will allow 22 non-U.S. patents and 49 non-U.S. patent applications that do not relate to our clinical product candidates to
expire or become abandoned and have not included such patents and patent applications in the totals above.

Our
agreement with GSK provides that we will retain all of our right, title and interest in intellectual property for which we possess the right to license or sublicense as of the
effective date of the agreement and throughout the term of the agreement. Each party will remain the sole owner of intellectual property developed by its personnel under the research collaboration.
Intellectual property that is jointly developed by GSK and us under the collaboration will be jointly owned by GSK and us, subject to exclusive licenses that may be granted to GSK or us pursuant to
the terms of the agreement.

Our
commercial success will depend in part on obtaining and maintaining patent protection and trade secret protection of our current and future product candidates and the methods used to
manufacture them, as well as successfully defending these patents against third-party challenges. Our ability to stop third parties from making, using, selling, offering to sell or importing our
products

22

---



Table of Contents

depends
on the extent to which we have rights under valid and enforceable patents or trade secrets that cover these activities. There can be no assurance that our pending patent applications will
result in issued patents.

Manufacturing and Supply

Our current product candidates are low molecular weight molecules that are synthesized chemically and, therefore, we believe they are
easier to manufacture at relatively lower cost than biologic drugs from cell-based sources. All of our current clinical drug product manufacturing activities are in compliance with current
Good Manufacturing Practices, or cGMP, and are outsourced to qualified third parties with oversight by our employees. We have limited in-house, non-GMP manufacturing capacity
for research activities. We rely on third-party cGMP manufacturers for scale-up of the active ingredient, process development work and to produce sufficient quantities of product
candidates for use in clinical trials. We intend to continue to rely on third-party cGMP manufacturers for any future clinical trials and large-scale commercialization of all of our compounds for
which we have manufacturing responsibility. We have established multiple sources of supply for the reagents necessary for the manufacture of our compounds. We believe this manufacturing strategy will
enable us to direct financial resources to the development and commercialization of products rather than diverting resources to establishing a manufacturing infrastructure.

Prior
to entering into the agreement with Schering in 2007, we had successfully outsourced AN2690 cGMP manufacturing to a contract manufacturer at a scale that would have been sufficient
to conduct Phase 3 clinical trials. Under our agreement with Schering, the formulation for AN2690 was finalized and manufactured at one of Schering's GMP facilities. In November 2009, Schering
merged with Merck and in May 2010, we regained the worldwide rights to AN2690. As part of the transition from Merck to us, we believe that we received sufficient drug product to initiate and
sufficient active ingredient to complete our planned Phase 3 clinical trials of AN2690. We have transferred AN2690 manufacturing to a third party that operates in compliance with cGMP
regulations and will need to scale up and manufacture additional active ingredient and drug product in order to complete our NDA submission. We outsource global process development work and product
manufacturing to third parties for AN2728, AN2718 and AN2898.

Competition



If approved for the treatment of onychomycosis, we anticipate AN2690 and AN2718 would compete with other approved onychomycosis
therapeutics including:



In
addition to approved onychomycosis therapeutics, the marketing of several over-the-counter products is directed toward persons suffering from onychomycosis,
even though none of these products is FDA-approved for onychomycosis treatment.

There
are also several pharmaceutical product candidates under development that could potentially be used to treat onychomycosis and compete with AN2690. Product candidates in
late-stage development include a novel topical triazole in Phase 3 development by Dow Pharmaceutical Sciences, or DPS, a wholly-owned subsidiary of Valeant Pharmaceuticals
International, an undisclosed topical

23

---



Table of Contents

product
candidate in Phase 3 development by Promius Pharma, LLC, a wholly-owned subsidiary of Dr. Reddy's Laboratories, and a topical reformulation of terbinafine in
Phase 3 development by Celtic Pharma Management L.P. There are also several companies pursuing various devices for onychomycosis, including laser technology. In 2010, a laser device
marketed by PinPointe USA, Inc. was cleared by the FDA for onychomycosis. In addition, there are a number of earlier stage therapeutics and devices in various stages of development for the
treatment of onychomycosis.



If approved for the treatment of psoriasis, we anticipate AN2728 and AN2898 would compete with other marketed psoriasis therapeutics
including:



In
addition to the marketed psoriasis therapeutics, there are product candidates in Phase 3 development that could potentially be used to treat psoriasis and compete with AN2728
and AN2898, including an injectable therapy from Abbott, and oral therapies from Celgene and Isotechnika. In addition to these, a number of topical, oral and injectable product candidates are in
various stages of development for the treatment of psoriasis.



If approved for the treatment of atopic dermatitis, we anticipate AN2728 and AN2898 would compete with other marketed atopic dermatitis
therapeutics. Current atopic dermatitis treatments attempt to reduce inflammation and itchiness to maintain the protective integrity of the skin. Combinations of antibiotics, antihistamines, topical
corticosteroids and topical immunomodulators, such as Elidel (pimecrolimus) and Protopic (tacrolimus), are the current standard of care. In addition, while the use of ultraviolet light is not approved
by the FDA, it has been applied to the treatment of atopic dermatitis.



If approved for the treatment of infections caused by Gram-negative bacteria, we anticipate GSK '052 would compete
with other marketed broad spectrum and Gram-negative antibiotics.



24

---



Table of Contents



Government Regulation



Prescription drug products are subject to extensive pre- and post-market regulation by the FDA, including
regulations that govern the testing, manufacturing, safety, efficacy, labeling, storage, record keeping, advertising and promotion of such products under the Federal Food, Drug and Cosmetic Act, or
FFDCA, and its implementing regulations. The process of obtaining FDA approval and achieving and maintaining compliance with applicable laws and regulations requires the expenditure of substantial
time and financial resources. Failure to comply with applicable FDA or other requirements may result in refusal to approve pending applications, a clinical hold, warning letters, civil or criminal
penalties, recall or seizure of products, partial or total suspension of production or withdrawal of the product from the market. FDA approval
is required before any new drug or dosage form, including a new use of a previously approved drug, can be marketed in the United States. All applications for FDA approval must contain, among other
things, information relating to safety and efficacy, pharmaceutical formulation, stability, manufacturing, processing, packaging, labeling and quality control.



The FDA's new drug approval process generally involves:



The
preclinical and clinical testing and approval process requires substantial time, effort and financial resources, and we cannot guarantee that any approvals for our product candidates
will be granted on a timely basis, if at all. Preclinical tests include laboratory evaluation of product chemistry, formulation and stability, as well as studies to evaluate toxicity in animals. The
results of preclinical tests, together with manufacturing information and analytical data, are submitted as part of an IND

25

---



Table of Contents

application
to the FDA. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA raises concerns or questions about the submission, including concerns that human
research subjects will be exposed to unreasonable health risks. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before clinical trials can begin. Our submission of an
IND may not result in FDA authorization to commence clinical trials. A separate submission to an existing IND must also be made for each successive clinical trial conducted during product development.
Further, an independent institutional review board, or IRB, covering each medical center proposing to conduct clinical trials must review and approve the plan for any clinical trial before it
commences at that center and it must monitor the study until completed. The FDA, the IRB or the Sponsor may suspend a clinical trial at any time on various grounds, including a finding that the
subjects or patients are being exposed to an unacceptable health risk. As a separate amendment to an IND, a sponsor may submit a request for a Special Protocol Assessment, or SPA, from the FDA. Under
the SPA procedure, a sponsor may seek the FDA's agreement on the design and size of a clinical trial intended to form the primary basis of an effectiveness and safety claim. If the FDA agrees in
writing, the study design may not be changed after the trial begins, except in limited circumstances, such as when a substantial scientific issue essential to determining the safety and effectiveness
of a product candidate is identified. If the outcome of the trial is successful, the sponsor will ordinarily be able to rely on it as the primary basis for approval with respect to effectiveness and
safety. Clinical testing also must satisfy extensive Good Clinical Practice, or GCP, regulations, which include requirements that all research subjects provide informed consent and that all clinical
studies be conducted under the supervision of one or more qualified investigators.

For
purposes of an NDA submission and approval, human clinical trials are typically conducted in the following sequential phases, which may overlap:



26

---





Table of Contents

Progress reports detailing the results of the clinical studies must be submitted at least annually to the FDA and safety reports must be submitted to the FDA and
the investigators for serious and unexpected adverse events. Concurrent with clinical studies, sponsors usually complete additional animal safety studies and must also develop additional information
about the chemistry and physical characteristics of the product and finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing
process must be capable of consistently producing quality batches of the product candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality
and purity of the final product. Moreover, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidate does not undergo
unacceptable deterioration over its shelf life.

The
results of product development, preclinical studies and clinical trials, along with the aforementioned manufacturing information, are submitted to the FDA as part of an NDA. NDA's
must also contain extensive manufacturing information. Under the Prescription Drug User Fee Act, or PDUFA, the FDA agrees to specific goals for NDA review time through a two-tiered
classification system, Standard Review and Priority Review. Standard Review is applied to a drug that offers at most, only minor improvement over existing marketed therapies. Standard Review NDAs have
a goal of being completed within a ten-month timeframe, although a review can take a significantly longer amount of time. A Priority Review designation is given to drugs that offer major
advances in treatment, or provide a treatment where no adequate therapy exists. A Priority Review means that the time it takes the FDA to review an NDA is reduced such that the goal for completing a
Priority Review initial review cycle is six months. It is likely that our product candidates will be granted Standard Reviews. The review process is often significantly extended by FDA requests for
additional
information or clarification. The FDA may refer the application to an advisory committee for review, evaluation and recommendation as to whether the application should be approved. The FDA is not
bound by the recommendation of an advisory committee, but it generally follows such recommendations.

The
FDA may deny approval of an NDA if the applicable regulatory criteria are not satisfied, or it may require additional clinical data or additional pivotal Phase 3 clinical
trials. Even if such data are submitted, the FDA may ultimately decide that the NDA does not satisfy the criteria for approval. Data from clinical trials are not always conclusive and the FDA may
interpret data differently than we do. Once issued, product approval may be withdrawn by the FDA if ongoing regulatory requirements are not met or if safety problems occur after the product reaches
the market. In addition, the FDA may require testing, including Phase 4 clinical trials, Risk Evaluation and Mitigation Strategies (REMS) and surveillance programs to monitor the effect of
approved products that have been commercialized, and the FDA has the power to prevent or limit further marketing of a product based on the results of these post-marketing programs. Drugs
may be marketed only for the approved indications and in accordance with the provisions of the approved label. Further, if there are any modifications to the drug, including changes in indications,
labeling or manufacturing processes or facilities, approval of a new or supplemental NDA may be required, which may involve conducting additional preclinical studies and clinical trials.



Under the Drug Price Competition and Patent Term Restoration Act of 1984, known as the Hatch-Waxman Amendments, a portion of a
product's patent term that was lost during clinical development and application review by the FDA may be restored. The Hatch-Waxman Amendments also provide for a statutory protection, known as
nonpatent market exclusivity, against the FDA's acceptance or approval of certain competitor applications.

Patent
term restoration can compensate for time lost during product development and the regulatory review process by returning up to five years of patent life for a patent that covers a
new

27

---



Table of Contents

product
or its use. This period is generally one-half the time between the effective date of an IND (falling after issuance of the patent) and the submission date of an NDA, plus the time
between the submission date of an NDA and the approval of that application. Patent term restorations, however, cannot extend the remaining term of a patent beyond a total of 14 years. The
application for patent term extension is subject to approval by the United States Patent and Trademark Office in conjunction with the FDA. It takes at least six months to obtain approval of the
application for patent term extension. Up to five years of interim one year extensions are available if a product is still undergoing development or FDA review at the time of its expiration.

The
Hatch-Waxman Amendments also provide for a period of statutory protection for new drugs that receive NDA approval from the FDA. If a new drug receives NDA approval as a new chemical
entity, meaning that the FDA has not previously approved any other new drug containing the same active moiety, then the Hatch-Waxman Amendments prohibit submission of an Abbreviated New Drug
Application, or ANDA, or a 505(b)(2) NDA (each as described below) by another company for a generic version of such drug, or modification to the previously approved version, with some exceptions, for
a period of five years from the date of approval of the NDA. The statutory protection provided pursuant to the Hatch-Waxman Amendments will not prevent the filing or approval of a full NDA. In order
to gain approval of a full NDA, however, a competitor would be required to conduct its own preclinical investigations and clinical trials. If NDA approval is received for a new drug containing an
active ingredient that was previously approved by the FDA but the NDA is for a drug that includes an innovation over the previously approved drug and if such NDA approval was dependent upon the
submission to the FDA of new clinical investigations, other than bioavailability studies, then the Hatch-Waxman Amendments prohibit the FDA from making effective the approval of an ANDA or a 505(b)(2)
NDA for a generic version of such drug or modification of the previously approved version for a period of three years from the date of the NDA approval. This three year exclusivity, however, only
covers the innovation associated with the NDA to which it attaches. Thus, the three year exclusivity does not prohibit the FDA, with limited exceptions, from approving ANDAs or 505(b)(2) NDAs for
drugs containing the same active ingredient but without the new innovation.

While
the Hatch-Waxman Amendments provide certain patent term restoration and exclusivity protections to innovator drug manufacturers, it also permits the FDA to approve ANDAs for
generic versions of their drugs. The ANDA process permits competitor companies to obtain marketing approval for a drug with the same active ingredient for the same uses but does not require the
conduct and submission of clinical trials demonstrating safety and effectiveness for that product. Instead of safety and effectiveness data, an ANDA applicant needs only to submit data demonstrating
that its product is bioequivalent to the innovator product as well as relevant chemistry, manufacturing and product data. The Hatch-Waxman Amendments also instituted a third type of drug application
that requires the same information as an NDA including full reports of clinical and preclinical studies except that some of the information from the reports required for marketing approval comes from
studies that the applicant does not own or for which the applicant does not have a legal right of reference. This type of application, a "505(b)(2) NDA," permits a manufacturer to obtain marketing
approval for a drug without needing to conduct or obtain a right of reference for all of the required studies.

Finally,
the Hatch-Waxman Amendments require, in some circumstances, an ANDA or a 505(b)(2) NDA applicant to notify the patent owner and the holder of the approved NDA of the factual and
legal basis of the applicant's opinion that the patent listed by the holder of the approved NDA in FDA'sApproved Drug Products with Therapeutic Equivalence
Evaluationsmanual is not valid or will not be infringed (the patent certification process). Upon receipt of this notice, the patent owner and the NDA holder have
45 days to bring a patent infringement suit in federal district court and obtain a 30-month stay against the company seeking to reference the NDA. The NDA or patent holder could
still file a patent suit after the 45 days, but if they did, they would not have the benefit of a 30-month stay. Alternatively, after this 45-day period, the
applicant may file a declaratory judgment action,

28

---



Table of Contents

seeking
a determination that the patent is invalid or will not be infringed. The discovery, trial and appeals process in such suits can take several years. If such a suit is timely commenced, the
Hatch-Waxman Amendments provide a 30-month stay on the approval of the competitor's ANDA or 505(b)(2) NDA. If the litigation is resolved in favor of the competitor or the challenged patent
expires during a 30-month stay period, unless otherwise extended by court order, the stay is lifted and the FDA may approve the application. The patent owner and the NDA holder have the
opportunity to trigger only a single 30-month stay per ANDA or 505(b)(2) NDA. Once the ANDA or 505(b)(2) NDA applicant has notified the patent owner and the NDA holder of the infringement,
the applicant cannot be subjected to another 30-month stay, even if the applicant becomes aware of additional patents that may be infringed by its product.



In addition to regulations in the United States, we will be subject to a variety of foreign regulations governing clinical trials and
commercial sales and distribution of our future products. Whether or not we obtain FDA approval for a product, we must obtain approval of a product by the comparable regulatory authorities of foreign
countries before we can commence clinical trials or marketing of the product in those countries. The approval process varies from country to country, and the time may be longer or shorter than that
required for FDA approval. The requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from country to country.

Under
European Union regulatory systems, marketing authorizations may be submitted either under a centralized or a mutual recognition procedure. The centralized procedure provides for
the grant of a single marketing authorization that is valid for all European Union member states. The mutual recognition procedure provides for mutual recognition of national approval decisions. Under
this procedure, the holder of a national marketing authorization may submit an application to the remaining member states. Within 90 days of receiving the applications and assessment report,
each member state must decide whether to recognize approval.



Although none of our product candidates has been commercialized for any indication, if they are approved for marketing, commercial
success of our product candidates will depend, in part, upon the availability of coverage and reimbursement from third-party payors at the federal, state and private levels. Government payor programs,
including Medicare and Medicaid, private health care insurance companies and managed-care plans have attempted to control costs by limiting coverage and the amount of reimbursement for
particular drug treatments. The U.S. Congress and state legislatures from time to time propose and adopt initiatives aimed at cost-containment. Ongoing federal and state government
initiatives directed at lowering the total cost of health care will likely continue to focus on health care reform, the cost of prescription pharmaceuticals and on the reform of the Medicare and
Medicaid payment systems. Examples of how limits on drug coverage and reimbursement in the United States may cause reduced payments for drugs in the future include:



Indeed,
the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively, the Healthcare Reform Act, which was
recently signed into law in March of 2010, substantially changes the way health care is financed by both

29

---



Table of Contents

governmental
and private insurers, and significantly impacts pharmaceutical manufacturers. The Healthcare Reform Act includes, among other things, the following measures:



Additionally,
some third-party payors also require pre-approval of coverage for new or innovative drug therapies before they will reimburse health care providers who use such
therapies. While we cannot predict whether any proposed cost-containment measures will be adopted or otherwise implemented in the future, the announcement or adoption of these proposals
could have a material adverse effect on our ability to obtain adequate prices for our product candidates and operate profitably.



We rely, and expect to continue to rely, on third parties for the production of clinical and eventually, commercial, quantities of our
products. We and our third-party manufacturers must comply with applicable FDA regulations relating to FDA's cGMP regulations. The cGMP regulations include requirements relating to organization of
personnel, buildings and facilities, equipment, control of components and drug product containers and closures, production and process controls, packaging and labeling controls, holding and
distribution, laboratory controls, records and reports and returned or salvaged products. The manufacturing facilities for our products must meet cGMP requirements to the satisfaction of the FDA
pursuant to a pre-approval inspection before we can use them to manufacture our products. We and our third-party manufacturers are also subject to periodic inspections of facilities by the
FDA and other authorities, including procedures and operations used in the testing and manufacture of our products to assess our compliance with applicable regulations. Failure to comply with
statutory and regulatory requirements subjects a manufacturer to possible legal or regulatory action, including warning letters, the seizure or recall of products, injunctions, consent decrees placing
significant restrictions on or suspending manufacturing operations and civil and criminal penalties. Adverse experiences with the product must be reported to the FDA and could result in the imposition
of market restriction through labeling changes or in product removal. Product approvals may be withdrawn if compliance with regulatory requirements is not maintained or if problems concerning safety
or efficacy of the product occur following approval.



With respect to post-market product advertising and promotion, the FDA imposes a number of complex regulations on entities
that advertise and promote pharmaceuticals, which include, among others, standards for direct-to-consumer advertising, off-label promotion, industry-sponsored
scientific and educational activities and promotional activities involving the internet. The FDA has very broad enforcement authority under the FFDCA, and failure to abide by these regulations can
result in penalties, including the issuance of a warning letter directing entities to correct deviations from FDA

30

---



Table of Contents

standards,
a requirement that future advertising and promotional materials be pre-cleared by the FDA and state and federal civil and criminal investigations and prosecutions.

We
are also subject to various laws and regulations regarding laboratory practices, the experimental use of animals and the use and disposal of hazardous or potentially hazardous
substances in connection with our research. In each of these areas, as above, the FDA has broad regulatory and enforcement powers, including the ability to levy fines and civil penalties, suspend or
delay issuance of approvals, seize or recall products and withdraw approvals, any one or more of which could have a material adverse effect on us.

Legal Proceedings

We are not currently a party to any material legal proceedings.

Employees

As of December 31, 2010, we had 65 full-time employees, 29 of whom held Ph.D. or M.D. degrees and 53 of whom were
engaged in full-time research and development activities. We plan to continue to expand our product development programs. To support this growth and to support public company requirements,
we will need to expand
our managerial, development, finance and other functions. None of our employees are represented by a labor union and we consider our employee relations to be good.

Facilities

Our corporate headquarters are located in Palo Alto, California, where we lease a 36,960 square-foot building with
laboratory and office space. The lease will terminate in March 2018.

We
also lease approximately 15,300 square feet of laboratory and office space in another building in Palo Alto, California under a lease agreement that terminates in December 2011. We
may terminate the lease by providing four months' written notice.

Corporate and Available Information

Our principal corporate offices are located at 1020 East Meadow Circle, Palo Alto, California 94303-4230 and our telephone
number is (650) 543-7600. We were incorporated in Delaware in December 2000 and began business operations in March 2002. Our internet address is www.anacor.com. We make available on
our website, free of charge, our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and any amendments to
those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, as soon as reasonably practicable after we electronically file such
material with, or furnish it to, the Securities and Exchange Commission, or the SEC. Our SEC reports can be accessed through the Investors section of our internet website. Further, a copy of this
Annual Report on Form 10-K is located at the SEC's Public Reference Rooms at 100 F Street, N.E., Washington, D. C. 20549. Information on the operation of the
Public Reference Room can be obtained by calling the SEC at 1-800-SEC-0330. The SEC maintains a website that contains reports, proxy and information statements and
other information regarding our filings at http://www.sec.gov. The information found on our internet website is not incorporated by reference into this Annual Report on Form 10-K or
any other report we file with or furnish to the SEC.

31

---





Table of Contents

ITEM 1A.    RISK FACTORS

Investing in our common stock involves a high degree of risk. You should carefully consider the following risk
factors, as well as the other information in this Annual Report on Form 10-K, before deciding whether to invest in shares of our common stock. The occurrence of any of the following
adverse developments described in the following risk factors could harm our business, financial condition, results of operations or prospects. In that case, the trading price of our common stock could
decline, and you may lose all or part of your investment.

Risks Relating to Our Financial Position and Need for Additional Capital

We have never been profitable. Currently, we have no products approved for commercial sale, and to date we have not generated any revenue from product sales. As a result,
our ability to curtail our losses and reach profitability is unproven, and we may never achieve or sustain profitability.

We are not profitable and do not expect to be profitable in the foreseeable future. We have incurred net losses in each year since our
inception, including net losses of approximately $21.6 million, $24.8 million and $10.1 million for 2008, 2009 and 2010, respectively, and as of December 31, 2010, we had
an accumulated deficit of approximately $111.2 million. We have devoted most of our financial resources to research and development, including our preclinical development activities and
clinical trials. We have not completed development of any product candidate and we have therefore not generated any revenues from product sales. We expect to incur increased expenses as we continue
Phase 3 clinical trials of AN2690, commence Phase 3 clinical trials of AN2728, advance our other product candidates and expand our research and development programs. We also expect an
increase in our expenses associated with preparing for commercialization of our product candidates and creating additional infrastructure to support operations as a public company. As a result of the
foregoing, we expect to continue to experience net losses and negative cash flows for the foreseeable future. These losses and negative cash flows have had, and will continue to have, an adverse
effect on our stockholders' equity and working capital.

Because
of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or
when, or if, we will be able to achieve or maintain profitability. In addition, our expenses could increase more than currently anticipated if we are required by the United States Food and Drug
Administration, or FDA, to perform studies in addition to those that we currently expect. To date, we have financed our operations primarily through the sale of equity securities, debt arrangements,
government contracts and grants and the payments under our agreements with GlaxoSmithKline LLC, or GSK, Schering Corporation, or Schering, Eli Lilly and Company, or Lilly, and Medicis
Pharmaceutical Corporation, or Medicis. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenues. Revenues from our
collaboration with GSK are uncertain because GSK may not continue to develop GSK2251052, or GSK '052 (formerly known as AN3365) the product candidate recently licensed by GSK, milestones under our
agreements with GSK may not be achieved, GSK may not exercise its option to license additional product candidates that may be identified pursuant to our collaboration with them, these product
candidates may not receive regulatory approval or, if they are approved, such product candidates may not be accepted in the market. In addition, we may not be able to enter into other collaborations
that will generate significant cash. If we are unable to develop and commercialize one or more of our product candidates, or if revenues from any product candidate that receives marketing approval are
insufficient, we will not achieve profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability.

32

---



Table of Contents

We have a limited operating history and we expect a number of factors to cause our operating results to fluctuate on a quarterly and annual basis, which may make it
difficult to predict our future performance.

Our operations to date have been primarily limited to developing our technology and undertaking preclinical studies and clinical trials
of our product candidates. We have not yet obtained regulatory approvals for any of our product candidates. Consequently, any predictions you make about our future success or viability may not be as
accurate as they could be if we had a longer operating history and/or approved products on the market. Our financial condition and operating results have varied significantly in the past and will
continue to fluctuate from quarter-to-quarter or year-to-year due to a variety of factors, many of which are beyond our control. Factors relating to our
business that may contribute to these fluctuations include the following risk factors, as well as other factors described elsewhere in this Annual Report on
Form 10-K:



33

---



Table of Contents

Due
to the various factors mentioned above, and others, the results of any quarterly or annual periods should not be relied upon as indications of future operating performance.

If we are unable to raise capital when needed, we would be forced to delay, reduce or eliminate our product development programs.

Developing pharmaceutical products, including conducting preclinical studies and clinical trials, is expensive. We expect our research
and development expenses to increase in connection with our ongoing activities, particularly our Phase 3 clinical trials of AN2690 and AN2728. If the FDA requires that we perform additional
studies beyond those that we currently expect, our expenses could increase beyond what we currently anticipate and the timing of any potential product approval may be delayed. Under the GSK agreement,
we are required to use diligent efforts to identify and optimize product candidates and to provide certain numbers of personnel and other resources under drug development projects. We currently have
no commitments or arrangements for any additional financing to fund our research and development programs other than through our loan facility, research funding under our collaboration with Lilly,
reimbursements from our various collaborations with leading not-for-profit organizations related to our neglected diseases initiatives and contingent milestone or royalty
payments from GSK, Lilly or Medicis, which we may not receive. We believe our existing cash, cash equivalents and short-term investments and interest thereon will be sufficient to fund our
projected operating requirements for at least the next 12 months. However, we may need to raise substantial additional capital in the future to complete the development and commercialization of
our product candidates.

Until
we can generate a sufficient amount of revenue from our products, if ever, we expect to finance future cash needs through public or private equity offerings, debt financings or
corporate collaborations and licensing arrangements. Additional funds may not be available when we need them on terms that are acceptable to us, or at all. If adequate funds are not available, we may
be required to delay, reduce the scope of or eliminate one or more of our research or development programs or our commercialization efforts. To the extent that we raise additional funds by issuing
equity securities, our stockholders may experience additional dilution, and debt financing, if available, may involve restrictive covenants. To the extent that we raise additional funds through
collaborations and licensing arrangements, it may be necessary to relinquish some rights to our technologies or our product candidates or grant licenses on terms that may not be favorable to us. We
may seek to access the public or private capital markets whenever conditions are favorable, even if we do not have an immediate need for additional capital at that time.

Our
forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement and involves risks and uncertainties,
and actual results could vary as a result of a number of factors, including the factors discussed elsewhere in this "Risk Factors" section. We have based this estimate on assumptions that may prove to
be wrong, and we could utilize our available capital resources sooner than we currently expect.

Our
future funding requirements, both near and long-term, will depend on many factors, including, but not limited to:



34

---



Table of Contents



Raising funds through lending arrangements may restrict our operations or produce other adverse results.

Our current loan and security agreement with Oxford Finance Corporation and Horizon Technology Finance Corporation, which we entered
into in March 2011, contains a variety of affirmative and negative covenants, including required financial reporting, limitations on certain dispositions of assets, limitations on the incurrence of
additional debt and other requirements. To secure our performance of our obligations under this loan and security agreement, we granted a security interest in substantially all of our assets, other
than intellectual property assets, to the lenders. Our failure to comply with the covenants in the loan and security agreement, the occurrence of a material impairment in our prospect of repayment or
in the perfection or priority of the lender's lien on our assets, as determined by the lenders, or the occurrence of certain other specified events could result in an event of default that, if not
cured or waived, could result in the acceleration of all or a substantial portion of our debt, potential foreclosure on our assets, and other adverse results.

Risks Relating to the Development, Regulatory Approval and Commercialization of Our Product Candidates

We cannot be certain that AN2690, AN2728, AN2898, GSK '052 or any of our other product candidates will receive regulatory approval, and without regulatory approval our
product candidates will not be able to be marketed.

We have invested a significant portion of our efforts and financial resources in the development of our most advanced product
candidates, especially AN2690. Our ability to generate revenue related to product sales, which we do not expect will occur for at least the next several years, if ever, will depend on the successful
development and regulatory approval of our product candidates.

In
August 2010, we filed a Special Protocol Assessment request with the FDA in order to reach agreement on key endpoint measures and trial design to be used in our first of two identical
planned Phase 3 clinical trials of AN2690. We have received the FDA's agreement on what we believe are the major parameters associated with the design and conduct of our first Phase 3
trial for AN2690, and we commenced Phase 3 clinical trials in the fourth quarter of 2010. We may conduct lengthy and expensive Phase 3 clinical trials of AN2690 only to learn that this
drug candidate is not a safe or effective treatment, in which case these clinical trials may not lead to regulatory approval for AN2690. Similarly, our clinical development programs for AN2728, AN2898
and our other product candidates and GSK's development programs for GSK '052 may not lead to regulatory approval from the FDA and similar foreign regulatory agencies. This failure to obtain regulatory
approvals would prevent our product candidates from being marketed and would have a material and adverse effect on our business.

We
currently have no products approved for sale and we cannot guarantee that we will ever have marketable products. The development of a product candidate, including preclinical and
clinical testing, manufacturing, quality systems, labeling, approval, record-keeping, selling, promotion, marketing and distribution of products, is subject to extensive regulation by the FDA in the
United States and

35

---



Table of Contents

regulatory
authorities in other countries, with regulations differing from country to country. We are not permitted to market our product candidates in the United States until we receive approval of a
new drug application, or NDA, from the FDA. We have not submitted an NDA for any of our product candidates. Obtaining approval of an NDA is a lengthy, expensive and uncertain process. An NDA must
include extensive preclinical and clinical data and supporting information to establish the product candidate's safety and effectiveness for each indication. The approval application must also include
significant information regarding the chemistry, manufacturing and controls for the product. The FDA review process typically takes years to complete and approval is never guaranteed. If a product is
approved, the FDA may limit the indications for which the product may be used, include extensive warnings on the product labeling or require costly ongoing requirements for post-marketing
clinical studies and surveillance or other risk management measures to monitor the safety or efficacy of the product candidate. Markets outside of the United States also have requirements for approval
of drug candidates with which we must comply prior to marketing. Obtaining regulatory approval for marketing of a product candidate in one country does not ensure we will be able to obtain regulatory
approval in other countries but a failure or delay in obtaining regulatory
approval in one country may have a negative effect on the regulatory process in other countries. Also, any regulatory approval of any of our products or product candidates, once obtained, may be
withdrawn. If AN2690, AN2728, AN2898, GSK '052 or any of our other product candidates do not receive regulatory approval, we may not be able to generate sufficient revenue to become profitable or to
continue our operations.

Delays in the commencement, enrollment and completion of clinical trials could result in increased costs to us and delay or limit our ability to obtain regulatory approval
for our product candidates.

Delays in the commencement, enrollment and completion of clinical trials could increase our product development costs or limit the
regulatory approval of our product candidates. We do not know whether clinical trials of AN2690, AN2728, AN2898, GSK '052 or other product candidates will begin on time or, if commenced, will be
completed on schedule or at all. The commencement, enrollment and completion of clinical trials can be delayed for a variety of reasons, including:



36

---



Table of Contents

In
addition, a clinical trial may be suspended or terminated by us, our current or any future partners, the FDA or other regulatory authorities due to a number of factors,
including:



If
we are required to conduct additional clinical trials or other testing of our product candidates beyond those currently contemplated, we may be delayed in obtaining, or may not be
able to obtain, marketing approval for these product candidates. In addition, if our current or any future partners assume development of our product candidates, they may suspend or terminate their
development and commercialization efforts, including clinical trials for our product candidates, at any time. For example, with the license of GSK '052, GSK now controls the development and
commercialization of GSK '052.

Changes
in regulatory requirements and guidance may occur and we or any partners may need to amend clinical trial protocols to reflect these changes with appropriate regulatory
authorities. Amendments may require us or any partners to resubmit clinical trial protocols to IRBs for re-examination, which may impact the costs, timing or successful completion of a
clinical trial. If we or any of our partners experience delays in the completion of, or if we or our partners terminate, clinical trials, the commercial prospects for our product candidates will be
harmed, and our ability to generate revenue from sales of our products will be prevented or delayed. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion
of clinical trials may also ultimately lead to the denial of regulatory approval of a product candidate.

Clinical failure can occur at any stage of clinical development. Because the results of earlier clinical trials are not necessarily predictive of future results, any product
candidate we, GSK or our potential future partners advance through clinical trials may not have favorable results in later clinical trials or receive regulatory approval.

Clinical failure can occur at any stage of our clinical development. Clinical trials may produce negative or inconclusive results, and
we or our partners may decide, or regulators may require us, to conduct additional clinical or preclinical testing. In addition, data obtained from tests are susceptible to varying interpretations,
and regulators may not interpret our data as favorable as we do, which may delay, limit or prevent regulatory approval. Success in preclinical testing and early clinical trials does not ensure that
later clinical trials will generate the same results or otherwise provide adequate data to demonstrate the efficacy and safety of a product candidate. Frequently, product candidates that have shown
promising results in early clinical trials have subsequently suffered significant setbacks in later clinical trials. In addition, the design of a clinical trial can determine whether its results will
support approval of a product and flaws in the design of a clinical trial may not become apparent until the clinical trial is well advanced. We have limited experience in designing clinical trials and
may be unable to design and execute a clinical trial to support regulatory approval. Further, clinical trials of potential products often reveal that it is not practical or feasible to continue
development efforts. If AN2690, AN2728, AN2898, GSK '052 or our other product candidates are found to be unsafe or lack efficacy, we will not be able to obtain regulatory approval for them and our
business would be harmed. For example, if the results of our current Phase 3 clinical trials of AN2690 and planned Phase 3 clinical

37

---



Table of Contents

trials
of AN2728 do not achieve the primary efficacy endpoints or demonstrate an acceptable safety level, the prospects for approval of AN2690 and AN2728 would be materially and adversely affected. A
number of companies in the pharmaceutical industry, including those with greater resources and experience than us, have suffered significant setbacks in Phase 3 clinical trials, even after
seeing promising results in earlier clinical trials.

In
some instances, there can be significant variability in safety and/or efficacy results between different trials of the same product candidate due to numerous factors, including
changes in trial protocols, differences in size and type of the patient populations, adherence to the dosing regimen, particularly for self-administered topical drugs, and other trial
protocols and the rate of dropout among clinical trial participants. We do not know whether any Phase 2, Phase 3 or other clinical trials we or any partners may conduct will demonstrate
consistent and/or adequate efficacy and safety to obtain regulatory approval to market our product candidates.

We have never conducted a Phase 3 clinical trial or submitted an NDA before, and may be unable to do so for AN2690, AN2728 and other product candidates we are
developing.

We are conducting the Phase 3 clinical trials of AN2690 and plan to conduct the Phase 3 clinical trials of AN2728. The
conduct of Phase 3 clinical trials and the submission of a successful NDA is a complicated process. We have not conducted a Phase 3 clinical trial before, have limited experience in
preparing, submitting and prosecuting regulatory filings, and have not submitted an NDA before. Consequently, we may be unable to successfully and efficiently execute and complete these planned
clinical trials in a way that leads to NDA submission and approval of AN2690, AN2728 and other product candidates we are developing. We may require more time and incur greater costs than our
competitors and may not succeed in obtaining regulatory approvals of products that we develop. Failure to commence or complete, or delays in, our planned clinical trials, would prevent us from or
delay us in commercializing AN2690, AN2728 and other product candidates we are developing.

Our product candidates may have undesirable side effects which may delay or prevent marketing approval, or, if approval is received, require them to be taken off the market
or otherwise limit their sales.

Unforeseen side effects from any of our product candidates could arise either during clinical development or, if approved, after the
approved product has been marketed. For example, a small number of patients who received AN2690 treatment experienced some skin irritation around their toenails during clinical trials of AN2690 for
onychomycosis. In addition, a small number of patients who received AN2728 treatment experienced some skin irritation during clinical trials of AN2728 for psoriasis, and one serious adverse event was
reported in a patient who developed a rash after receiving an injection of penicillin outside the trial for a sore throat and needed to be hospitalized for this non-life threatening
reaction. GSK '052 is being developed for the systemic treatment of infections caused by Gram-negative bacteria and is still in the early stages of clinical development. The range and
potential severity of possible side effects from systemic therapies is greater than for topically administered drugs. The results of future clinical trials may show that our product candidates cause
undesirable or unacceptable side effects, which could interrupt, delay or halt clinical trials, resulting in delay of, or failure to obtain, marketing approval from the FDA and other regulatory
authorities.

If
any of our product candidates receives marketing approval and we or others later identify undesirable or unacceptable side effects caused by such products:



38

---



Table of Contents



Any
of these events could prevent us, GSK or our potential future partners from achieving or maintaining market acceptance of the affected product or could substantially increase
commercialization costs and expenses, which in turn could delay or prevent us from generating significant revenues from the sale of our products.

All of our product candidates require regulatory review and approval prior to commercialization. Any delay in the regulatory review or approval of any of our product
candidates will harm our business.

All of our product candidates require regulatory review and approval prior to commercialization. Any delays in the regulatory review or
approval of our product candidates would delay market launch, increase our cash requirements and result in additional operating losses.

The
process of obtaining FDA and other required regulatory approvals, including foreign approvals, often takes many years and can vary substantially based upon the type, complexity and
novelty of the products involved. Furthermore, this approval process is extremely complex, expensive and uncertain. We, GSK or our potential future partners may be unable to submit any NDA in the
United States or any marketing approval application or other foreign applications for any of our products. If we or our partners submit any NDA, including any amended NDA or supplemental NDA, to the
FDA seeking marketing approval for any of our product candidates, the FDA must decide whether to either accept or reject the submission for filing. We cannot be certain that any of these submissions
will be accepted for filing and reviewed by the FDA, or that the marketing approval application submissions to any other regulatory authorities will be accepted for filing and review by those
authorities. We cannot be certain that we or our partners will be able to respond to any regulatory requests during the review period in a timely manner without delaying potential regulatory action.
We also cannot be certain that any of our product candidates will receive favorable recommendations from any FDA advisory committee or foreign regulatory bodies or be approved for marketing by the FDA
or foreign regulatory authorities. In addition, delays in approvals or rejections of marketing applications may be based upon many factors, including regulatory requests for additional analyses,
reports, data and studies, regulatory questions regarding data and results, changes in regulatory policy during the period of product development and the emergence of new information regarding our
product candidates or other products.

Data
obtained from preclinical studies and clinical trials are subject to different interpretations, which could delay, limit or prevent regulatory review or approval of any of our
product candidates. In addition, as a routine part of the evaluation of any potential drug, clinical trials are generally conducted to assess the potential for drug-to-drug
interactions that could impact potential product safety. To date, we have not been requested to perform drug-to-drug interaction studies on our topical product candidates, but
any such request, which would be more typical with a systemic product candidate, may delay any potential product approval and may increase the expenses associated with clinical programs. Furthermore,
regulatory attitudes towards the data and results required to demonstrate safety and efficacy can change over time and can be affected by many factors, such as the emergence of new information,
including on other products, policy changes and agency funding, staffing and leadership. We do not know whether future changes to the regulatory environment will be favorable or unfavorable to our
business prospects.

39

---



Table of Contents

In
addition, the environment in which our regulatory submissions may be reviewed changes over time. For example, average review times at the FDA for NDAs have fluctuated over the last
ten years, and we cannot predict the review time for any of our submissions with any regulatory authorities. Review times can be affected by a variety of factors, including budget and funding levels
and statutory, regulatory and policy changes. Moreover, in light of widely publicized events concerning the safety risk of certain drug products, regulatory authorities, members of Congress, the
Government Accounting Office, medical professionals and the general public have raised concerns about potential drug safety issues. These events have resulted in the withdrawal of drug products,
revisions to drug labeling that further limit use of the drug products and establishment of risk evaluation and mitigation strategies, or REMS, that may, for instance, restrict distribution of drug
products. The increased attention to drug safety issues may result in a more cautious approach by the FDA to clinical trials. Data from clinical trials may receive greater scrutiny with respect to
safety, which may make the FDA or other regulatory authorities more likely to terminate clinical trials before completion, or require longer or additional clinical trials that may result in
substantial additional expense and a delay or failure in obtaining approval or may result in approval for a more limited indication than originally sought.

Our use of boron chemistry to develop pharmaceutical product candidates is novel and may not prove successful in producing approved products. Undesirable side effects of any
of our product candidates, or of boron-based drugs developed by others, may extend the time period required to obtain regulatory approval or harm market acceptance of our product candidates, if
approved.

All of our product development activities are centered around compounds containing boron. The use of boron chemistry to develop new
drugs is largely unproven. If boron-based compounds developed by us or others have significant adverse side effects, regulatory authorities could require additional studies of our boron-based
compounds, which could delay the timing of and increase the cost for regulatory approvals of our product candidates. Additionally, adverse side effects for other boron-based compounds could affect the
willingness of third-party payors and medical providers to provide reimbursement for or use our boron-based drugs and could impact market acceptance of our products.

Additionally,
there can be no assurance that boron-based products will be free of significant adverse side effects. During clinical trials, a small number of our patients who received
AN2690 experienced some skin irritation around their toenails and a few patients who received AN2728 experienced some skin irritation around their psoriasis plaques. In addition, during the course of
a clinical trial of AN2728 for psoriasis, one serious adverse event was reported in a patient who developed a rash after receiving an injection of penicillin outside of the trial for a sore throat and
needed to be hospitalized for this non-life-threatening reaction. If boron-based drug treatments result in significant adverse side effects, they may not be useful as
therapeutic agents. If we are unable
to develop products that are safe and effective using our boron chemistry platform, our business will be materially and adversely affected.

If any of our product candidates for which we receive regulatory approval do not achieve broad market acceptance, the revenues that are generated from their sales will be
limited.

The commercial success of AN2690, AN2728, AN2898, GSK '052 or our other product candidates will depend upon the acceptance of these
products among physicians, patients and the medical community. The degree of market acceptance of our product candidates will depend on a number of factors, including:



40

---



Table of Contents



If
our product candidates are approved, but do not achieve an adequate level of acceptance by physicians, health care payors and patients, sufficient revenue may not be generated from
these products, and we may not become or remain profitable. In addition, efforts to educate the medical
community and third-party payors on the benefits of our product candidates may require significant resources and may never be successful.

We have never marketed a drug before, and if we are unable to establish an effective sales force and marketing infrastructure, or enter into acceptable third-party sales and
marketing or licensing arrangements, we may not be able to commercialize our product candidates successfully.

We plan to develop a sales and marketing infrastructure to market and sell our products in certain U.S. specialty markets. We currently
do not have any sales, distribution and marketing capabilities, the development of which will require substantial resources and will be time consuming. These costs may be incurred in advance of any
approval of our product candidates. In addition, we may not be able to hire a sales force in the United States that is sufficient in size or has adequate expertise in the medical markets that we
intend to target. If we are unable to establish our sales force and marketing capability, our operating results may be adversely affected. In addition, we plan to enter into sales and marketing or
licensing arrangements with third parties for non-specialty markets in the United States and for international sales of any approved products. If we are unable to enter into any such
arrangements on acceptable terms, or at all, we may be unable to market and sell our products in these markets.

We expect that our existing and future product candidates will face competition and most of our competitors have significantly greater resources than we do.

The pharmaceutical industry is highly competitive, with a number of established, large pharmaceutical companies, as well as many
smaller companies. Most of these companies have significant financial resources, marketing capabilities and experience in obtaining regulatory approvals for product candidates. There are many
pharmaceutical companies, biotechnology companies, public and private universities, government agencies and research organizations actively engaged in research and development of products that may
target the same markets as our product candidates. We expect any future products we develop to compete on the basis of, among other things, product efficacy, price, lack of significant adverse side
effects and convenience and ease of treatment.

Compared
to us, many of our potential competitors have substantially greater:



41

---





Table of Contents



As
a result of these factors, our competitors may obtain regulatory approval of their products more rapidly than we are able to or may obtain patent protection or other intellectual
property rights that limit our ability to develop or commercialize our product candidates. Our competitors may also develop drugs that are more effective, more widely used and less costly than ours
and may also be more successful than us in manufacturing and marketing their products.

The dermatology market is competitive, which may adversely affect our ability to commercialize our dermatological product candidates.

If AN2690 is approved for the treatment of onychomycosis, we anticipate that it would compete with other marketed nail fungal
therapeutics including Lamisil, Sporanox, Penlac and generic versions of those compounds. AN2690 will also compete against over-the-counter products and possibly various
devices under development for onychomycosis. If approved for the treatment of psoriasis, AN2728 will compete against a number of approved topical treatments, including Taclonex (a combination of
calcipotriene and the high potency corticosteroid betamethasone dipropionate), Dovonex (calcipotriene), Tazorac (tazarotene) and generic versions, where available. AN2728 would also compete against
systemic treatments for psoriasis, which include oral products such as methotrexate and cyclosporine and injected biologic products such as Enbrel, Remicade, Stelara, Simponi, Amevive, and Humira. A
number of other treatments are used for psoriasis, including light based treatments and non-prescription topical treatments. In atopic dermatitis, our product candidates, if approved,
would compete with other marketed atopic dermatitis therapeutics, which typically include combinations of antibiotics, antihistamines, topical corticosteroids and topical immunomodulators, such as
Elidel (pimecrolimus) and Protopic (tacrolimus).

Even
if a generic product or an over-the-counter product is less effective than our product candidates, a less effective generic or
over-the-counter product may be more quickly adopted by health insurers and patients than our competing product candidates based upon cost or convenience. In addition, each of
our product candidates may compete against product candidates currently under development by other companies.

Reimbursement decisions by third-party payors may have an adverse effect on pricing and market acceptance. If there is not sufficient reimbursement for our products, it is
less likely that our products will be widely used.

Successful commercialization of pharmaceutical products usually depends on the availability of adequate coverage and reimbursement from
third-party payors. Patients or healthcare providers who purchase drugs generally rely on third-party payors to reimburse all or part of the costs associated with such products. Adequate coverage and
reimbursement from governmental payors, such as Medicare and Medicaid, and commercial payors, such as HMOs and insurance companies, can be central to new product acceptance.

Current
treatments for onychomycosis are often not reimbursed by third-party payors. We do not know the extent to which AN2690 will be reimbursed if it is approved. Reimbursement
decisions by

42

---



Table of Contents

third-party
payors may have an effect on pricing and market acceptance. Our other product candidates, such as AN2728 and GSK '052, will also be subject to uncertain reimbursement decisions by
third-party payors. Our products are less likely to be used if they do not receive adequate reimbursement.

The
market for our product candidates may depend on access to third-party payors' drug formularies, or lists of medications for which third-party payors provide coverage and
reimbursement. Industry competition to be included in such formularies results in downward pricing pressures on pharmaceutical companies. Third-party payors may refuse to include a particular branded
drug in their formularies when a competing generic product is available.

All
third-party payors, whether governmental or commercial, are developing increasingly sophisticated methods of controlling healthcare costs. In addition, in the United States, no
uniform policy of coverage and reimbursement for medicines exists among all these payors. Therefore, coverage of and reimbursement for drugs can differ significantly from payor to payor and can be
difficult and costly to obtain.

Healthcare policy changes, including the Healthcare Reform Act, may have a material adverse effect on us.

Healthcare costs have risen significantly over the past decade. On March 23, 2010, the President signed one of the most
significant healthcare reform measures in decades. The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively, the
Healthcare Reform Act, substantially changes the way healthcare is financed by both governmental and private insurers, and significantly impacts the pharmaceutical industry. The Healthcare Reform Act
contains a number of provisions, including those governing enrollment in federal healthcare programs, reimbursement changes and fraud and abuse, which will impact existing government healthcare
programs and will result in the development of new programs, including Medicare payment for performance initiatives and improvements to the physician quality reporting system and feedback program. We
anticipate that if we obtain approval for our products, some of our revenue may be derived from U.S. government healthcare programs, including Medicare. Furthermore, beginning in 2011, the Healthcare
Reform Act imposed a non-deductible excise tax on pharmaceutical manufacturers or importers who sell "branded prescription drugs," which includes innovator drugs and biologics (excluding
orphan drugs or generics) to U.S. government programs. We expect that the Healthcare Reform Act and other healthcare reform measures that may be adopted in the future could have a material adverse
effect on our industry generally and our ability to successfully commercialize our products or could limit or eliminate our spending on development projects.

In
addition to the Healthcare Reform Act, there will continue to be proposals by legislators at both the federal and state levels, regulators and third-party payors to keep these costs
down while expanding individual healthcare benefits. Certain of these changes could impose limitations on the prices we will be able to charge for any products that are approved or the amounts of
reimbursement available for these products from governmental agencies or third-party payors or may increase the tax requirements for life sciences companies such as ours. While it is too early to
predict what effect the recently enacted Healthcare Reform Act or any future legislation or regulation will have on us, such laws could have a material adverse effect on our business, financial
position and results of operations.

We expect that a substantial portion of the market for our products will be outside the United States. Our product candidates may never receive approval or be commercialized
outside of the United States.

We plan to enter into sales and marketing arrangements with third parties for international sales of any approved products. To market
and commercialize any product candidates outside of the United States, we, GSK or any other third parties that are marketing or selling our products must establish and comply with numerous and varying
regulatory requirements of other countries regarding safety and efficacy. Approval procedures vary among countries and can involve additional product testing and

43

---



Table of Contents

additional
administrative review periods. The regulatory approval process in other countries may include all of the risks detailed above regarding failure to obtain FDA approval in the United States
as well as other risks. Regulatory approval in one country does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country may have a negative
effect on the regulatory process in others. Failure to obtain regulatory approval in other countries or any delay or setback in obtaining such approval could have the same adverse effects detailed
above regarding FDA approval in the United States. As described above, such effects include the risks that our product candidates may not be approved for all indications requested, or at all, which
could limit the uses of our product candidates and have an adverse effect on product sales and potential royalties, and that such approval may be subject to limitations on the indicated uses for which
the product may be marketed or require costly post-marketing follow-up studies.

Even if our product candidates receive regulatory approval, we may still face future development and regulatory difficulties.

Even if regulatory approval is obtained for any of our product candidates, regulatory authorities may still impose significant
restrictions on a product's indicated uses or marketing or impose ongoing requirements for potentially costly post-approval studies. Given the number of high profile adverse safety events
with certain drug products, regulatory authorities may require, as a condition of approval, costly risk evaluation and mitigation strategies, which may include safety surveillance, restricted
distribution and use, patient education, enhanced labeling, expedited reporting of certain adverse events, pre-approval of promotional materials and restrictions on
direct-to-consumer advertising. For example, any labeling approved for any of our product candidates may include a restriction on the term of its use, or it may not include one
or more of our intended indications. Furthermore, any new legislation addressing drug safety issues could result in delays or increased costs during the period of product development, clinical trials
and regulatory review and approval, as well as increased costs to assure compliance with any new post-approval regulatory requirements. Any of these restrictions or requirements could
force us or our partners to conduct costly studies.

Our
product candidates will also be subject to ongoing regulatory requirements for the labeling, packaging, storage, advertising, promotion, record-keeping and submission of safety and
other post-market information on the drug. In addition, approved products, manufacturers and manufacturers' facilities are required to comply with extensive FDA requirements, including
ensuring that quality control and manufacturing procedures conform to current Good Manufacturing Practices, or cGMP. As such, we and our contract manufacturers are subject to continual review and
periodic inspections to assess compliance with cGMP. Accordingly, we and others with whom we work must continue to expend time, money, and effort in all areas of regulatory compliance, including
manufacturing, production, and quality control. We will also be required to report certain adverse reactions and production problems, if any, to the FDA, and to comply with certain requirements
concerning advertising and promotion for our products. Promotional communications with respect to prescription drugs are subject to a variety of legal and regulatory restrictions and must be
consistent with the information in the product's approved label. As such, we may not promote our products for indications or uses for which they do not have approval.

If
a regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the
product is manufactured, or disagrees with the promotion, marketing, or labeling of a product, a regulatory agency may impose restrictions on that product or us, including requiring withdrawal of the
product from the market. If our product candidates fail to comply with applicable regulatory requirements, a regulatory agency may:



44

---



Table of Contents



Guidelines and recommendations published by various organizations may affect the use of our products.

Government agencies may issue regulations and guidelines directly applicable to us, GSK or our potential future partners and our
product candidates. In addition, professional societies, practice management groups, private health/science foundations, and organizations involved in various diseases from time to time publish
guidelines or recommendations to the health care and patient communities. These various sorts of recommendations may relate to such matters as product usage, dosage, route of administration and use of
related or competing therapies. Changes to these recommendations or other guidelines advocating alternative therapies could result in decreased use of our products, which may adversely affect our
results of operations.

Risks Related to Our Dependence on Third Parties

We are dependent on our existing third party collaborations to fund additional development opportunities and expect to continue to expend resources in our current
collaborations with GSK, Lilly and Medicis. These research collaborations may fail to successfully identify product candidates, or our collaboration partners may elect not to license, develop or
commercialize any of the resulting compounds, including, in the case of GSK, compounds in development by us with respect to which GSK has option rights as well as a compound (GSK '052) for which GSK
has sole development and commercialization rights. In the event our collaborator does not elect to exercise its option or elects not to develop or commercialize our collaboration candidate products,
our operating results and financial condition could be materially and adversely affected.

We
currently have three ongoing collaboration agreements: our most advanced arrangement, an October 2007 research and development collaboration, option and license agreement with GSK for
the discovery, development, manufacture and worldwide commercialization of novel systemic anti-infectives for viral and bacterial diseases utilizing our boron-based chemistry; an August
2010 collaborative research, license and commercialization agreement with Lilly for the discovery, development, and worldwide commercialization of animal health products for specific applications; and
a February 2011 research and development option and license agreement with Medicis for the discovery, development, and worldwide commercialization of novel boron-based compounds directed against a
specific target for the treatment of acne.

During
the research terms of the collaborations, we (and in some cases also our partner) are committed to use our diligent efforts to discover and develop compounds and to provide
specified resources, including certain numbers of full-time equivalent scientists, on a project-by-project basis. We are either reimbursed our research costs, or
each party is responsible for its own research costs, but in

45

---



Table of Contents

all
cases we expect to continue to expend resources on the collaborations. If we fail to successfully identify product candidates or, in some cases, demonstrate
proof-of-concept for those product candidates we identify, our operating results and financial condition could be materially and adversely affected. In addition, we may
mutually agree with our collaboration partner not to pursue all of the research activities contemplated under the applicable agreement. Our collaboration partners have the option, but are not
required, to exclusively
license or select for further development certain product candidates under the agreement once the product candidate meets specified criteria, subject to continuing obligations to make milestone
payments and royalty payments on commercial sales, if any, of such licensed compounds. Typically, the collaboration partner is obligated to make payments to us upon the achievement of certain initial
discovery and developmental milestones, but further, more significant milestone payments are payable only on compounds that the partner chooses to license or develop, such as GSK '052 in the case of
GSK. If we devote significant resources to a research project and our collaboration partner elects not to exercise its option with respect to or develop any resulting product candidates, our financial
condition could be materially and adversely affected. In certain cases, if our partner does not exercise a given option or terminates development, we may request a license to develop and commercialize
products containing the relevant compounds. If we make such request, we will be obligated to pay certain milestones and royalties if we elect to develop and commercialize such products.

If
our collaboration partner elects to license or develop a compound, like GSK has with GSK '052, the partner assumes sole responsibility for further development, regulatory approval and
commercialization of such compound. For example, under the GSK collaboration, we developed and GSK exercised an exclusive license to GSK '052, which is our lead systemic antibiotic for the treatment
of infections caused by Gram-negative bacteria. We are dependent on GSK for the further development and commercialization of this compound. Thus, even with respect to compounds that our
partner chooses to develop, the timing of development and future payments to us, including milestone and royalty payments, will depend on the extent to which such licensed compounds advance through
development, regulatory approval and commercialization by our partner. Additionally, our partner can choose to terminate the agreement with a specified notice period or its license to any compounds at
any time with no further obligation to develop and commercialize such compounds. In such event, we would not be eligible to receive further payments for the affected compounds. We would retain rights
to develop and market any such product candidates. However, we would be required to fund further development and commercialization ourselves or with other partners if we continue to pursue these
product candidates, and in some cases would owe our previous partner royalties to continue to develop and commercialize any such product candidates.

If
our partner does not devote sufficient resources to the research, development and commercialization of compounds identified through our research collaboration, including GSK in the
case of GSK '052, or is ineffective in doing so, our operating results could be materially and adversely affected. In particular, if our partner independently develops products that compete with our
compounds, it could elect to advance such products and not develop or commercialize our product candidates, even while complying with applicable exclusivity provisions. We cannot assure you that our
collaboration partners will fulfill their obligations under the agreements or develop and commercialize compounds identified by the research collaborations, including GSK in the case of GSK '052. If
our partners fail to fulfill their obligations under the agreements or terminate the agreements, we would need to obtain the capital necessary to fund the development and commercialization of the
returned compounds, enter into alternative arrangements with a third party or halt our development efforts in these areas. We could also become involved in disputes with our partners, which could lead
to delays in or termination of the research collaborations or the development and commercialization of identified product candidates and time-consuming and expensive litigation or
arbitration. If our partners terminate or breach their agreements with us or otherwise do not advance the compounds identified by

46

---



Table of Contents

our
research collaborations, our chances of successfully developing or commercializing such compounds could be materially and adversely affected.

We may not be successful in establishing and maintaining development and commercialization collaborations, which could adversely affect our ability to develop certain of our
product candidates and our financial condition and operating results.

Developing pharmaceutical products, conducting clinical trials, obtaining regulatory approval, establishing manufacturing capabilities
and marketing approved products is expensive. Consequently, we plan to establish collaborations for development and commercialization of product candidates and research programs. For example, if
AN2690, AN2728, AN2898 or any of our other product candidates receives marketing approval, we intend to enter into sales and marketing arrangements with third parties for non-specialty
markets in the United States and for international sales, and to develop our own sales force targeting dermatologists and other specialty markets in the United States. If we are unable to enter into
any such arrangements on acceptable terms, if at all, we may be unable to market and sell our products in these markets. We expect to face competition in seeking appropriate collaborators. Moreover,
collaboration arrangements are complex and time consuming to negotiate, document and implement and they may require substantial resources to maintain. We may not be successful in our efforts to
establish and implement collaborations or other alternative arrangements for the development of our product candidates. When we partner with a third party for development and commercialization of a
product candidate, we can expect to relinquish some or all of the control over the future success of that product candidate to the third party. Our collaboration partner may not devote sufficient
resources to the commercialization of our product candidates or may otherwise fail in their commercialization. The terms of any collaboration or other arrangement that we establish may not be
favorable to us. In addition, any collaboration that we enter into may be unsuccessful in the development and commercialization of our product candidates. In some cases, we may be responsible for
continuing preclinical and initial clinical development of a partnered product candidate or research program, and the payment we receive from our collaboration partner may be insufficient to cover the
cost of this development. If we are unable to reach agreements with
suitable collaborators for our product candidates we would face increased costs, we may be forced to limit the number of our product candidates we can commercially develop or the territories in which
we commercialize them and we might fail to commercialize products or programs for which a suitable collaborator cannot be found. If we fail to achieve successful collaborations, our operating results
and financial condition will be materially and adversely affected.

We depend on third-party contractors for a substantial portion of our operations and may not be able to control their work as effectively as if we performed these functions
ourselves.

We outsource substantial portions of our operations to third-party service providers, including chemical synthesis, biological
screening and manufacturing. Our agreements with third-party service providers and clinical research organizations are on a study-by-study basis and are typically
short-term. In all cases, we may terminate the agreements with notice and are responsible for the supplier's previously incurred costs.

Because
we have relied on third parties, our internal capacity to perform these functions is limited. Outsourcing these functions involves risk that third parties may not perform to our
standards, may not produce results in a timely manner or may fail to perform at all. In addition, the use of third-party service providers requires us to disclose our proprietary information to these
parties, which could increase the risk that this information will be misappropriated. There is a limited number of third-party service providers that specialize or have the expertise required to
achieve our business objectives. Identifying, qualifying and managing performance of third-party service providers can be difficult, time consuming and cause delays in our development programs. We
currently have a small number of

47

---



Table of Contents

employees,
which limits the internal resources we have available to identify and monitor our third-party providers. To the extent we are unable to identify, retain and successfully manage the
performance of third-party service providers in the future, our business may be adversely affected.

We have no experience manufacturing our product candidates on a large clinical or commercial scale and have no manufacturing facility. As a result, we are dependent on
numerous third parties for the manufacture of our product candidates and our supply chain, and if we experience problems with any of these suppliers, the manufacturing of our product candidates or
products could be delayed.

We do not own or operate facilities for the manufacture of our product candidates. We have a small number of personnel with experience
in drug product manufacturing. We
currently outsource all manufacturing and packaging of our preclinical and clinical product candidates to third parties and intend to continue to do so. Under our agreement with Schering, the
formulation for AN2690 was finalized and manufactured at one of Schering's GMP facilities. In November 2009, Schering merged with Merck, and in May 2010, we regained the worldwide rights to AN2690. As
part of the transition from Merck to us, we received sufficient drug product to initiate and sufficient active ingredient to complete our Phase 3 clinical trials of AN2690. We have transferred
manufacturing of additional supplies of AN2690 to a third-party manufacturer that operates in compliance with cGMP regulations and will need to scale up and manufacture additional active ingredient
and drug product in order to complete our NDA submission. The inability to manufacture sufficient supplies of the drug product could adversely effect clinical trial enrollment or timing or, if AN2690
is approved, product commercialization. We also outsource active ingredient process development work and product manufacturing to third parties for AN2728, AN2718 and AN2898. We do not currently have
any agreements with third-party manufacturers for the long-term commercial supply of our product candidates, including AN2690. We may encounter technical difficulties or delays in the
transfer of AN2690 manufacturing on a commercial scale to a third-party manufacturer. We may be unable to enter into agreements for commercial supply with third party manufacturers, or may be unable
to do so on acceptable terms. We may not be able to establish additional sources of supply for our products. Such suppliers are subject to regulatory requirements, covering manufacturing, testing,
quality control and record keeping relating to our product candidates and subject to ongoing inspections by the regulatory agencies. Failure by any of our suppliers to comply with applicable
regulations may result in long delays and interruptions to our product candidate supply while we seek to secure another supplier that meets all regulatory requirements.

Reliance
on third-party manufacturers entails risks to which we would not be subject if we manufactured the product candidates ourselves, including:



Any
of these factors could cause the delay of clinical trials, regulatory submissions, required approvals or commercialization of our products, cause us to incur higher costs and prevent
us from commercializing our product candidates successfully. Furthermore, if any of our product candidates are approved and contract manufacturers fail to deliver the required commercial quantities of
finished product on a timely basis and at commercially reasonable prices and we are unable to find one or more replacement manufacturers capable of production at a substantially equivalent cost, in
substantially equivalent volumes and quality and on a timely basis, we would likely be unable to meet demand for our products and could lose potential revenue. It may take several years to establish
an alternative source of supply for our product candidates and to have any such new source approved by the FDA.

48

---



Table of Contents

If we lose our relationships with contract research organizations, our drug development efforts could be delayed.

We are substantially dependent on third-party vendors and contract research organizations for preclinical studies and clinical trials
related to our drug discovery and development efforts. If we lose our relationship with any one or more of these providers, we could experience a significant delay in both identifying another
comparable provider and then contracting for its services, which could adversely affect our development efforts. We may be unable to retain an alternative provider on reasonable terms, if at all. Even
if we locate an alternative provider, it is likely that this provider will need additional time to respond to our needs and may not provide the same type or level of services as the original provider.
In addition, any contract research organization that we retain will be subject to the FDA's regulatory requirements and similar foreign standards and we do not have control over compliance with these
regulations by these providers. Consequently, if these practices and standards are not adhered to by these providers, the development and commercialization of our product candidates could be delayed,
which could severely harm our business and financial condition.

Risks Relating to Our Intellectual Property

It is difficult and costly to protect our proprietary rights, and we may not be able to ensure their protection.

Our commercial success will depend in part on obtaining and maintaining patent protection and trade secret protection of our current
and future product candidates and the methods used to manufacture them, as well as successfully defending these patents against third-party challenges. Our ability to stop third parties from making,
using, selling, offering to sell or importing our products is dependent upon the extent to which we have rights under valid and enforceable patents or trade secrets that cover these activities.

The
patent positions of pharmaceutical companies can be highly uncertain and involve complex legal and factual questions for which important legal principles remain unresolved. No
consistent policy regarding the breadth of claims allowed in pharmaceutical patents has emerged to date in the United States or in many foreign jurisdictions. Changes in either the patent laws or in
interpretations of patent laws in the United States and foreign jurisdictions may diminish the value of our intellectual property. Accordingly, we cannot predict the breadth of claims that may be
enforced in the patents that may be issued from the applications we currently or may in the future own or license from third parties. Further, if any patents we obtain or license are deemed invalid
and unenforceable, it could impact our ability to commercialize or license our technology.

The
degree of future protection for our proprietary rights is uncertain because legal means afford only limited protection and may not adequately protect our rights or permit us to gain
or keep our competitive advantage. For example:



49

---



Table of Contents

As
of February 15, 2011, we are the owner of record of 8 issued U.S. patents and 4 non-U.S. patents with claims to boron-containing compounds and methods of using
these compounds in various indications. We are actively pursuing, either solely or with a collaborator, 28 U.S. patent applications (10 provisional and 18 non-provisional), 16
international (PCT) patent applications and 103 non-U.S. patent applications in at least 39 jurisdictions. Of these actively pursued applications, 3 U.S. patent applications (2 provisional
and 1 non-provisional) and 1 international (PCT) patent application are solely owned by a collaborator as of February 15, 2011. In 2011, we estimate that we will allow 22
non-U.S. patents and 49 non-U.S. patent applications that do not relate to our clinical product candidates to expire or become abandoned and have not included such patents and
patent applications in the totals above.

Due
to the patent laws of a country, or the decisions of a patent examiner in a country, or our own filing strategies, we may not obtain patent coverage for all of the product candidates
or methods involving these candidates in the parent patent application. We plan to pursue divisional patent applications and/or continuation patent applications in the United States and many other
countries to obtain claim coverage for inventions which were disclosed but not claimed in the parent patent application.

We
also may rely on trade secrets to protect our technology, especially where we do not believe patent protection is appropriate or obtainable. However, trade secrets are difficult to
protect. Although we use reasonable efforts to protect our trade secrets, our employees, consultants, contractors, outside scientific collaborators and other advisors may unintentionally or willfully
disclose our information to competitors. Enforcing a claim that a third party illegally obtained and is using any of our trade secrets is expensive and time consuming, and the outcome is
unpredictable. In addition, courts outside the United States are sometimes less willing to protect trade secrets. Moreover, our competitors may independently develop equivalent knowledge, methods and
know-how. Our patent applications would not prevent others from taking advantage of the chemical properties of boron to discover and develop new therapies, including therapies for the
indications we are targeting. If others seek to develop boron-based therapies, their research and development efforts may inhibit our ability to conduct research in certain areas and expand our
intellectual property portfolio.

We may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights and we may be unable to enforce or
protect our rights to, or use, our technology.

If we choose to go to court to stop another party from using the inventions claimed in any patents we obtain, that individual or
company has the right to ask the court to rule that such patents are invalid or should not be enforced against that third party. These lawsuits are expensive and would consume time and resources and
divert the attention of managerial and scientific personnel even if we were successful in stopping the infringement of such patents. In addition, there is a risk that the court will decide that such
patents are not valid and that we do not have the right to stop the other party from using the inventions. There is also the risk that, even if the validity of such patents is upheld, the court will
refuse to stop the other party on the ground that such other party's activities do not infringe our rights to such patents. In addition, the U.S. Supreme Court has recently modified some tests used by
the U.S. Patent Office in granting patents over the past 20 years, which may decrease the likelihood that we will be able to obtain patents and increase the likelihood of challenge of any
patents we obtain or license.

Furthermore,
a third party may claim that we or our manufacturing or commercialization partners are using inventions covered by the third party's patent rights and may go to court to
stop us from engaging in our normal operations and activities, including making or selling our product candidates. These lawsuits are costly and could affect our results of operations and divert the
attention of managerial and scientific personnel. There is a risk that a court would decide that we or our commercialization partners are infringing the third party's patents and would order us or our
partners

50

---



Table of Contents

to
stop the activities covered by the patents. In that event, we or our commercialization partners may not have a viable way around the patent and may need to halt commercialization of the relevant
product with it. In addition, there is a risk that a court will order us or our partners to pay the other party damages for having violated the other party's patents. In the future, we may agree to
indemnify our commercial partners against certain intellectual property infringement claims brought by third
parties. The pharmaceutical and biotechnology industries have produced a proliferation of patents, and it is not always clear to industry participants, including us, which patents cover various types
of products or methods of use. The coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform. If we are sued for patent infringement, we would need
to demonstrate that our products or methods either do not infringe the patent claims of the relevant patent or that the patent claims are invalid, and we may not be able to do this. Proving invalidity
is difficult. For example, in the United States, proving invalidity requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents.

Because
some patent applications in the United States may be maintained in secrecy until the patents are issued, because patent applications in the United States and many foreign
jurisdictions are typically not published until eighteen months after filing, and because publications in the scientific literature often lag behind actual discoveries, we cannot be certain that
others have not filed patent applications for technology covered by our pending applications, or that we were the first to invent the technology. Our competitors may have filed, and may in the future
file, patent applications covering technology similar to ours. Any such patent application may have priority over our patent applications, which could further require us to obtain rights to issued
patents covering such technologies. If another party has filed a U.S. patent application on inventions similar to ours, we may have to participate in an interference proceeding declared by the U.S.
Patent and Trademark Office to determine priority of invention in the United States. The costs of these proceedings could be substantial, and it is possible that such efforts would be unsuccessful if,
unbeknownst to us, the other party had independently arrived at the same or similar invention prior to our own invention, resulting in a loss of our U.S. patent position with respect to such
inventions.

Patents
covering the composition of matter of AN2690 and AN2718 that were owned by others have expired. Our patent applications and patents include or support claims on other aspects of
AN2690 or AN2718, such as pharmaceutical formulations containing AN2690 or AN2718, methods of using AN2690 or AN2718 to treat disease and methods of manufacturing AN2690 or AN2718. Without patent
protection on the composition of matter of AN2690 or AN2718, our ability to assert our patents to stop others from using or selling AN2690 or AN2718 in a non-pharmaceutically acceptable
formulation may be limited.

Some
of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. In addition, any
uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations.

We do not have exclusive rights to intellectual property we developed under U.S. federally funded research grants and contracts in connection with certain of our neglected
diseases initiatives, and, in the case of U.S. funded research, we could ultimately lose the rights we do have under certain circumstances.

Some of our intellectual property rights related to compounds that are not in clinical development as of February 15, 2011 were
initially developed in the course of research funded by the U.S. government. As a result, the U.S. government may have certain rights to intellectual property embodied in our current or future
products pursuant to the Bayh-Dole Act of 1980. Government rights in certain inventions developed under a government-funded program include a non-exclusive,
non-transferable, irrevocable worldwide license to use inventions for any governmental purpose. In addition, the U.S. government has the right to require us to grant exclusive licenses to
any of these inventions to a third

51

---



Table of Contents

party
if they determine that: (i) adequate steps have not been taken to commercialize the invention; (ii) government action is necessary to meet public health or safety needs; or
(iii) government action is necessary to meet requirements for public use under federal regulations. The U.S. government also has the right to take title to these inventions if we fail to
disclose the invention to the government and fail to file an application to register the intellectual property within specified time limits. In addition, the U.S. government may acquire title in any
country in which a patent application is not filed within specified time limits.

Some
of our intellectual property rights related to boron-containing compounds that are not in clinical development as of February 15, 2011 were developed through a collaboration
with the Drugs for Neglected Diseases initiative, or DNDi. We accept research funding from DNDi. We have a co-exclusive, royalty-free, sublicensable license with DNDi to make,
use, import and manufacture a product for treatment of human African trypanosomiasis, Chagas disease, and cutaneous and visceral leishmaniasis in humans in all countries of the world, specifically
excluding Japan, Australia, New Zealand, Russia, China, and all countries of North America and Europe, or DNDi Territory. We also grant to DNDi an exclusive, royalty-free, sublicensable
license to distribute, including uses by, or on behalf of, a public sector agency, a product containing molecules synthesized under the research plan for treatment of human African trypanosomiasis,
Chagas disease, and cutaneous and visceral leishmaniasis in humans in the DNDi Territory. As a result, we may not be able to realize any revenue in the DNDi Territory for any human therapeutics that
we discover for these diseases. As of February 15, 2011, the boron-containing compounds being studied in this collaboration are structurally distinct from our five clinical product candidates.
As of February 15, 2011, none of our five clinical product candidates are being considered for use in the DNDi collaboration.

Some
of our intellectual property rights related to boron-containing compounds that are not in clinical development as of February 15, 2011 were developed through a collaboration
with the Global Alliance for TB Drug Development, or TB Alliance. We accept research funding from the TB Alliance, and we provide the TB Alliance with a non-exclusive, worldwide,
royalty-free, sublicensable license to make, have made, use, sell, offer for sale and import for the purpose of
treating tuberculosis, boron-containing small molecule compounds that have a high level of effectiveness against the bacteria associated with tuberculosis, but a low level of effectiveness against
certain other bacteria which are associated with other human diseases. As a result, we may not be able to realize any revenue from any human therapeutics generated under the agreement for
tuberculosis. As of February 15, 2011, the boron-containing compounds under development in this collaboration are structurally distinct from our five clinical product candidates. As of
February 15, 2011, none of our five clinical product candidates are being considered for use in the TB Alliance collaboration.

Some
of our intellectual property rights related to boron-containing compounds that are not in clinical development as of February 15, 2011 were developed through a collaboration
with Medicines for Malaria Venture, or MMV. We accept research funding from MMV, and we provide MMV with a worldwide, royalty-free non-exclusive license (without the right to
sublicense, except with prior Anacor written approval) to intellectual property rights arising under the collaboration to develop human therapeutics for the treatment of malaria under the agreement.
If the research is successful, we are obligated to negotiate in good faith with MMV a preclinical and clinical development agreement and compound license. As of February 15, 2011, the
boron-containing compounds under development in this collaboration are structurally distinct from our five clinical product candidates. As of February 15, 2011, none of our five clinical
product candidates are being considered for use in the MMV collaboration.

52

---





Table of Contents

Risks Related to Employee Matters and Managing Growth

We will need to expand our operations and increase the size of our company, and we may experience difficulties in managing growth.

As we increase the number of product development programs we have underway and advance our product candidates through preclinical
studies and clinical trials, we will need to increase our product development, scientific and administrative headcount to manage these programs. In addition, to meet our obligations as a public
company, we will need to increase our general and administrative headcount. Our management, personnel and systems currently in place may not be adequate to support this future growth. Our need to
effectively manage our operations, growth and various projects requires that we:



If
we are unable to successfully manage this growth, our business may be adversely affected.

We may not be able to manage our business effectively if we are unable to attract and retain key personnel.

We may not be able to attract or retain qualified management, finance, scientific and clinical personnel in the future due to the
intense competition for qualified personnel among biotechnology, pharmaceutical and other businesses, particularly in Northern California. If we are not able to attract and retain necessary personnel
to accomplish our business objectives, we may experience constraints that will significantly impede the achievement of our development objectives, our ability to raise additional capital and our
ability to implement our business strategy.

Our
industry has experienced a high rate of turnover of management personnel in recent years. We are highly dependent on the development, regulatory, commercialization and business
development expertise of our executive officers and key employees. If we lose one or more of our executive officers or key employees, our ability to implement our business strategy successfully could
be seriously harmed. We have entered into change of control and severance agreements with each of our officers as part of our retention efforts. Replacing executive officers and key employees may be
difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to develop, gain regulatory approval
of and commercialize products successfully. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these additional key personnel. Our failure
to retain key personnel could materially harm our business.

If we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired, which would
adversely affect our business and our stock price.

As a new public company, following our November 2010 initial public offering, we operate in an increasingly demanding regulatory
environment, which requires us to comply with the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, and the related rules and regulations of the Securities and Exchange Commission, expanded
disclosure requirements, accelerated reporting requirements and more complex accounting rules. Company responsibilities required by the Sarbanes-Oxley Act include establishing adequate internal
control over financial reporting and disclosure controls and procedures. Effective internal controls are necessary for us to produce reliable financial reports and are important

53

---



Table of Contents

to
help prevent financial fraud. The growth of our operations and our initial public offering created a need for additional resources within the accounting and finance functions in order to produce
timely financial information and to create the level of segregation of duties customary for a U.S. public company.

Our
management is responsible for establishing and maintaining adequate internal control over financial reporting to provide reasonable assurance regarding the reliability of our
financial reporting and the preparation of financial statements for external purposes in accordance with U.S. generally accepted accounting principles. Our management does not expect that our internal
control over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that
the control system's objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or
fraud will not occur or that all control issues and instances of fraud, if any, within our company will have been detected.

We
will be required for the first time to comply with Section 404 of the Sarbanes-Oxley Act, or Section 404, in connection with our Annual Report on
Form 10-K for the year ending December 31, 2011. We expect to expend significant resources in developing the necessary documentation and testing procedures required by
Section 404. We cannot be certain that the actions we will be taking to improve our internal control over financial reporting will be sufficient, or that we will be able to implement our
planned processes and procedures in a timely manner. In addition, if we are unable to produce accurate financial statements on a timely basis, investors could lose confidence in the reliability of our
financial statements, which could cause the market price of our common stock to decline and make it more difficult for us to finance our operations and growth.

Other Risks Relating to Our Business

We face potential product liability exposure, and if successful claims are brought against us, we may incur substantial liability for a product candidate and may have to
limit its commercialization.

The use of our product candidates in clinical trials and the sale of any products for which we may obtain marketing approval expose us
to the risk of product liability claims. Product liability claims may be brought against us or our partners by participants enrolled in our clinical trials, patients, health care providers or others
using, administering or selling our products. If we cannot successfully defend ourselves against any such claims, we would incur substantial liabilities. Regardless of merit or eventual outcome,
product liability claims may result in:



We
have obtained limited product liability insurance coverage for our clinical trials domestically and in selected foreign countries where we are conducting clinical trials. Our coverage
is currently limited to $5.0 million per occurrence and $5.0 million in the aggregate per year. As such, our insurance coverage may not reimburse us or may not be sufficient to reimburse
us for any expenses or

54

---



Table of Contents

losses
we may suffer. Moreover, insurance coverage is becoming increasingly expensive, and, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient
amounts to protect us against losses due to product liability. We intend to expand our insurance coverage for products to include the sale of commercial products if we obtain marketing approval for
our product candidates in development, but we may be unable to obtain commercially reasonable product liability insurance for any products approved for marketing. Large judgments have been awarded in
class action lawsuits based on drugs that had unanticipated side effects. A successful product liability claim or series of claims brought against us, particularly if judgments exceed our insurance
coverage, could decrease our cash and adversely affect our business.

Our operations involve hazardous materials, which could subject us to significant liabilities.

Our research and development processes involve the controlled use of hazardous materials, including chemicals. Our operations produce
hazardous waste products. We cannot eliminate the risk of accidental contamination or discharge or injury from these materials. Federal, state and local laws and regulations govern the use,
manufacture, storage, handling and disposal of these materials. We could be subject to civil damages in the event of exposure of individuals to hazardous materials. In addition, claimants may sue us
for injury or contamination that results from our use of these materials and our liability may exceed our total assets. We have general liability insurance of up to $5.0 million per occurrence,
with an annual aggregate limit of $6.0 million, which excludes
pollution liability. This coverage may not be adequate to cover all claims related to our biological or hazardous materials. Furthermore, if we were to be held liable for a claim involving our
biological or hazardous materials, this liability could exceed our insurance coverage, if any, and our other financial resources. Compliance with environmental and other laws and regulations may be
expensive and current or future regulations may impair our research, development or production efforts.

Our insurance policies are expensive and protect us only from some business risks, which will leave us exposed to significant uninsured liabilities.

We do not carry insurance for all categories of risk that our business may encounter. For example, we do not carry earthquake
insurance. In the event of a major earthquake in our region, our business could suffer significant and uninsured damage and loss. Some of the policies we currently maintain include general liability,
employment practices liability, property, auto, workers' compensation, products liability and directors' and officers' insurance. We do not know, however, if we will be able to maintain existing
insurance with adequate levels of coverage. Any significant uninsured liability may require us to pay substantial amounts, which would adversely affect our cash position and results of operations.

Risks Relating to Owning Our Common Stock

Our executive officers, directors and principal stockholders have the ability to control all matters submitted to our stockholders for approval.

As of February 15, 2011 our executive officers, directors and stockholders who own more than 5% of our outstanding common stock,
together beneficially own shares representing more than 80% of our common stock. As a result, if these stockholders were to choose to act together, they would be able to control all matters submitted
to our stockholders for approval, as well as our management and affairs. For example, these persons, if they choose to act together, will control the election of directors and approval of any merger,
consolidation, sale of all or substantially all of our assets or other business combination or reorganization. This concentration of voting power could delay or prevent an acquisition of us on terms
that other stockholders may desire. The interests of this group of stockholders may not always coincide with your interests or the interests of other stockholders and they may act in a manner that
advances their best interests and not necessarily those of other stockholders,

55

---



Table of Contents

including
seeking a premium value for their common stock, and might affect the prevailing market price for our common stock.

We do not anticipate paying cash dividends, and accordingly, stockholders must rely on stock appreciation for any return on their investment.

We do not anticipate paying cash dividends in the future. As a result, only appreciation of the price of our common stock, which may
never occur, will provide a return to stockholders. Investors seeking cash dividends should not invest in our common stock. In addition, our ability to pay cash dividends is currently prohibited by
the terms of our loan and security agreement with Oxford Finance Corporation and Horizon Technology Finance Corporation.

Our share price may be volatile and could decline significantly.

The market price of shares of our common stock could be subject to wide fluctuations in response to many risk factors listed in this
section, and others beyond our control, including:



Furthermore,
the stock markets have experienced extreme price and volume fluctuations that have affected and continue to affect the market prices of equity securities of many companies.
These fluctuations often have been unrelated or disproportionate to the operating performance of those companies. These broad market and industry fluctuations, as well as general economic, political
and market conditions such as recessions, interest rate changes or international currency fluctuations, may

56

---



Table of Contents

negatively
impact the market price of shares of our common stock. You may not realize any return on an investment in us and may lose some or all of your investment.

We may be subject to securities litigation, which is expensive and could divert management attention.

Our share price may be volatile, and in the past companies that have experienced volatility in the market price of their stock have
been subject to securities class action litigation. We may be the target of this type of litigation in the future. Securities litigation against us could result in substantial costs and divert our
management's attention from other business concerns, which could seriously harm our business.

A significant portion of our total outstanding shares of common stock is restricted from immediate resale but may be sold into the market in the near future. This could
cause the market price of our common stock to drop significantly, even if our business is doing well.

Sales of a substantial number of shares of our common stock in the public market could occur in the future. These sales, or the
perception in the market that the holders of a large number of shares of common stock intend to sell shares, could reduce the market price of our common stock. Sales of 14,614,227 shares of our common
stock are currently restricted under securities laws or as a result of lock-up agreements but will be able to be resold beginning upon expiration of the lock-up agreements,
which will occur in May 2011, unless extended under certain circumstances. Moreover, holders of an aggregate of 13,318,572 shares of our common stock have rights, subject to some conditions, to
require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders.

As a public company we are subject to additional expenses and administrative burden.

As a new public company, we incur significant legal, accounting and other expenses that we did not incur as a private company. In
addition, our administrative staff are required to perform additional tasks. For example, we must adopt additional internal controls and disclosure controls and procedures, retain a transfer agent and
bear all of the internal and external costs of preparing and distributing periodic public reports in compliance with our obligations under the securities laws.

In
addition, changing laws, regulations and standards relating to corporate governance and public disclosure, including the Sarbanes-Oxley Act and related regulations implemented by the
Securities and Exchange Commission and the NASDAQ Global Market, are creating uncertainty for public companies, increasing legal and financial compliance costs and making some activities more time
consuming. We are currently evaluating and monitoring these rules and proposed changes to rules, and cannot predict or estimate the amount of additional costs we may incur or the timing of such costs.
These laws, regulations and standards are subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as
new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure
and governance practices. We intend to invest resources to comply with evolving laws, regulations and standards, and this investment will result in increased general and administrative expenses and
may divert management's time and attention from product development activities. If our efforts to comply with new laws, regulations and standards differ from the activities intended by regulatory or
governing bodies due to ambiguities related to practice, regulatory authorities may initiate legal proceedings against us and our business may be harmed. In the future, it may be more expensive for us
to obtain director and officer liability insurance, and we may be required to accept reduced coverage or incur substantially higher costs to obtain coverage. These factors could also make it more
difficult for us to attract and retain qualified members of our board of directors, particularly to serve on our audit committee and compensation committee, and qualified executive officers.

57

---



Table of Contents

Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more
difficult and may prevent attempts by our stockholders to replace or remove our current management.

Provisions in our amended and restated certificate of incorporation and our bylaws may delay or prevent an acquisition of us. In
addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our
board of directors, who are responsible for
appointing the members of our management team. In addition, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which prohibits, with some exceptions,
stockholders owning in excess of 15% of our outstanding voting stock from merging or combining with us. Finally, our charter documents establish advanced notice requirements for nominations for
election to our board of directors and for proposing matters that can be acted upon at stockholder meetings. Although we believe these provisions together provide for an opportunity to receive higher
bids by requiring potential acquirers to negotiate with our board of directors, they would apply even if the offer may be considered beneficial by some stockholders.

ITEM 1B.    UNRESOLVED STAFF COMMENTS

None.

ITEM 2.    PROPERTIES

We lease a 36,960 square-foot building consisting of office and laboratory space in Palo Alto, California, which serves as
our corporate headquarters. The lease term commenced in March 2008 and has scheduled annual rent increases through the lease expiration in March 2018. We also have a lease for a 15,300
square-foot building consisting of office and laboratory space in Palo Alto, California, which we extended through December 2011 and is cancelable with four months' notice. We believe that
the facilities that we currently lease are adequate for our needs for the immediate future and that, should it be needed, additional space can be leased to accommodate any future growth.

ITEM 3.    LEGAL PROCEEDINGS

We are not currently a party to any material litigation or other material legal proceedings.

ITEM 4.    RESERVED

58

---





Table of Contents

PART II

ITEM 5.    MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

PRICE RANGE OF COMMON STOCK

Our common stock began trading on the NASDAQ Global Market under the symbol "ANAC" on November 24, 2010. Prior to this date,
there was no public market for our common stock. The following table sets forth the high and low closing prices of our common stock for the period indicated since our initial public offering, or IPO,
as reported on the NASDAQ Global Market.

High

LowNovember 24, 2010 to December 31, 2010

$
5.37

$
4.90


As
of February 28, 2011, there were 27,996,928 shares of our common stock issued and outstanding with approximately 67 stockholders of record. A significantly larger number of
stockholders may be "street name" or beneficial holders, whose shares of record are held by banks, brokers and other financial institutions.

59

---



Table of Contents

STOCK PRICE PERFORMANCE GRAPH

The following stock performance graph compares our total stock return with the total return for (i) the NASDAQ Composite Index
and the (ii) the NASDAQ Biotechnology Index for the period from November 24, 2010 (the date our common stock commenced trading on the NASDAQ Global Market) through December 31,
2010. The figures represented below assume an investment of $100 in our common stock at the closing price of $5.09 on November 24, 2010 and in the NASDAQ Composite Index and the NASDAQ
Biotechnology Index on November 24, 2010 and the reinvestment of dividends into shares of common stock. The comparisons in the table are required by the Securities and Exchange Commission, or
SEC, and are not intended to forecast or be indicative of possible future performance of our common stock. This graph shall not be deemed "soliciting material" or be deemed "filed" for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, or otherwise subject to the liabilities under that Section, and shall not be deemed to be incorporated by
reference into any of our filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language
in any such filing.

CHART

$100 investment in stock or index

Ticker

11/24/10

Nov 10

Dec 10Anacor

ANAC


100.00


98.23


105.50NASDAQ Composite Index

IXIC


100.00


98.23


104.32NASDAQ Biotechnology Index

NBI


100.00


97.76


104.51


DIVIDEND POLICY

We have never declared or paid any cash dividends. We currently expect to retain earnings for use in the operation and expansion of our
business, and therefore do not anticipate paying any cash dividends in the foreseeable future. In addition, our ability to pay cash
dividends is currently prohibited by the terms of our loan and security agreement with Oxford Finance Corporation and Horizon Technology Finance Corporation.

60

---



Table of Contents

USE OF PROCEEDS

Under the Registration Statement on Form S-1, as amended (File No. 333-169322) that was declared
effective on November 23, 2010, we registered the offering and sale of an aggregate of 13,800,000 shares of our common stock, including 1,800,000 shares pursuant to an
over-allotment option granted to the underwriters. 13,382,651 shares of common stock registered under the Registration Statement, which included 1,382,651 shares of our common stock sold
pursuant to the exercise an over-allotment option granted to the underwriters, were sold at a price to the public of $5.00 per share. The aggregate offering price for shares sold in the
offering was $66,913,255. Citigroup Global Markets Inc. and Deutsche Bank Securities, Inc. acted as joint book running managers for the offering, and Cowen and Company, LLC and
Wedbush PacGrow Life Sciences acted as co-managers for the offering. The offering commenced on November 24, 2010 and closed on November 30, 2010. The sale of shares pursuant
to the over-allotment occurred on December 28, 2010.

Concurrent
with the closing of the IPO on November 30, 2010, we completed a private placement offering to affiliates of an existing investor for 2,000,000 shares of common stock
at a price of $5.00 per share (see Recent Sale of Unregistered Securities). As a result of our IPO and concurrent private placement offering, we raised a total of $76.9 million in gross
proceeds, and approximately $71.0 million in net proceeds after deducting underwriting discounts of $3.2 million and estimated offering expenses of $2.7 million paid by us. We did
not pay, directly or indirectly, any offering expenses to any of our directors or officers or persons owning ten percent or more our securities or to their associates, or to our affiliates, other than
payments in the ordinary course of business to officers for salaries and to non-employee directors as compensation for board or board committee service.

There
has been no material change in our planned use of proceeds from the IPO from that described in the final prospectus filed with the SEC pursuant to Rule 424(b) on
November 24, 2010. We invested the funds received in a variety of capital preservation instruments, including short- and long-term interest-bearing obligations, direct or guaranteed
obligations of the U.S. government, certificates of deposit and money market funds.

RECENT SALE OF UNREGISTERED SECURITIES

On November 30, 2010, we sold and issued 2,000,000 shares of common stock to Venrock Healthcare Capital Partners, L.P.
and VHCP Co-Investment Holdings, LLC (affiliates of an existing investor), or Venrock, at a price of $5.00 per share in a private placement offering for aggregate gross proceeds of
$10.0 million pursuant to a common stock purchase agreement dated as of November 23, 2010. The private placement offering closed concurrently with the closing of our IPO of shares of our
common stock. The sale and issuance of shares of common stock in the private placement was made in reliance on Rule 506 promulgated under the Securities Act of 1933, as amended, and was made
without general solicitation or advertising. Each purchaser represented that it was an accredited investor with access to information about us sufficient to evaluate the investment and that the common
stock being acquired constituted restricted securities. Pursuant to a registration rights agreement, we granted certain registration rights pursuant to which, under certain conditions, we will
register shares of common stock held by Venrock affiliates, including the shares of common stock sold in the private placement offering, for resale on a registration statement on
Form S-3.

61

---





Table of Contents

ITEM 6.    SELECTED FINANCIAL DATA

The following selected data are derived from our financial statements which have been audited by Ernst & Young LLP,
independent registered public accounting firm. Ernst & Young LLP's report on the financial statements for the year ended December 31, 2010 appears elsewhere herein. The data in
the tables below should be read together with our financial statements and accompanying notes and "Management's Discussion and Analysis of Financial Condition and Results of Operations" appearing
elsewhere in this Annual Report on Form 10-K. The selected financial data in this section is not intended to replace our financial statements and the accompanying notes. Our
historical results are not necessarily indicative of our future results.

The
statements of operations data for 2006 and 2007 and the balance sheet data as of December 31, 2006, 2007 and 2008 were derived from our audited financial statements not
included in this report. The statements of operations data for 2008, 2009 and 2010 and the balance sheet data as of December 31, 2009 and 2010 were derived from our audited financial statements
appearing elsewhere in this report.

Year Ended December 31,2006

2007

2008

2009

2010(in thousands, except share and per share data)Statement of Operations Data:Revenues:Contract revenue

$


$
20,738

$
19,776

$
9,793

$
8,448Contract revenue-related party





500


5,300


8,850


17,909Government contract and grant revenue


861


51








1,467Total revenues


861


21,289


25,076


18,643


27,824Operating expenses:Research and development


16,627


24,597


36,189


34,083


29,866General and administrative


3,629


7,924


10,171


7,054


7,452Total operating expenses


20,256


32,521


46,360


41,137


37,318Loss from operations


(19,395
)

(11,232
)

(21,284
)

(22,494
)

(9,494
)Interest income


311


1,469


500


154


25Interest expense


(369
)

(1,268
)

(2,298
)

(2,434
)

(2,005
)Other income (expense)


(136
)

(580
)

1,413


(80
)

1,416Loss before income tax benefit


(19,589
)

(11,611
)

(21,669
)

(24,854
)

(10,058
)Income tax benefit








44


15


Net loss

$
(19,589
)
$
(11,611
)
$
(21,625
)
$
(24,839
)
$
(10,058
)Net loss per common sharebasic and diluted

$
(15.87
)
$
(8.48
)
$
(15.39
)
$
(17.55
)
$
(2.71
)Weighted-average number of common shares used in calculating net loss per common sharebasic and diluted(1)


1,234,538


1,368,999


1,405,140


1,415,083


3,705,505


(1)Please
see Note 2 to our audited financial statements for an explanation of the method used to calculate basic and diluted net loss per common share
attributable to common stockholders and the number of shares used in the computation of the per share amounts.


As of December 31,2006

2007

2008

2009

2010(in thousands)Balance Sheet Data:Cash, cash equivalents and short-term investments

$
5,236

$
32,491

$
47,305

$
14,503


78,591Working capital (deficit)


2,304


4,189


29,836


3,633


66,687Total assets


6,517


37,873


54,515


17,945


83,964Notes payable


7,863


8,262


14,289


10,724


7,741Convertible preferred stock


37,637


37,637


87,473


87,473


Accumulated deficit


(43,047
)

(54,658
)

(76,283
)

(101,122
)

(111,180
)Total stockholders' equity (deficit)


(42,530
)

(53,211
)

(72,911
)

(95,284
)

56,393


62

---





Table of Contents

ITEM 7.    MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

You should read the following discussion and analysis together with our financial statements and the notes to
those statements included elsewhere in this Annual Report on Form 10-K. This discussion contains forward-looking statements that involve risks and uncertainties. As a result of many
factors, such as those set forth under "Risk Factors" and elsewhere in this Annual Report on Form 10-K, our actual results may differ materially from those anticipated in these
forward-looking statements.

Overview

We are a biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapeutics derived
from our boron chemistry platform. We have discovered, synthesized and developed five molecules that are currently in clinical development.

Our
three lead programs are: AN2690, a topical antifungal for the treatment of onychomycosis, a fungal infection of the nail and nail bed; AN2728, a topical anti-inflammatory
for the treatment of psoriasis and atopic dermatitis; and GSK '052, a systemic antibiotic for the treatment of infections caused by Gram-negative bacteria. Our most advanced product
candidate is AN2690. We initiated our Phase 3 clinical trials for AN2690 in the fourth quarter of 2010. In June 2010, we completed a Phase 2b dose-ranging trial in psoriasis
for AN2728, and we initiated a final Phase 2b clinical trial in psoriasis in the first quarter of 2011. In June 2010, we completed a Phase 1 trial of GSK2251052, or GSK '052 (formerly
referred to as AN3365), and achieved proof-of-concept as defined under our collaboration agreement with GlaxoSmithKline LLC, or GSK. In July 2010, GSK exercised its
option to obtain an exclusive license to develop and commercialize GSK '052 and paid us an option exercise fee of $15.0 million in August 2010. In addition to our three lead programs, we have
two other clinical product candidates, AN2718, our second topical antifungal product candidate, and AN2898, our second topical anti-inflammatory product candidate. We also have a pipeline
of internally discovered topical and systemic boron-based compounds in development. In August 2010, we entered into a collaboration with Eli Lilly and Company, or Lilly, under which we will
collaborate to discover products for a variety of animal health applications and in February 2011, we entered into a research and development collaboration with Medicis Pharmaceutical Corporation, or
Medicis, to discover and develop compounds directed against a target for the potential treatment of acne.

In
February 2007, we entered into an exclusive license, development and commercialization agreement with Schering Corporation, or Schering, for the development and worldwide
commercialization of AN2690. Pursuant to the agreement, Schering paid us a $40.0 million non-refundable, non-creditable upfront fee and assumed sole responsibility for
development and commercialization of AN2690. In addition, in accordance with the agreement, Schering invested $10.0 million in a preferred stock financing completed in December 2008. The
agreement also obligated Schering to pay all of the remaining costs for development and commercialization of AN2690, including paying us for our development-related activities to transition AN2690 to
Schering. In November 2009, Schering merged with Merck & Co., Inc., or Merck, and in May 2010, we entered into a mutual termination and release agreement with Merck. Under this
agreement we regained the exclusive worldwide rights to AN2690, Merck paid us $5.8 million and we released each other from any and all claims, liabilities or other types of obligations under
the 2007 agreement. Merck did not retain any rights to this compound.

In
October 2007, we entered into a research and development collaboration, option and license agreement with GSK for the discovery, development and worldwide commercialization of
boron-based systemic anti-infectives. Under the agreement, we are currently working to identify and develop multiple product candidates in three target-based project areas.

63

---



Table of Contents

In
each project, GSK has the option to obtain an exclusive license to develop, commercialize and market worldwide a specified number of product candidates once such candidates have
achieved certain proof-of-concept criteria. We are primarily responsible for the discovery and development of each product candidate from the research stage until GSK exercises
an option for such product candidate, at which point GSK will assume sole responsibility for the further development and commercialization of such product candidate on a worldwide basis. During the
research term, we are committed to use reasonable efforts to discover and optimize compounds pursuant to agreed research plans and to provide specified resources, including certain numbers of
full-time equivalent scientists, on a project-by-project basis. Each party is responsible for its own research and development costs.

Pursuant
to the agreement, GSK paid us a $12.0 million non-refundable, non-creditable upfront fee in October 2007. In addition, GSK is obligated to make
payments to us if certain development, regulatory and commercial milestones are met on a compound-by-compound basis, which range from up to $252.8 million to
$330.5 million in the aggregate per product candidate, depending on the product profile of the candidate. Milestone payments may be lower for designated programs depending upon: whether GSK
makes the selection of the product candidate before or after initiation of Phase I clinical trial dosing (10%-15% reduction if selected before such dosing); if certain target
product profile characteristics are not achieved (20%-40% reduction); and whether the product candidate is designated after the initial two product candidate designations in a program (50%
reduction). GSK is further obligated to pay us tiered double-digit royalties with the potential to reach the mid-teens on annual net sales of products containing optioned compounds in
jurisdictions where there is a valid patent claim covering composition of matter or method of use of the product and lesser royalties for sales in jurisdictions where there is no such valid patent
claim. Such royalties shall continue until the later of expiration of such valid patent claims or ten years from the first commercial sale on a product-by-product and
country-by-country basis. GSK also invested $30.0 million in a preferred stock financing completed in December 2008, at which time GSK became a related party.
Subsequently, in November 2010, GSK invested an additional $5.0 million in our common stock in connection with our initial public offering, or IPO. From execution of the agreement through
December 31, 2010, in addition to the $12.0 million upfront payment, we have received $25.1 million for achievement of performance milestones, including milestones related to GSK
'052 for lead declaration, candidate selection, first patient dosing in a clinical trial and an option to obtain an exclusive license to develop and commercialize GSK '052. GSK has assumed
responsibility for further development of GSK '052 and any resulting commercialization.

In
August 2010, we entered into a collaboration agreement with Lilly, under which the companies will collaborate to discover products for a variety of animal health applications. Lilly
will be responsible for worldwide development and commercialization of compounds advancing from these efforts. We received a non-refundable, non-creditable upfront payment of
$3.5 million
in September 2010 and will receive a minimum of $6.0 million in research funding with the potential of up to $12.0 million in research funding, if successful. In addition, we will be
eligible to receive payments upon the achievement of specified development and regulatory milestones, as well as tiered royalties escalating from high single digit to in the tens royalties on sales,
depending in part upon the mix of products sold.

In
February 2011, we entered into a research and development agreement with Medicis to discover and develop boron-based small molecule compounds directed against a target for the
potential treatment of acne. Under the terms of the agreement, we received a $7.0 million upfront payment from Medicis in February 2011 and will be primarily responsible for discovering and
conducting early development of product candidates that utilize our proprietary boron chemistry platform. Medicis will have an option to obtain an exclusive license for products covered by the
agreement. We will be eligible for future research, development, regulatory and sales milestones of up to $153.0 million, as well as high single-digit to in the tens royalties on sales by
Medicis. Medicis will be responsible for further development and commercialization of the licensed products on a worldwide basis.

64

---



Table of Contents

We
began business operations in March 2002. To date, we have not generated any revenue from product sales and have never been profitable. As of December 31, 2010, we have an
accumulated deficit of $111.2 million. We have funded our operations primarily through the sale of equity securities, upfront payments and milestone payments under our agreements with Schering,
GSK and Lilly, government contracts and grants and borrowings under debt arrangements. We expect to incur losses in future periods. The size of our future losses will depend, in part, on the rate of
growth of our expenses, our ability to enter into additional licensing, research and development agreements and future payments earned under our agreements with GSK, Lilly, Medicis or any such future
partners. Our intent is to enter into licensing and development agreements with additional partners to further develop certain of our product candidates and to fund other areas of our research. If the
GSK, Lilly and/or Medicis agreements are terminated or we are unable to enter into other collaboration agreements, we may incur additional operating losses and our ability to expand and continue our
research and development activities and move our product candidates into later stages of development may be limited. We will need to seek additional capital through collaborations, equity and debt
financings to fund our operations.

Financial Operations Overview

Revenues

Our recent revenues are comprised primarily of collaboration agreement-related revenues and government grants, while historically we
also had government contract revenues. Collaboration agreement-related revenues have included license fees, development reimbursements and development milestones. In addition, we have received a
termination and release payment with respect to our previous agreement with Schering. Government grant revenues have consisted of grant funding received from government entities and government
contract revenues have included cost and cost plus fixed fee reimbursements for allowable costs.

We
have generated approximately $109.9 million in revenue from inception through December 31, 2010. Through 2004, we had recognized cumulative revenues of
$16.1 million through our contract with the U.S. Department of Defense for the development of antibiotics against infective anthrax. From 2005 through 2007, we recognized $1.0 million in
revenue from a National Institutes of Health, or NIH, grant for the identification of targets for certain antifungal compounds, which included work on the mechanism of action of AN2690. In March 2007,
we received from Schering a $40.0 million upfront fee that was recognized ratably over the estimated period during which we performed development-related activities to transition AN2690 to
Schering. The estimated period was based on the research transition plan jointly developed by Schering and us. In addition to the upfront fee, we were paid for our development-related activities,
which included certain preclinical and clinical activities. Through December 31, 2010, we recognized revenue of $49.5 million under the Schering agreement, which was comprised of the
full recognition of the $40.0 million upfront fee and $9.5 million for our development-related transition activities. In November 2009, Schering merged with Merck and in May 2010, upon
termination of the 2007 agreement, we regained the exclusive worldwide rights to AN2690 and received a $5.8 million payment from Merck, which was recognized as revenue during 2010.

In
October 2007, we received a $12.0 million upfront fee under our agreement with GSK, which we are recognizing ratably over the six-year research term. Through
December 31, 2010, we recognized $32.5 million under this agreement which was comprised of $6.5 million related to the upfront fee, $25.1 million for achievement of
performance milestones and $0.9 million in reimbursement for patent costs, procurement of drug material and performance of certain clinical studies for GSK '052. In the future, revenue under
our agreement with GSK may include fees for our GSK product candidates achieving development, regulatory and sales milestones and product royalties.

65

---



Table of Contents

In
September 2010, we received a non-creditable, non-refundable upfront fee of $3.5 million under our agreement with Lilly, which we are recognizing over
the four-year research term on a straight-line basis. Under this agreement, we
will receive a minimum of $6.0 million in research funding with the potential of up to $12.0 million in research funding, if successful. Through December 31, 2010, we have
recognized $1.4 million under this agreement, which was comprised of $0.3 million related to the upfront fee and $1.1 million in research funding.

From
inception through December 31, 2010, we have recognized $2.1 million of revenue for research relating to animal health indications and for research performed under our
agreements with not-for-profit organizations for neglected diseases.

In
October 2010, we were awarded $1.5 million from the United States Department of the Treasury under the Qualifying Therapeutic Discovery Project Program to support research for
six projects with the potential to produce new therapies. The full amount was recognized as government grant revenue in 2010.

Research and Development Expenses

Research and development expenses consist primarily of costs associated with research activities, as well as costs associated with our
product development efforts, including preclinical studies and clinical trials. Research and development expenses, including those paid to third parties, are recognized as incurred. Research and
development expenses include:



Our
expenses associated with preclinical studies and clinical trials are based upon the terms of the service contracts, the amount of the services provided and the status of the related
activities. We expect that research and development expenses will increase significantly in the future as we progress our product candidates through clinical development, conduct our research and
development activities under our agreements with GSK, Lilly and Medicis, advance our discovery research projects into the preclinical stage, and continue our early-stage research.

The
table below sets forth our research and development expenses for 2008, 2009 and 2010, and for the period from January 1, 2004 through December 31, 2010 for our five
clinical-stage product candidates, other work conducted under the GSK agreement, work on neglected diseases and other programs, including programs that are currently inactive. Prior to
January 1, 2004, we did not separately track expenses for AN2690 or any other product candidates due to the early stage of their development. A portion of our research and development costs,
including indirect costs relating to our

66

---



Table of Contents

product
candidates, are not tracked on a program basis and are allocated based on the personnel resources assigned to each program.

Year Ended
December 31,Total from
January 1, 2004 to
December 31, 20102008

2009

2010(in thousands)AN2690, including NIH grant expenses

$
2,253

$
363

$
4,824

$
32,173AN2728


4,978


3,124


6,839


20,792AN2718


3,167


1,112


169


7,730AN2898


2,962


1,023


670


4,859GSK programs:GSK '052


3,389


7,803


2,156


13,348Other GSK programs


14,804


14,515


5,237


36,723Neglected diseases


172


1,643


2,502


4,318Other programs


4,464


4,500


7,469


46,029Total research and development expenses

$
36,189

$
34,083

$
29,866

$
165,972


We
expect our research and development expenses to increase in future periods. Our costs associated with AN2690 will increase as we advance our Phase 3 clinical trials. We expect
costs associated with AN2728 and AN2898 to increase as we expand the clinical and preclinical activities for these programs. Due to the option exercise by GSK for GSK '052 in July 2010, GSK has
assumed all future development costs for this product candidate and therefore our expenses associated with GSK '052 are expected to be minimal in the future. In addition, spending for our early-stage
research programs, including our other GSK programs, will be dependent upon our success in developing and advancing new product candidates for these programs. We also expect costs associated with our
early stage research activities to increase in future periods primarily as a result of our recent collaborations with Lilly and Medicis and work on neglected diseases.

We
cannot determine with certainty the duration and completion costs of the current or future clinical trials of our product candidates or if, when, or to what extent we will generate
revenues from the commercialization and sale of any of our product candidates. We or our partners may never succeed in achieving marketing approval for any of our product candidates. The duration,
costs and timing of clinical trials and development of our product candidates will depend on a variety of factors, including the uncertainties of future clinical and preclinical studies, uncertainties
in clinical trial enrollment rates and significant and changing government regulation and whether our current or future collaborators are committed to and make progress in programs licensed to them.
For example, the timing to complete development of GSK '052 will be controlled by GSK because they have exercised their option to license
this product candidate. In addition, the probability of success for each product candidate will depend on numerous factors, including competition, manufacturing capability and commercial viability.
Consequently, we are unable to provide a meaningful estimate of the period in which material cash inflows will be received. We will determine which programs to pursue and how much to fund each program
in response to the scientific and clinical success of each product candidate, as well as an assessment of each product candidate's commercial potential.

Our
strategy includes entering into additional collaborations with third parties for the development and commercialization of some of our product candidates. To the extent that third
parties have control over preclinical development or clinical trials for some of our product candidates, we will be dependent upon their efforts for the progress of such product candidates. We cannot
forecast with any degree of certainty which of our product candidates, if any, will be subject to future collaborations or how such arrangements would affect our development plans or capital
requirements.

67

---



Table of Contents

General and Administrative Expenses

General and administrative expenses consist primarily of salaries and related costs for our personnel, including stock-based
compensation and travel expenses, in executive, finance, business development and other administrative functions. Other general and administrative expenses include facility-related costs not otherwise
included in research and development expenses, consulting costs associated with financial services, professional fees for legal services, including patent-related expenses, and auditing and tax
services. We expect that general and administrative expenses will increase in the future as we expand our operating activities, hire additional staff and incur additional costs associated with
operating as a public company.

Critical Accounting Policies and Significant Judgments and Estimates

Our management's discussion and analysis of our financial condition and results of operations is based on our financial statements,
which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires us to make estimates and judgments
that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenues and
expenses during the reporting periods. We base our estimates on
historical experience and on various other factors that we believe to be reasonable under the circumstances and review our estimates on an ongoing basis. Actual results may differ from these estimates
under different assumptions or conditions.

While
our significant accounting policies are described in more detail in Note 2 of our financial statements included in this Annual Report on Form 10-K, we
believe the following accounting policies to be critical to the judgments and estimates used in the preparation of our financial statements.

Revenue Recognition

Our contract revenues are generated primarily through research and development collaboration agreements, which typically may include
non-refundable, non-creditable upfront fees, funding for research and development efforts, payments for achievement of specified development, regulatory and sales milestones,
and royalties on product sales of licensed products.

For
multiple element arrangements, we evaluate the components of each arrangement as separate elements based on certain criteria. Accordingly, revenues from collaboration agreements are
recognized based on the performance requirements of the agreements. We recognize revenue when persuasive evidence of an arrangement exists; transfer of technology has been completed, services are
performed or products have been delivered; the fee is fixed and determinable; and collection is reasonably assured.

Upfront
payments for licensing our intellectual property generally are not separable from the activity of providing research and development services because the license does not have
stand-alone value separate from the research and development services provided. Such upfront payments are recorded as deferred revenue in the balance sheet and are recognized as contract revenue over
the contractual or estimated performance period, which is consistent with the term of the research and development obligations contained in the research and development collaboration agreement. We
regularly review the basis for our estimates, and we may change the estimates if circumstances change. These changes can significantly increase or decrease the amount of revenue recognized. To date,
we have not experienced significant changes in our estimates.

Payments
resulting from our research and development efforts under license agreements or government grants are recognized as the activities are performed and are presented on a gross
basis. Revenue is recorded gross because we act as a principal, with discretion to choose suppliers, bear credit

68

---



Table of Contents

risk
and perform part of the services. The costs associated with these activities are reflected as a component of research and development expense in the statements of operations and approximate
revenue recognized.

Substantive,
at-risk milestone payments are recognized as revenue when the milestone is achieved and collectibility is assured. When payments are not for substantive and
at-risk milestones, revenue is recognized over the estimated remaining term of the service period.

Royalties
based on reported sales of licensed products will be recognized based on contract terms when reported sales are reliably measurable and collectability is reasonably assured. To
date, we have not earned any royalty revenue from product sales.

Preclinical Study and Clinical Trial Accruals and Deferred Advance Payments

We estimate our preclinical study and clinical trial expenses based on the services performed pursuant to contracts with research
institutions and clinical research organizations that conduct these activities on our behalf. In recording service fees, we estimate the time period over which the related services will be performed
and compare the level of effort expended through the end of each period to the cumulative expenses recorded and payments made for such services and, as appropriate, accrue additional service fees or
defer any non-refundable advance payments until the related services are performed. If the actual timing of the performance of services or the level of effort varies from the estimate, we
will adjust our accrual or deferred advance payment accordingly. If we underestimate or overestimate the level of services performed or the costs of these services, our actual expenses could differ
from our estimates. To date, we have not experienced significant changes in our estimates of preclinical study and clinical trial accruals.

Stock-Based Compensation

Employee stock-based compensation cost is measured at the grant date, based on the fair value of the award, and is recognized as an
expense over the employee's requisite
service period (generally the vesting period). We use the Black-Scholes option-pricing model as the most appropriate fair-value method for our stock-based awards. For options granted prior
to January 1, 2006, we used the graded-vested (multiple option) method for expense attribution and, prior to January 1, 2006, recognized option forfeitures as they occurred. For options
granted after January 1, 2006, we use the straight-line (single option) method for expense attribution and estimate forfeitures and recognize expense only for those shares expected
to vest.

We
account for equity instruments issued to nonemployees based on their fair values on the measurement dates using the Black-Scholes option-pricing model. The fair values of the options
granted to nonemployees are remeasured as they vest. As a result, the noncash charge to operations for nonemployee options with vesting is affected each reporting period by changes in the fair value
of our common stock.

We
recorded noncash stock-based compensation expense for employee and nonemployee stock option grants of $2.0 million, $2.5 million, and $2.8 million during 2008,
2009 and 2010, respectively. Based on stock options outstanding as of December 31, 2010, we had unrecognized stock-based compensation expense for employees, net of estimated forfeitures, of
$3.6 million, which will be recognized over a weighted-average period of 1.9 years. We expect to continue to grant stock options in the future, which will increase our stock-based
compensation expense in future periods. If any of the assumptions used in the Black-Scholes model change significantly, stock-based compensation expense may differ materially in the future from that
recorded in the current period.

As
of December 31, 2010, we had outstanding vested options to purchase 1,275,609 shares of our common stock and unvested options to purchase 667,643 shares of our common stock
with intrinsic

69

---



Table of Contents

values
of $3.0 million and $0.1 million, respectively, based on the differences between the exercise prices of the underlying options and the year-end closing price of our
common stock of $5.37 per share.

Fair Values of Preferred Stock Warrants

Prior to the our IPO, outstanding warrants to purchase shares of our convertible preferred stock were freestanding warrants that were
exercisable into convertible preferred stock that was subject to redemption and were therefore classified as liabilities in the balance sheet at fair value. The initial liability recorded was adjusted
for changes in the fair values of our preferred stock warrants during each reporting period and was recorded as a component of other income (expense) in the statement of operations for that period.

We
estimated the fair values of these warrants using the Black-Scholes option-pricing model based on inputs for the estimated fair value of the underlying convertible preferred stock at
the valuation measurement date, the remaining contractual terms of the warrant, risk-free interest rates, expected dividend rates and expected volatility of the price of the underlying
convertible preferred stock. We estimated the fair value of the convertible preferred stock using valuation analysis methods, inputs and assumptions consistent with those we used for our common stock
valuations, giving consideration to the preferences and other terms of the convertible preferred stock. Our estimates were based, in part, on subjective assumptions.

Upon
closing of our IPO and the conversion of the underlying preferred stock to common stock, all outstanding warrants to purchase shares of our preferred stock were automatically
converted into warrants to purchase shares of our common stock. The aggregate fair value of our warrants upon the closing of the IPO was reclassified from liabilities to additional paid-in
capital, a component of stockholders' equity (deficit), and we ceased recording any related periodic fair value adjustments as all such amounts are recorded in additional paid in capital.

Results of Operations

Comparison of Years Ended December 31, 2009 and 2010

Year Ended December 31,2009

2010

Increase/
(decrease)(in thousands)Contract revenue

$
9,793

$
8,448

$
(1,345
)Contract revenue-related party


8,850


17,909


9,059Government grant revenue





1,467


1,467Research and development expenses(1)


34,083


29,866


(4,217
)General and development expenses(1)


7,054


7,452


398Interest income


154


25


(129
)Interest expense


2,434


2,005


(429
)Other income (expense)


(80
)

1,416


1,496






Research and development expenses

$
1,557

$
1,631

$
74General and administrative expenses


893


1,155


262


70

---





Table of Contents

Contract revenue.During 2009, we recognized the final $8.7 million of the $40.0 million non-refundable,
non-creditable, upfront fee under our license agreement with Schering as we completed all development-related transition activities. We also recognized $0.3 million of revenue from
these transition activities performed by us. In addition, we recognized $0.8 million of revenue for research performed under other agreements, including under agreements with
not-for-profit organizations for neglected diseases. During 2010, we recognized in full the $5.8 million fee that we received from Merck in connection with the
termination of the Schering license agreement. We also recognized $1.1 million for research funding and $0.3 million of the $3.5 million non-refundable,
non-creditable upfront fee we received under the Lilly agreement and $1.3 million of revenue for research performed under other agreements, including under agreements with
not-for-profit organizations for neglected diseases.

Contract revenue-related party.During each of 2009 and 2010, we recognized $2.0 million of the $12.0 million
non-refundable, non-creditable upfront fee received from GSK. We also recognized $6.8 million and $15.0 million in 2009 and 2010, respectively, for development
milestones earned under this collaboration. In addition, during 2010, we recognized $0.9 million of revenue for reimbursement of patent and clinical trial costs related to GSK '052.

Government grant revenue.During 2010, we recognized the full $1.5 million of the Qualifying Therapeutic Discovery Project grant
funds awarded
to us in October 2010 by the United States Department of the Treasury for eligible investments we made in six of our projects during 2009 and 2010.

Research and development expenses.The decrease in research and development expenses for 2010 compared to 2009 was primarily due to
decreases of
$9.3 million and $5.6 million in our other GSK programs and GSK '052, respectively. In the latter part of 2009, we redirected some of our resources away from our early-stage GSK programs
to focus our efforts more on GSK '052. This led to the reduction in spending on the other GSK programs in 2010. In 2009, we were in the midst of multiple development activities for GSK '052 whereas
during 2010, our activities were limited to conducting the Phase 1 clinical trial for this compound. Furthermore, GSK became solely responsible for expenditures related to GSK '052 following
their licensing of GSK '052 in July 2010. These two factors resulted in an overall reduction in GSK '052 expenses from 2009 to 2010.

Our
GSK program spending decreases were partially offset by increases of $4.5 million, $3.7 million and $3.0 million in our AN2690, AN2728 and other research
programs, respectively. Due to Merck notifying us in January 2010 that they were terminating our licensing agreement with Schering, we were actively transitioning AN2690 materials and documents from
Schering back to us during 2010, as well as preparing to initiate the Phase 3 clinical trials, which commenced in the fourth quarter of 2010. In contrast, during the prior year, we were winding
down our AN2690 development work in anticipation of Schering beginning Phase 3 trials later that year. During 2010, we were conducting our first Phase 2b trial for AN2728, completing
some preclinical studies and initiating manufacturing activities in anticipation of starting additional preclinical studies and our final Phase 2b clinical trial in psoriasis for AN2728. This
caused us to incur higher expenses for AN2728 in 2010 than during 2009 when we were winding down our initial Phase 2b clinical trial and initiating startup activities for our final
Phase 2b psoriasis trial for AN2728.

Our
efforts on our internal early-stage research projects increased during 2010 as compared to 2009 with increased expenses of $1.7 million for animal health-related research,
including under our collaboration with Lilly, and $1.3 million more for other early-stage research projects.

General and administrative expenses.The increase in general and administrative expenses in the 2010 as compared to 2009 was primarily
due to higher
stock-based compensation expenses, increased fees for audit services and an increase in bonus expenses as we achieved a higher percentage of our

71

---



Table of Contents

corporate
goals in 2010 than in 2009. These increases were only partially offset by lower corporate legal expenses.

Interest income.The decrease in interest income was due to the reduction in investment balances and lower yields.

Interest expense.Interest expense decreased in 2010 due to the lower outstanding balance on our debt and the increase in the term over
which we are
now amortizing the final payment and debt discounts as a result of our January 2010 loan restructuring. This decrease was partially offset by additional interest expenses associated with the January
2010 loan restructuring in the form of accrued interest for the loan modification fee and amortization of the additional debt discount associated with the new warrant issued at that time.

Other income (expense).The increase in other income (expense) in 2010 compared to 2009 reflected the net post-issuance reduction in
the
fair values of our preferred stock warrants during 2010 in contrast with 2009 when the fair values of these warrants increased.

Comparison of Years Ended December 31, 2008 and 2009

Year Ended
December 31,Increase/
(decrease)2008

2009(in thousands)Contract revenue

$
19,776

$
9,793

$
(9,983
)Contract revenue-related party


5,300


8,850


3,550Research and development expenses(1)


36,189


34,083


(2,106
)General and administrative expenses(1)


10,171


7,054


(3,117
)Interest income


500


154


(346
)Interest expense


2,298


2,434


136Other income (expense)


1,413


(80
)

(1,493
)






Research and development expenses

$
1,263

$
1,557

$
294General and administrative expenses


728


893


165


Contract revenue.During 2008, under our license agreement with Schering, we recognized $17.5 million of the $40.0 million
non-refundable, non-creditable, upfront fee received in March 2007 and $2.3 million of revenue from development-related transition activities performed by us. During
2009, we recognized the remaining $8.7 million of the upfront fee and $0.3 million of revenue from transition activities. Transition activities were completed in June 2009 in accordance
with our earlier estimates. During 2009, we also recognized $0.8 million of revenue for research performed under our other research agreements, including under agreements with
not-for-profit organizations for neglected diseases.

Contract revenue-related party.In each of 2008 and 2009, we recognized $2.0 million of the $12.0 million non-refundable,
non-creditable upfront fee received in October 2007 from GSK. We also recognized $3.3 million and $6.8 million in 2008 and 2009, respectively, for development milestones
earned under the GSK collaboration.

Research and development expenses.The decrease in research and development expenses for 2009 compared to 2008 was due to decreases of
$1.9 million, $1.9 million, $2.l million and $1.9 million in our AN2690, AN2728, AN2718 and AN2898 programs, respectively. In 2009, our transition activities for

72

---



Table of Contents

AN2690
were winding down in preparation for the Phase 3 trials to be initiated by Schering. For our other clinical programs, the decreases were due to our decision to prioritize our 2009
spending on the GSK programs. Partially offsetting these decreases was an increase of $4.1 million in our GSK programs. In 2008, we were in the early research stage for our GSK programs, while
in 2009, we advanced the development of these programs, including moving GSK '052 into preclinical and clinical development. In addition, partially offsetting these decreases was a $1.5 million
increase in our neglected disease programs in 2009 compared to 2008.

General and administrative expenses.The decrease in general and administrative expenses for 2009 compared to 2008 was primarily due to
the
$2.4 million expensing of offering costs in 2008 when we withdrew our registration statement for an initial public offering of common stock with the Securities and Exchange Commission. In
addition, salaries and benefits expenses declined by $0.6 million, primarily related to the resignations of two of our officers.

Interest income.The decrease in interest income was attributable to lower yields on our investment balances during 2009 as compared to
those earned
in 2008.

Interest expense.Interest expense increased in 2009 due to a full year's interest expense for the additional $7 million borrowing
that
occurred in April 2008 offset by lower interest expense on the original $8 million borrowing. Debt discount amortization related to the warrants associated with the debt increased due to the
additional shares which became exercisable in January 2009 and the full year's amortization of the discount associated with the shares that became exercisable in May 2008.

Other income (expense).The decrease in other income (expense) reflects the increase in the fair values of the preferred stock warrants
during 2009
in contrast with 2008 when other income (expense) reflected a decrease in the fair values of these warrants.

Income Taxes

At December 31, 2010, we had net operating loss carryforwards for federal income tax purposes of $95.5 million and
federal research and development tax credit carryforwards of $4.6 million. Our utilization of the net operating loss and tax credit carryforwards may be subject to annual limitations due to the
ownership change limitations provided by the Internal Revenue Code and similar state provisions. The annual limitations may result in the expiration of net operating losses and credits prior to
utilization. We recorded a valuation allowance to offset in full the benefit related to the deferred tax assets because realization of this benefit was uncertain.

Liquidity and Capital Resources

Since our inception, we have financed our operations primarily through our initial public offering in November 2010, the private
placement of equity securities, funding from our agreements with Schering, GSK and Lilly, government contract and grant funding and debt arrangements. In 2010, we received $61.0 million in net
proceeds from the public sale of our common stock and $10.0 million from a concurrent private placement of our common stock. Through December 31, 2010, we have received aggregate net
proceeds of $87.5 million from the issuance of convertible preferred stock which converted into common stock upon our initial public offering. In 2007, we received a $40.0 million
non-refundable, non-creditable upfront fee from Schering and a $12.0 million non-refundable, non-creditable upfront fee from GSK. In 2010, we
received a $3.5 million non-refundable, non-creditable upfront fee from Lilly and $1.1 million in research funding. In addition, from 2007 through 2010, we
received $9.5 million and $26.0 million in reimbursements for development activities and milestone fees from Schering and GSK, respectively. In May 2010, we also received
$5.8 million from Merck, in connection with the termination of our 2007 agreement with Schering. Through December 31, 2010, we have received $18.5 million from government contract
and grant revenues and

73

---



Table of Contents

borrowed
$15.0 million under a loan agreement. We have also earned interest on our cash, cash equivalents and short-term investments.

The
following table sets forth the primary sources and uses of cash for each of the periods presented below (in thousands):

Year Ended
December 31,2008

2009

2010Net cash used in operating activities

$
(39,390
)
$
(27,824
)
$
(3,182
)Net cash provided by (used in) investing activities


21,250


(6,440
)

(51,153
)Net cash provided by (used in) financing activities


56,119


(4,457
)

67,494Net increase (decrease) in cash and cash equivalents

$
37,979

$
(38,721
)
$
13,159


The
use of cash by operating activities in 2008 and 2009 resulted primarily from our net losses adjusted for non-cash items and changes in operating assets and liabilities,
including the amortization of the deferred revenue amounts that arose in 2007 from the $52.0 million upfront license payments received under our collaboration agreements with Schering and GSK.
The cash used in operating activities for 2010 resulted primarily from our net loss adjusted for non-cash items and changes in operating assets and liabilities, including the amortization
of the deferred revenue that arose in 2007 from the $12.0 million upfront license payment received from GSK and an increase in accrued liabilities due to increased preclinical and clinical
activities late in the year and liabilities arising from our initial public offering. The decrease in cash used by our operating activities in 2009 as
compared with 2008 resulted primarily from a decline in deferred revenue amortization as we recognized only the remaining six-month portion of the Schering upfront payment in 2009 versus a
full year of amortization in the prior year. The winding down of our AN2690 transition development obligations under the Schering agreement and our decision to defer certain development activities for
our clinical stage programs to preserve our cash resources also contributed to the 2009 decrease. The decrease in cash used by operating activities during 2010 versus 2009 was primarily a result of
the receipt of a $15.0 million milestone payment from GSK, a $5.8 million payment from Merck in connection with their termination of our agreement with Schering and a $3.5 million
upfront license fee payment from Lilly in 2010 compared to the receipt of $9.8 million in milestone payments from GSK in 2009. A decrease in our spending on our GSK programs, only partially
offset by increases in our development and clinical spending for AN2690 and AN2728, also contributed to the net decrease in cash used by operating activities in 2010.

During
2008, 2009 and 2010, our investing activities provided (used) cash of $21.3 million, $(6.4) million, and $(51.2) million, respectively. The cash provided by investing
activities for 2008 was due primarily to the net result of maturities and purchases of short-term investments, which was partially offset by purchases of property and equipment of
$2.1 million. The cash used by investing activities for 2009 was due primarily to the net result of purchases, maturities and sales of short-term investments. The cash used by
investing activities for 2010 was primarily the net result of purchases and maturities of short-term investments as we invested the net proceeds from our initial public offering and our
concurrent private placement.

During
2008, 2009 and 2010, our financing activities provided (used) cash of $56.1 million, $(4.5) million and $67.5 million, respectively. The cash provided by financing
activities in 2008 was due primarily to the sale and issuance of 2,774,512 shares of Series E convertible preferred stock for total net proceeds of $46.8 million. Proceeds of
$3.0 million from the issuance of convertible promissory notes, which along with the related accrued interest were converted into 177,771 shares of Series E convertible preferred stock,
and proceeds of $7.0 million from the issuance of notes payable, net of $0.7 million in principal payments on notes payable, also contributed to the cash provided by financing

74

---



Table of Contents

activities
in 2008. Cash used by financing activities in 2009 was primarily a result of principal payments on notes payable. The cash provided by financing activities in 2010 was primarily due to our
initial public offering of common stock. The Company sold 13,382,651 shares of common stock, including the over-allotment of 1,382,651 shares granted to the underwriters for net proceeds
of $61.0 million. Concurrent with the closing of the offering, 2,000,000 common shares were sold through a private placement with net proceeds of $10.0 million. Partially offsetting
these proceeds were principal payments on notes payable of $3.1 million and a loan restructuring fee payment of $0.5 million in 2010.

As
of December 31, 2010, we had approximately $78.6 million in cash, cash equivalents and short-term investments. We believe that our existing cash, cash
equivalents and short-term investments as of December 31, 2010, along with interest thereon, will be sufficient to meet our anticipated cash requirements for at least the next
twelve months. However, our forecast of the period of time through which our financial resources will be adequate to support our
operations is a forward-looking statement that involves risks and uncertainties, and actual results could vary materially.

Our
future capital requirements are difficult to forecast and will depend on many factors, including:



75

---



Table of Contents

Contractual Obligations

The following table summarizes our contractual obligations at December 31, 2010 and the effect such obligations are expected to
have on our liquidity and cash flow in future years.

Payments due by period (in thousands)Total

Less than
1 year

1-3 years

3-5 years

More than
5 yearsContractual obligations:Operating leases

$
11,708

$
1,815

$
2,955

$
3,150

$
3,788Notes payable (including interest) due in 2011 as of December 31, 2010 (See Notes Payable below as these amounts were refinanced in 2011.)


8,430


8,430








Total contractual obligations

$
20,138

$
10,245

$
2,955

$
3,150

$
3,788




We lease a 36,960 square-foot building in Palo Alto, California consisting of office and laboratory space which serves as
our corporate headquarters. The lease commenced in April 2008 and will terminate in March 2018.

We
also have a lease for a 15,300 square-foot building consisting of office and laboratory space in Palo Alto, California, which was extended through December 2011 and is
cancelable with four months' notice.



On March 18, 2011, we entered into a loan and security agreement with new lenders to provide up to $30.0 million,
available in three tranches of $10.0 million each (see Note 16 to the financial statements). The first $10.0 million tranche was drawn on March 18, 2011, at which time we
repaid $6.6 million of the remaining obligations under our existing loan with Lighthouse Capital Partners V, L.P., or Lighthouse. At December 31, 2010, $6.2 million of the
existing note payable balance has been classified as a long-term liability in the balance sheet. Future payments related to the first $10.0 million tranche of the new loan are
$0.7 million, $2.9 million, $3.8 million, $3.8 million and $1.8 million in 2011, 2012, 2013, 2014 and 2015, respectively, and are not included as contractual
obligations at December 31, 2010 in the table above.

As
of December 31, 2010, our loan agreement with Lighthouse, required twelve remaining payments of principal and interest through December 1, 2011 and a $1.5 million
final payment also due on December 1, 2011. From January 1, 2011 to March 1, 2011, we made loan payments to Lighthouse totaling $1.7 million prior to paying our remaining
obligations to Lighthouse from the proceeds of the first tranche borrowed under our new March 2011 loan and security agreement.



We enter into contracts in the normal course of business with clinical research organizations for clinical trials and clinical supply
manufacturing and with vendors for preclinical research studies, research supplies and other services and products for operating purposes.
These contracts generally provide for termination on notice, and therefore we believe that our noncancelable obligations under these agreements are not material.

76

---



Table of Contents

Off-Balance Sheet Arrangements

Since inception, we have not engaged in the use of off-balance sheet arrangements, such as structured finance, special
purpose entities or variable interest entities.

Recent Accounting Pronouncements

In October 2009, the FASB issued an Accounting Standards Update (ASU) No. 2009-13, which requires companies to
allocate revenue in multiple element arrangements based on an element's estimated selling price if vendor-specific or other third-party evidence of value is not available. The standard is effective
beginning January 1, 2011, although earlier application is permitted. We are currently evaluating both the timing and the impact of the pending adoption of this standard on our financial
statements.

In
April 2010, the FASB amended ASU 2010-17 which provides guidance on the milestone method of revenue recognition for research or development arrangements. An entity can
make an accounting policy election to recognize a payment that is contingent upon the achievement of a substantive milestone in its entirety in the period in which the milestone is achieved. The
milestone method is not required and is not the only acceptable method of revenue recognition for milestone payments. The standard is effective on a prospective basis for annual periods, and interim
periods within those years, on or after June 15, 2010, although earlier application is permitted. We do not expect the adoption of this standard to have a material impact on our financial
statements.

ITEM 7A.    QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

The primary objective of our investment activities is to preserve our capital for the purpose of funding operations while at the same
time maximizing the income we receive from our investments without significantly increasing risk. To achieve these objectives, our investment policy allows us to maintain a portfolio of cash
equivalents and short-term investments in a variety of high credit quality securities, including U.S. government instruments, commercial paper, money market funds and corporate debt
securities. Our investment policy prohibits us from holding auction rate securities or derivative financial instruments. To the extent that the investment portfolios of companies whose commercial
paper is included in our investment portfolio may be subject to interest rate risks, which could be negatively impacted by reduced liquidity in auction rate securities or derivative financial
instruments, we may also be subject to these risks. However, our investments as of December 31, 2010 are comprised of U.S treasury securities, federal agency securities with a minimum rating of
AAA or A1, and U.S. government guaranteed corporate bonds with a remaining average maturity of the entire portfolio of one hundred fifty-five days. Due to the short-term nature
of our investments, we believe that there is no material exposure to interest rate risk and we are not aware of any material exposure to market risk.

77

---





Table of Contents

ITEM 8.    FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

Index to Financial Statements        Contents



Report of Independent Registered Public Accounting Firm

79Balance Sheets

80Statements of Operations

81Statements of Convertible Preferred Stock and Stockholders' Equity
(Deficit)

82Statements of Cash Flows

83Notes to Financial Statements

84


78

---





Table of Contents

Report of Independent Registered Public Accounting Firm

The
Board of Directors and Stockholders
Anacor Pharmaceuticals, Inc.

We
have audited the accompanying balance sheets of Anacor Pharmaceuticals, Inc. (the Company) as of December 31, 2009 and 2010 and the related statements of operations,
convertible preferred stock and stockholders' equity (deficit) and cash flows for each of the three years in the period ended December 31, 2010. These financial statements are the
responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits.

We
conducted our audits in accordance with standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to
obtain reasonable assurance about whether the financial statements are free of material misstatement. We were not engaged to perform an audit of the Company's internal control over financial
reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose
of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis,
evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial
statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In
our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Anacor Pharmaceuticals, Inc. at December 31,
2009 and 2010, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2010, in conformity with U.S. generally accepted accounting
principles.

/s/ ERNST & YOUNG LLP


Palo
Alto, California
March 29, 2011

79

---





Table of Contents

Anacor Pharmaceuticals, Inc.        Balance Sheets        (In Thousands, Except Share and Per Share Data)

December 312009

2010AssetsCurrent assets:Cash and cash equivalents

$
8,584

$
21,743Short-term investments


5,919


56,848Contract receivable


73


1,066Contract receivablerelated party





18Government grant receivable





108Prepaid expenses and other current assets


620


1,537Total current assets


15,196


81,320Property and equipment, net


2,462


1,844Restricted investments


196


197Other assets


91


603Total assets

$
17,945

$
83,964Liabilities, convertible preferred stock and stockholders' equity (deficit)Current liabilities:Accounts payable

$
1,746

$
2,138Accrued liabilities


3,628


6,963Accrued liabilitiesrelated party





125Notes payable


2,866


1,522Preferred stock warrants liability


1,273


Deferred revenue


2,050


3,885Total current liabilities


11,563


14,633Deferred rent


835


902Notes payable, less current portion


7,858


6,219Deferred revenue, less current portion


5,500


5,817Commitments and contingenciesConvertible preferred stock: $0.001 par value; authorized: 55,672,227 shares and no shares at December 31, 2009 and 2010, respectively; issued and
outstanding: 10,909,478 shares and no shares at December 31, 2009 and 2010, respectively; aggregate liquidation value of $87,920 and none at December 31, 2009 and 2010, respectively;


87,473


Stockholders' equity (deficit):Preferred stock, $0.001 par value; authorized: no shares and 10,000,000 shares at December 31, 2009 and 2010, respectively; issued and outstanding: no
shares at December 31, 2009 and 2010





Common stock, $0.001 par value; authorized: 75,500,000 shares and 100,000,000 shares at December 31, 2009 and 2010; issued and outstanding: 1,443,696
shares and 27,996,878 shares at December 31, 2009 and 2010, respectively.


1


28Additional paid-in capital


5,835


167,559Accumulated other comprehensive income (loss)


2


(14
)Accumulated deficit


(101,122
)

(111,180
)Total stockholders' equity (deficit)


(95,284
)

56,393Total liabilities, convertible preferred stock and stockholders' equity (deficit)

$
17,945

$
83,964


See accompanying notes.

80

---





Table of Contents

Anacor Pharmaceuticals, Inc.        Statements of Operations        (In Thousands, Except Share and Per Share Data)

Year Ended December 312008

2009

2010Revenues:Contract revenue

$
19,776

$
9,793

$
8,448Contract revenuerelated party


5,300


8,850


17,909Government grant revenue








1,467Total revenues


25,076


18,643


27,824Operating expenses:Research and development


36,189


34,083


29,866General and administrative


10,171


7,054


7,452Total operating expenses


46,360


41,137


37,318Loss from operations


(21,284
)

(22,494
)

(9,494
)Interest income


500


154


25Interest expense


(2,298
)

(2,434
)

(2,005
)Other income (expense)


1,413


(80
)

1,416Loss before income tax benefit


(21,669
)

(24,854
)

(10,058
)Income tax benefit


44


15


Net loss

$
(21,625
)
$
(24,839
)
$
(10,058
)Net loss per common sharebasic and diluted

$
(15.39
)
$
(17.55
)
$
(2.71
)Weighted-average number of common shares used in calculating net loss per common sharebasic and diluted


1,405,140


1,415,083


3,705,505


See
accompanying notes.

81

---





Table of Contents

Anacor Pharmaceuticals, Inc.      Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)      (In Thousands, Except Share Data)

Convertible
Preferred StockPreferred Stock

Common Stock



Accumulated
Other
Comprehensive
Income



Total
Stockholders'
Equity
(Deficit)Additional
Paid-In
Capital

Accumulated
DeficitShares

Amount

Shares

Amount

Shares

AmountBalance at December 31, 2007


7,957,195

$
37,637




$



1,402,595

$
1

$
1,366

$
80

$
(54,658
)
$
(53,211
)Issuance of Series E convertible preferred stock, net of financing costs


2,774,512


46,825























Issuance of Series E convertible preferred stock upon conversion of promissory notes and accrued interest


177,771


3,011























Issuance of common stock upon exercise of stock options














5,921





14








14Stock-based compensation on options issued to consultants




















282








282Employee stock-based compensation expense




















1,709








1,709Comprehensive loss:Net loss


























(21,625
)

(21,625
)Change in unrealized gain on marketable securities























(80
)




(80
)Comprehensive loss





























(21,705
)Balance at December 31, 2008


10,909,478


87,473








1,408,516


1


3,371





(76,283
)

(72,911
)Issuance of common stock upon exercise of stock options














35,180





14








14Stock-based compensation on options issued to consultants




















193








193Employee stock-based compensation expense




















2,257








2,257Comprehensive loss:Net loss


























(24,839
)

(24,839
)Change in unrealized gain on marketable securities























2





2Comprehensive loss





























(24,837
)Balance at December 31, 2009


10,909,478


87,473








1,443,696


1


5,835


2


(101,122
)

(95,284
)Conversion of preferred stock to common stock


(10,909,478
)

(87,473
)







11,120,725


11


87,462








87,473Issuance of common stock upon initial public offering, net of issuance costs














12,000,000


12


54,583








54,595Issuance of common stock in a private placement offering concurrent with the closing of the initial public offering, net of issuance costs














2,000,000


2


9,982








9,984Issuance of common stock upon exercise of overallotment by underwriters, net of issuance costs














1,382,651


1


6,428








6,429Issuance of common stock upon exercise of stock options














49,806


1


55








56Reclassification of preferred stock warrants liability to additional paid-in capital in conjunction with the conversion of the convertible preferred stock to
common stock upon initial public offering




















428








428Stock-based compensation on options issued to consultants




















496








496Employee stock-based compensation expense




















2,290








2,290Comprehensive loss:Net loss


























(10,058
)

(10,058
)Change in unrealized gain on marketable securities























(16
)




(16
)Comprehensive loss





























(10,074
)Balance at December 31, 2010




$





$



27,996,878

$
28

$
167,559

$
(14
)
$
(111,180
)
$
56,393


See accompanying notes.

82

---





Table of Contents

Anacor Pharmaceuticals, Inc.        Statements of Cash Flows        (In Thousands)

Year Ended December 312008

2009

2010Operating activitiesNet loss

$
(21,625
)
$
(24,839
)
$
(10,058
)Adjustments to reconcile net loss to net cash used in operating activities:Depreciation and amortization


536


752


725Amortization of debt issuance costs


542


771


701Write-off of deferred initial public offering costs


2,136





Stock-based compensation


1,991


2,450


2,786Change in fair value of preferred stock warrants liability


(1,403
)

80


(1,415
)Amortization of premium on short-term investments


(291
)

322


100Accrual of final payment on notes payable


459


424


480Changes in assets and liabilities:Contract receivable


759


194


(993
)Contract receivablerelated party


(3,000
)

3,000


(18
)Government grant receivable








(108
)Prepaid and other current assets


(126
)

(10
)

(895
)Other assets


(45
)




(558
)Accounts payable


(1,793
)

(311
)

392Accrued liabilities


1,199


(89
)

3,335Accrued liabilitiesrelated party








125Deferred revenue


(19,455
)

(10,677
)

2,152Deferred rent


726


109


67Net cash used in operating activities


(39,390
)

(27,824
)

(3,182
)Investing activitiesPurchases of short-term investments


(1,474
)

(32,039
)

(56,936
)Maturities of short-term investments


24,850


23,785


5,890Sales of short-term investments





2,016


Acquisition of property and equipment


(2,126
)

(202
)

(107
)Net cash provided by (used in) investing activities


21,250


(6,440
)

(51,153
)Financing activitiesProceeds from the issuance of convertible preferred stock


46,825





Proceeds from initial public offering, net of issuance costs of $5,889








61,024Proceeds from the issuance of common stock from private placement concurrent with initial public offering, net of issuance costs of $16








9,984Proceeds from the exercise of stock options by employees and consultants


14


14


56Proceeds from convertible promissory notes


3,000





Proceeds from notes payable


7,000





Principal payments on notes payable


(720
)

(4,471
)

(3,120
)Payment of loan restructuring fee








(450
)Net cash provided by (used in) financing activities


56,119


(4,457
)

67,494Net increase (decrease) in cash and cash equivalents


37,979


(38,721
)

13,159Cash and cash equivalents at beginning of period


9,326


47,305


8,584Cash and cash equivalents at end of period

$
47,305

$
8,584

$
21,743Supplemental schedule of noncash financing activitiesConversion of promissory notes and accrued interest to convertible preferred stock

$
3,011

$


$
Conversion of preferred stock to common stock and additional paid-in capital

$


$


$
87,473Reclassification of preferred stock warrants liability to additional paid-in capital

$


$


$
428Supplemental disclosure of cash flow informationInterest paid, including payment of loan restructuring fee

$
1,288

$
1,238

$
1,273Fair value of warrants to purchase convertible preferred stock issued in connection with notes payable

$
1,216

$
256

$
570


See accompanying notes.

83

---





Table of Contents

Anacor Pharmaceuticals, Inc.        Notes to Financial Statements

1. The Company

Nature of Operation

Anacor Pharmaceuticals, Inc. (the Company) was incorporated in the state of Delaware on December 14, 2000 and began
business operations in March 2002. In November 2010, the Company completed an initial public offering (IPO) of its common stock (see Note 11). The Company is a biopharmaceutical
company focused on discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. The Company has discovered, synthesized and developed five
molecules that are currently in clinical development. Its three lead programs are AN2690, a topical antifungal for the treatment of onychomycosis; AN2728, a topical anti-inflammatory for
the treatment of psoriasis and atopic dermatitis; and GSK2251052 (GSK '052, formerly referred to as AN3365), a systemic antibiotic for the treatment of infections caused by
Gram-negative bacteria. In addition to its three lead programs, the Company has two other clinical product candidates, AN2718, its second topical antifungal product candidate, and AN2898,
its second topical anti-inflammatory product candidate. The Company also has a pipeline of internally discovered topical and systemic boron-based compounds in development.

The
Company is also conducting research on additional systemic antibiotics under an October 2007 collaboration agreement with GlaxoSmithKline LLC (GSK). The Company entered
into the six-year research and development collaboration, option and license agreement with GSK for the discovery, development and worldwide commercialization of boron-based systemic
therapeutics (see Note 8). As a result of the purchase of shares of the Company's Series E convertible preferred stock in December 2008, GSK became a related party (see
Notes 8 and 9).

In
August 2010, the Company entered into a research agreement with Eli Lilly and Company (Lilly), under which the Company will collaborate to discover products for a variety of
animal health applications using its boron-based technology platform and drug research capabilities and Lilly will be responsible for worldwide development and commercialization of compounds advancing
from these efforts (see Note 8).

In
February 2007, the Company entered into a worldwide license, development and commercialization agreement with Schering Corporation (Schering), a wholly owned subsidiary of
Schering-Plough, for the development and commercialization of AN2690 (see Note 8). In November 2009, Schering merged with Merck & Co., Inc. (Merck) and in
May 2010, Anacor regained the exclusive worldwide rights to AN2690. Merck did not retain any rights to this compound.

Management
believes that the Company's cash, cash equivalents and short-term investments as of December 31, 2010 will be sufficient to fund the Company's operations
through December 31, 2011. The Company has incurred cumulative losses of $111.2 million through December 31, 2010 and management expects the Company to incur losses for the next
several years. The Company's ultimate success depends on the outcome of its research and development activities. The Company may seek to raise funds through the sale of equity or debt securities or
through external borrowings. In addition, the Company may enter into additional collaborative arrangements or strategic partnerships for the development and commercialization of its compounds. If,
over the next several years, adequate funds are not available, the Company may be required to delay, reduce the scope of, or eliminate one or more of its development programs.

84

---



Table of Contents

Anacor Pharmaceuticals, Inc.

Notes to Financial Statements (Continued)

2. Summary of Significant Accounting Policies

Use of Estimates

The preparation of the financial statements in accordance with U.S. generally accepted accounting principles requires the Company to
make estimates and judgments in certain circumstances that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. In
preparing these financial statements, management has made its best estimates and judgments of certain amounts included in the financial statements, giving due consideration to materiality. On an
ongoing basis, the Company evaluates its estimates, including those related to revenue recognition, fair values of financial instruments in which we invest, convertible preferred stock and common
stock, income taxes, preclinical study and clinical trial accruals and other contingencies. Management bases its estimates on historical experience or on various other assumptions that it believes to
be reasonable under the circumstances. Actual results could differ from these estimates.

Cash, Cash Equivalents and Short-Term Investments

The Company considers all highly liquid investments with a maturity of three months or less at the time of purchase to be cash and cash
equivalents. Investments with a maturity date of more than three months, but less than twelve months, from the date of purchase are considered short-term investments and are classified as
current assets. The Company's short-term investments in marketable securities are classified as available for sale (see Note 3). Securities available for sale are carried at
estimated fair value, with unrealized gains and losses reported as part of accumulated other comprehensive income or loss, a separate component of stockholders' equity (deficit). The Company has
estimated the fair value amounts by using available market information. The cost of available-for-sale securities sold is based on the specific-identification method.

Fair Value of Financial Instruments

The carrying amounts of certain of the Company's financial instruments, including cash and cash equivalents, short-term
investments, restricted investments, contract receivables and accounts payable, approximate their fair value due to their short maturities. Based on the borrowing rates available to the Company for
loans with similar terms and average maturities, the carrying value of the Company's long-term notes payable approximate their fair values at December 31, 2009 and 2010.

Fair
value is considered to be the price at which an asset could be exchanged or a liability transferred (an exit price) in an orderly transaction between knowledgeable, willing parties
in the principal or most advantageous market for the asset or liability. Where available, fair value is based on or derived from observable market prices or other observable inputs. Where observable
prices or inputs are not available, valuation models are applied. These valuation techniques involve management estimation and judgment, the degree of which is dependent on the price transparency for
the instruments or market and the instruments' complexity.

Concentration of Credit Risk

Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents,
short-term investments and restricted investments. Substantially all the Company's cash, cash equivalents and restricted investments are held by two financial institutions that management
believes are of high credit quality. Such deposits may, at times, exceed federally insured limits. At December 31, 2009 and 2010, 91% and 62%, respectively, of the cash and cash equivalents

85

---



Table of Contents

Anacor Pharmaceuticals, Inc.

Notes to Financial Statements (Continued)

2. Summary of Significant Accounting Policies (Continued)

were
held in a money market fund invested in U.S. Treasuries, securities guaranteed as to principal and interest by the U.S. government and repurchase agreements in respect of such securities. The
Company's short-term investments at December 31, 2009 and 2010 were held in securities guaranteed as to principal and interest by the U.S. government. The Company has not
experienced any losses on its deposits of cash, cash equivalents, short-term investments and restricted investments.

Customer Concentration

The Company's revenues consist primarily of contract revenue from collaboration agreements with Schering and GSK. Collaborators have
accounted for significant revenues in the past and may not provide contract revenues in the future under existing agreements and/or new collaboration agreements, which may have a material affect on
the Company's operating results.

Collaborators
whose contract revenue or contract revenuerelated party accounted for 10% or more of total revenues were as follows:

Year Ended
December 312008

2009

2010Schering/Merck(1)


79
%

48
%

21
%GSK (related party)


21
%

47
%

64
%


(1)Agreement
with Schering was terminated in May 2010 (see Note 8).


Contract Receivables and Related Valuation Account

The Company's contract receivables are primarily composed of amounts due under collaboration agreements and the Company believes that
the credit risks associated with these collaborators are not significant. To date, the Company has not written-off any bad debt and, accordingly, does not have an allowance for doubtful
accounts at December 31, 2009 and 2010.

The
contract receivable at December 31, 2009 includes $0.1 million of reimbursable development costs due from Schering. The contract receivable at December 31, 2010
consists of $0.8 million in research funding due from Lilly (see Note 8) and $0.3 million due related to other contracts. The contract receivablerelated party at
December 31, 2010 represents reimbursable patent costs of $18,000 due from GSK (see Note 8). No amount was due from GSK at December 31, 2009.

Restricted Investments

Under its facility lease agreements, the Company is required to secure letters of credit. At December 31, 2009 and 2010, the
Company had approximately $0.2 million of restricted investments to secure these letters of credit.

Property and Equipment

Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation and amortization are calculated
using the straight-line method over the estimated useful

86

---



Table of Contents

Anacor Pharmaceuticals, Inc.

Notes to Financial Statements (Continued)

2. Summary of Significant Accounting Policies (Continued)

lives
of the respective assets, generally three to five years. Leasehold improvements are amortized over the shorter of the remaining lease term or the estimated useful economic lives of the related
assets.

Impairment of Long-Lived Assets

Losses from impairment of long-lived assets used in operations are recorded when indicators of impairment are present and
the undiscounted cash flows estimated to be generated by those assets are less than the assets' carrying amounts. The Company regularly evaluates its long-lived assets for indicators of
possible impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. An impairment loss would be recognized when
estimated undiscounted future cash flows expected to result from the use of an asset and its eventual disposition are less than its carrying amount. Impairment, if any, is assessed using discounted
cash flows.

Revenue Recognition

The Company's contract revenues are generated primarily through research and development collaboration agreements, which typically may
include non-refundable, non-creditable upfront fees, funding for research and development efforts, payments for achievement of specified development, regulatory and sales
milestones and royalties on product sales of licensed products.

For
multiple element arrangements, the Company evaluates the components of each arrangement as separate elements based on certain criteria. Accordingly, revenues from collaboration
agreements are recognized based on the performance requirements of the agreements. The Company recognizes revenue when persuasive evidence of an arrangement exists; transfer of technology has been
completed, services are performed or products have been delivered; the fee is fixed and determinable; and collection is reasonably assured.

Upfront
payments for licensing the Company's intellectual property generally are not separable from the activity of providing research and development services because the license does
not have stand-alone value separate from the research and development services provided. Such upfront payments are recorded as deferred revenue in the balance sheet and are recognized as contract
revenue over the contractual or estimated performance period, which is consistent with the term of the research and development obligations contained in the research and development collaboration
agreement.

Payments
resulting from the Company's research and development efforts under license agreements or government grants are recognized as the activities are performed and are presented on a
gross basis. Revenue is recorded gross because the Company acts as a principal, with discretion to choose suppliers, bears credit risk and performs part of the services. The costs associated with
these activities are
reflected as a component of research and development expense in the statements of operations and approximate revenue recognized.

Substantive,
at-risk milestone payments are recognized as revenue when the milestone is achieved and collectibility is reasonably assured. When payments are not for
substantive and at-risk milestones, revenue will be recognized over the estimated remaining term of the service period.

Royalties
based on reported sales of licensed products will be recognized based on contract terms when reported sales are reliably measurable and collectibility is reasonably assured. To
date, none of

87

---



Table of Contents

Anacor Pharmaceuticals, Inc.

Notes to Financial Statements (Continued)

2. Summary of Significant Accounting Policies (Continued)

the
Company's products have been approved and therefore the Company has not earned any royalty revenue from product sales.

Research and Development Expenses

All research and development expenses, including those funded by third parties, are expensed as incurred. Research and development
expenses include, but are not limited to, salaries, benefits, stock-based compensation, lab supplies, allocated overhead, fees for professional service providers and costs associated with product
development efforts, including preclinical studies and clinical trials.

Preclinical Study and Clinical Trial Accruals and Deferred Advance Payments

The Company estimates preclinical study and clinical trial expenses based on the services performed pursuant to contracts with research
institutions and clinical research organizations that conduct these activities on its behalf. In recording service fees, the Company estimates the time period over which the related services will be
performed and compares the level of effort expended through the end of each period to the cumulative expenses recorded and payments made for such services and, as appropriate, accrues additional
service fees or defers any non-refundable advance payments until the related services are performed. If the actual timing of the performance of services or the level of effort varies from
the estimate, the Company will adjust its accrual or deferred advance payment accordingly. If the Company later determines that it no
longer expects the services associated with a deferred non-refundable advance payment to be rendered, the deferred advance payment will be charged to expense in the period that such
determination is made.

Fair Values of Preferred Stock Warrants

Prior to the Company's IPO, outstanding warrants to purchase shares of its Series D and Series E convertible preferred
stock were freestanding warrants that were exercisable into convertible preferred stock that was subject to redemption and were therefore classified as liabilities in the balance sheet at fair value.
The initial liability recorded was adjusted for changes in the fair values of the Company's preferred stock warrants during each reporting period and was recorded as a component of other income
(expense) in the statement of operations for that period.

Upon
closing of the Company's IPO and the conversion of the underlying preferred stock to common stock, all outstanding warrants to purchase shares of preferred stock were automatically
converted into warrants to purchase shares of the Company's common stock. The aggregate fair value of these warrants upon the closing of the IPO was $0.4 million which was reclassified from
liabilities to additional paid-in capital, a component of stockholders' equity (deficit), and the Company ceased recording any related periodic fair value adjustments. The Company
estimated the fair values of these warrants using the Black-Scholes option-pricing model, based on the inputs for the estimated fair value of the underlying convertible preferred stock at the
valuation measurement date, the remaining contractual term of the warrant, risk-free interest rates, expected dividend rates and expected volatility of the price of the underlying
convertible preferred stock. These estimates were based on subjective assumptions.

88

---



Table of Contents

Anacor Pharmaceuticals, Inc.

Notes to Financial Statements (Continued)

2. Summary of Significant Accounting Policies (Continued)

Stock-Based Compensation

Employee stock-based compensation cost is measured at the grant date, based on the fair value of the award, and is recognized as an
expense over the employee's requisite service period (generally the vesting period). The Company uses the Black-Scholes option-pricing model to estimate the fair value of its stock-based awards. For
options granted prior to January 1, 2006, the Company used the graded-vested (multiple-option) method for expense attribution and, prior to January 1, 2006, recognized option forfeitures
as they occurred. For options granted after January 1,
2006, the Company uses the straight-line (single-option) method for expense attribution, estimates forfeitures and recognizes expense only for those shares expected to vest.

The
Company accounts for equity instruments issued to nonemployees based on their fair values on the measurement dates using the Black-Scholes option-pricing model. The fair values of
the options granted to nonemployees are remeasured as they vest. As a result, the noncash charge to operations for nonemployee options with vesting is affected each reporting period by changes in the
fair value of the Company's common stock.

Income Taxes

The Company utilizes the liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are
determined based on differences between financial reporting and tax reporting bases of assets and liabilities and are measured using enacted tax rates and laws that are expected to be in effect when
the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized.

The
Company recorded a full valuation allowance at each balance sheet date presented. Based on the available evidence, the Company believes that it is more likely than not that it will
be unable to utilize all of its deferred tax assets in the future. The Company intends to maintain the full valuation allowances until there is sufficient evidence to support the reversal of the
valuation allowances.

The
Company accounts for uncertain tax positions in the financial statements when it is more likely than not that the position will be sustained upon examination by the tax authorities.
Such tax positions must initially and subsequently be measured as the largest amount of tax benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the tax
authority assuming full knowledge of the position and relevant facts. The Company's policy is to recognize any interest and penalties related to income taxes in income tax expense.

Net Loss per Common Share

Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average
number of common shares outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is computed by dividing the net loss attributable to common
stockholders by the weighted-average
number of common share equivalents outstanding for the period determined using the treasury-stock method. For purposes of this calculation, potentially dilutive securities consisting of convertible
preferred stock, stock options and warrants are considered to be common stock equivalents and were excluded in the calculation of diluted net loss per share because their effect would be antidilutive.

89

---



Table of Contents

Anacor Pharmaceuticals, Inc.

Notes to Financial Statements (Continued)

2. Summary of Significant Accounting Policies (Continued)

The
following table presents the calculation of basic and diluted net loss per share of common stock (in thousands, except share and per share data):

Year Ended December 312008

2009

2010Historical net loss per common shareNumerator:Net loss

$
(21,625
)
$
(24,839
)
$
(10,058
)Denominator:Weighted-average number of common shares used in calculating net loss per common sharebasic and diluted


1,405,140


1,415,083


3,705,505Net loss per common sharebasic and diluted

$
(15.39
)
$
(17.55
)
$
(2.71
)


Comprehensive Loss

Comprehensive loss and its components are reported in the statements of convertible preferred stock and stockholders' equity (deficit).
Comprehensive loss consists of net loss and unrealized gains or losses on marketable securities.

Recent Accounting Pronouncements

In October 2009, the FASB issued an Accounting Standards Update (ASU) No. 2009-13, which requires companies
to allocate revenue in multiple element arrangements based on an element's estimated selling price if vendor-specific or other third-party evidence of value is not available. The standard is effective
for the Company beginning January 1, 2011, although earlier application is permitted. The Company is currently evaluating both the timing and the impact of the pending adoption of this standard
on its financial statements.

In
April 2010, the FASB amended ASU 2010-17 which provides guidance on the milestone method of revenue recognition for research or development arrangements. An
entity can make an accounting policy election to recognize a payment that is contingent upon the achievement of a substantive milestone in its entirety in the period in which the milestone is
achieved. The milestone method is not required and is not the only acceptable method of revenue recognition for milestone payments. The standard is effective on a prospective basis for annual periods,
and interim periods within those years, on or after June 15, 2010, although earlier application is permitted. The Company does not expect the adoption of this standard to have a material impact
on its financial statements.

90

---



Table of Contents

Anacor Pharmaceuticals, Inc.

Notes to Financial Statements (Continued)

3. Marketable Securities

At December 31, 2009, the amortized cost and fair value of marketable securities, with gross unrealized gains and losses, were as follows (in thousands):

Amortized Cost

Gross
Unrealized
Gains

Gross
Unrealized
Losses

Fair ValueMoney market fund

$
7,844

$


$


$
7,844Federal agency securities


5,917


2





5,919Total marketable securities

$
13,761

$
2

$


$
13,763Reported as:Cash and cash equivalents










$
7,844Short-term investments











5,919Total marketable securities










$
13,763


At
December 31, 2010, the amortized cost and fair value of marketable securities, with gross unrealized gains and losses, were as follows (in thousands):

Amortized Cost

Gross
Unrealized
Gains

Gross
Unrealized
Losses

Fair ValueMoney market fund

$
13,413

$


$


$
13,413U.S. treasury securities


14,363





(2
)

14,361Federal agency securities


29,259


1


(11
)

29,249U.S. government guaranteed corporate bonds


21,184


1


(3
)

21,182Total marketable securities

$
78,219

$
2

$
(16
)
$
78,205Reported as:Cash and cash equivalents










$
21,357Short-term investments











56,848Total marketable securities










$
78,205


All
marketable securities held at December 31, 2009 and 2010 had original maturities at the date of purchase of less than one year.

The
Company recognized gross realized gains of $4,000 in 2009 from the sale of marketable securities. There were no realized gains or losses recognized from the sale of marketable
securities in 2008 or 2010.

91

---



Table of Contents

Anacor Pharmaceuticals, Inc.

Notes to Financial Statements (Continued)

4. Balance Sheet Detail

Property and Equipment

Property and equipment consists of the following (in thousands):

December 312009

2010Laboratory equipment

$
2,910

$
2,944Furniture and fixtures


171


171Computer equipment and software


823


886Leasehold improvements


1,271


1,2785,175


5,279Less: accumulated depreciation and amortization


(2,713
)

(3,435
)Property and equipment, net

$
2,462

$
1,844


Accrued Liabilities

Accrued liabilities consist of the following (in thousands):

December 312009

2010Accrued compensation

$
1,212

$
1,656Accrued preclinical study and clinical trial costs


1,433


3,310Other


983


1,997Accrued liabilities

$
3,628

$
6,963


Accrued LiabilitiesRelated Party

The accrued liabilitiesrelated party balance of $0.1 million at December 31, 2010 consists of the unused
portion of an advance for GSK '052 clinical trial costs due to GSK. This amount will be repaid in 2011. No amount was due to GSK at December 31, 2009.

5. Fair Value Measurements

In measuring fair value, the Company evaluates valuation techniques such as the market approach, the income approach and the cost approach. A three-level valuation hierarchy that
prioritizes the inputs to valuation techniques is used to measure fair value based upon whether such inputs are observable or unobservable.

Observable
inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions made by the reporting entity. The three-level hierarchy for
the inputs to valuation techniques is briefly summarized as follows:



92

---



Table of Contents

Anacor Pharmaceuticals, Inc.

Notes to Financial Statements (Continued)

5. Fair Value Measurements (Continued)



The
Company's financial assets and financial liabilities subject to fair value measurements on a recurring basis and the levels of the inputs used in such measurements are as follows (in
thousands):

Fair Value Measurements on a Recurring Basis
at December 31, 2009Level 1

Level 2

Level 3

TotalQuoted Prices
in Active
Markets for
Identical Items

Significant
Other
Observable
Inputs

Significant
Unobservable
Inputs

Balance at
December 31,
2009Financial assets:Money market fund

$
7,844

$


$


$
7,844Federal agency securities





5,919





5,919Total marketable securities

$
7,844

$
5,919

$


$
13,763Financial liabilities:Preferred stock warrants liability

$


$


$
1,273

$
1,273




Fair Value Measurements on a Recurring Basis
at December 31, 2010Level 1

Level 2

Level 3

TotalQuoted prices
in Active
Markets for
Identical Items

Significant
Other
Observable
Inputs

Significant
Unobservable
Inputs

Balance at
December 31,
2010Financial assets:Money market fund

$
13,413

$


$


$
13,413U.S. treasury securities





14,361





14,361Federal agency securities





29,249





29,249U.S. government guaranteed corporate bonds





21,182





21,182Total marketable securities

$
13,413

$
64,792

$


$
78,205


The
fair values of the money market fund were derived from quoted market prices in an active market. Federal agency securities are valued using third-party pricing sources that apply
applicable inputs and other relevant data into their models to estimate fair value.

93

---



Table of Contents

Anacor Pharmaceuticals, Inc.

Notes to Financial Statements (Continued)

5. Fair Value Measurements (Continued)

The
following table presents changes in liabilities measured at fair value on a recurring basis using Level 3 inputs (in thousands):

Preferred
Stock
Warrants
LiabilityBalance at December 31, 2008

$
937Fair value of January 2009 increase in number of shares available for purchase under warrant issued in connection with 2008 borrowing (see
Note 6)


256Increase in fair value included in other expense


80Balance at December 31, 2009


1,273Fair value of new warrant issued in connection with January 2010 loan modification (see Note 6)


570Decrease in fair value included in other income


(1,415
)Reclassification of preferred stock warrants liability to additional paid-in capital in conjunction with the conversion of the convertible preferred
stock to common stock upon the IPO


(428
)Balance at December 31, 2010

$



The
Company's valuation technique to measure the fair value of the preferred stock warrants liability was based on valuations prepared by the Company, with the assistance of independent
consultants, using unobservable inputs, including the Company's assumptions about projected revenues, expenses, cash flows, risk-based rates of return on projected cash flows, expected
volatility and marketability discounts applicable to the Company's common and convertible preferred stock. The Company remeasured the fair value of the preferred stock warrants liability at each
reporting period using current assumptions, with decreases (increases) in fair value recorded as other income (expense). The preferred stock warrants liability was reclassified to additional
paid-in capital, a component of stockholders equity (deficit) subsequent to the Company's IPO in November 2010 (see Note 10).

6. Notes Payable

In 2006, the Company entered into a loan agreement for $8.0 million (the Original Loan). The related notes are secured by all assets of the Company except intellectual property.
The notes required interest-only payments for the period from initial borrowing through December 2007 at prime plus 2% resulting in interest rates that ranged from 9.50% to 10.25% per
annum, followed by 30 monthly payments of principal and interest at an interest rate of 9.25% per annum. A final payment of $0.8 million due one month after the 30 monthly
principal and interest payments, or in June 2010, was being accrued over the term of the loan into interest expense. A debt discount, related to the initial fair value of a warrant for shares of
Series D convertible preferred stock issued in conjunction with the Original Loan, is being amortized to interest expense over the term of the notes (see Note 10).

In
May 2008, the terms of the Original Loan were modified effective April 1, 2008, in conjunction with a new $7.0 million borrowing from the same lender. For the
$7.3 million Original Loan balance outstanding at March 31, 2008, the Company, in accordance with the new terms, was required to make

94

---



Table of Contents

Anacor Pharmaceuticals, Inc.

Notes to Financial Statements (Continued)

6. Notes Payable (Continued)

interest-only
payments through April 2009 at 9.75% per annum, followed by 24 monthly payments of principal and interest at an interest rate of 9.25% per annum. An amended final
payment of $1.1 million comprised of the original final payment of $0.8 million and a new loan amendment fee of $0.3 million, was due one month after the 24 monthly
principal and interest payments, or April 2011. The portion of this amended final payment not already accrued at March 31, 2008 is being accrued over the remaining revised term of the loan into
interest expense.

For
the additional $7.0 million borrowed by the Company in May 2008, the related note required interest-only payments through April 2009 at 12% per annum, followed by
24 monthly payments of principal and interest at an interest rate of 9.25%. A final payment of $0.4 million due at the end of the 36-month term, or April 2011, is being
accrued over the term of the loan into interest expense. A debt discount, related to the initial fair value of a warrant for shares of Series D convertible preferred stock issued in conjunction
with the additional $7.0 million borrowing in
May 2008 and the January 2009 increase in the number of shares available for purchase under this warrant, is being amortized to interest expense over the term of the new note (see Note 10). The
note is secured by all assets of the Company except intellectual property.

In
January 2010, the Company negotiated changes to the existing loan agreement and obtained an interest-only payment period of 6 months beginning on January 1,
2010. During the interest-only period, principal payments were deferred and interest was paid at a 9.25% annual interest rate. Monthly payments of principal and interest at the same annual
interest rate began on July 1, 2010 and run through December 1, 2011. A restructuring fee of $0.5 million was paid on July 1, 2010. On December 1, 2011, a
$1.5 million final payment, which includes all previous final payments, is due. Both the $0.5 million restructuring fee and the portion of the $1.5 million final payment not
already accrued at December 31, 2009 are being accrued into interest expense over the remaining revised term of the loan. In conjunction with the restructuring, the Company issued the
debt-holder a warrant to purchase 40,623 shares of the Company's Series E convertible preferred stock at an exercise price of $16.936 per share. The warrant is exercisable until
January 1, 2017.

In
connection with the closing of the IPO in November 2010, all three of the preferred stock warrants automatically converted to common stock warrants (see Note 10).

Future
payments at December 31, 2010 are as follows (in thousands):

Total minimum payments due in 2011 as of December 31, 2010;refinanced in 2011 (see below)

$
8,430Less amount representing interest


1,741Notes payable, gross


6,689Unamortized discount on notes payable


(236
)Accretion of the final payment


1,2887,741Less current portion of notes payable, including unamortized discount


1,522Notes payable, less current portion

$
6,219


On
March 18, 2011, the Company entered into a loan and security agreement with new lenders to provide up to $30.0 million, available in three tranches of
$10.0 million each (see Note 16). The first

95

---



Table of Contents

Anacor Pharmaceuticals, Inc.

Notes to Financial Statements (Continued)

6. Notes Payable (Continued)

$10.0 million
tranche was drawn on March 18, 2011, at which time the Company repaid $6.6 million of the remaining obligations under its existing loan. As of December 31,
2010, $6.2 million of the existing note payable balance has been classified, and is reflected in the table above, as a long-term liability in the balance sheet.

The
Company recorded interest expense related to all borrowings, including the amortization of the debt discounts, the amortization of direct financing costs related to the Original Loan
and the interest expense related to the accretion of the final payments of $2.3 million, $2.4 million and $2.0 million for 2008, 2009 and 2010, respectively. The annual effective
interest rate after consideration of the January
2010 restructuring, including the amortization of the debt discounts and accretion of the final payments is 21.42%.

7. Commitments and Contingencies

Operating Leases

The Company leases a 36,960 square-foot building consisting of office and laboratory space in Palo Alto, California, for
its corporate headquarters. The lease term commenced in March 2008 and has scheduled annual rent increases through the lease expiration in March 2018. Rent expense is recognized on a
straight-line basis over the term of the lease. The Company is also responsible for certain operating expenses. The lease provided a $0.4 million allowance from the landlord for
tenant improvements. This amount has been included in deferred rent in the accompanying December 31, 2009 and 2010 balance sheets and is being amortized over the term of the lease, on a
straight-line basis, as a reduction to rent expense. Under the lease agreement, the Company provided a security deposit in the amount of $0.1 million in the form of a standing
letter of credit.

The
Company also continues to lease a 15,300 square-foot building consisting of office and laboratory space in Palo Alto, California. The operating lease, which would have
expired in December 2009, was extended for one year to December 31, 2010. In September 2010, the Company exercised its option to extend the lease for another one-year extension to
December 31, 2011. The lease is cancelable with four months' notice. The Company currently provides a $0.1 million standing letter of credit as a security deposit under its lease
agreement, which it will continue to provide with any lease extensions.

Rent
expense under all facility operating leases was $1.5 million, $1.8 million and $1.8 million for 2008, 2009, and 2010, respectively. Deferred rent of
$0.8 million and $0.9 million at December 31, 2009 and 2010, respectively, is included in the accompanying balance sheets and represents the difference between recorded rent
expense and the cash payments related to the operating lease, plus the unamortized portion of the tenant improvement allowance.

96

---



Table of Contents

Anacor Pharmaceuticals, Inc.

Notes to Financial Statements (Continued)

7. Commitments and Contingencies (Continued)

At
December 31, 2010, future minimum cash payments under facility operating leases with initial terms in excess of one year are as follows (in thousands):

2011

$
1,8152012


1,4542013


1,5012014


1,5502015


1,600Thereafter


3,788Total future minimum lease payments

$
11,708


Guarantees and Indemnifications

The Company, as permitted under Delaware law and in accordance with its bylaws, indemnifies its officers and directors for certain
events or occurrences, subject to certain limits, while the officer or director is or was serving at the Company's request in such capacity. The term of the indemnification period is equal to the
officer's or director's lifetime.

The
maximum amount of potential future indemnification is unlimited; however, the Company currently holds director and officer liability insurance. This insurance limits the Company's
exposure and may enable it to recover a portion of any future amounts paid. The Company believes that the fair value of these indemnification obligations is minimal. Accordingly, the Company has not
recognized any liabilities relating to these obligations for any period presented.

The
Company has certain agreements with contract research organizations with which it does business that contain indemnification provisions pursuant to which the Company typically agrees
to indemnify the party against certain types of third-party claims. The Company accrues for known indemnification issues when a loss is probable and can be reasonably estimated. The Company would also
accrue for
estimated incurred but unidentified indemnification issues based on historical activity. There were no accruals for or expenses related to indemnification issues for any period presented.

8. License, Research, Development and Commercialization Agreements

GSK

In October 2007, the Company entered into a research and development collaboration, option and license agreement with GSK for the
discovery, development, and worldwide commercialization of boron-based systemic therapeutics. The collaborative research term of the agreement is six years, subject to an extension of up to two years
if agreed to by both parties. Under the agreement, the Company is currently working to identify and develop multiple product candidates in three target-based project areas. In each project, GSK has
the option to obtain an exclusive license to develop, commercialize and market worldwide a specified number of product candidates once they have achieved certain
proof-of-concept criteria.

Upon
exercise of an option, GSK assumes sole responsibility for the further development and commercialization of the applicable product candidate. GSK is obligated to make payments to
the Company if certain development, regulatory and commercial milestones are met on a

97

---



Table of Contents

Anacor Pharmaceuticals, Inc.

Notes to Financial Statements (Continued)

8. License, Research, Development and Commercialization Agreements (Continued)

compound-by-compound
basis. Additionally, the Company is eligible to receive commercial milestones for each approved drug based on sales of the drug. Milestone payments may be
lower for designated programs depending upon: whether GSK makes the selection of the product candidate before or after initiation of Phase I clinical trial dosing (10%-15%
reduction if selected before such dosing); if certain target product profile characteristics are not achieved (20%-40% reduction); and whether the product candidate is designated after the
initial two product candidate designations in a program (50% reduction). GSK is further obligated to pay the Company royalties on annual net sales of products. Such royalties shall continue until the
later of expiration of such valid patent claims or ten years from the first commercial sale on a product-by-product and country-by-country basis. To
date, no products have been approved and therefore no royalty fees have been earned under this agreement.

During
the research term, the Company is committed to use diligent efforts to discover and optimize compounds pursuant to agreed research plans and to provide specified resources,
including certain numbers of full-time-equivalent scientists, on a project-by-project basis. Each party is responsible for its own research and
development costs. The Company will be primarily responsible for the discovery and development of each product candidate from the research stage until GSK exercises an option for such product
candidate.

Unless
earlier terminated, the agreement will continue in effect until expiration of all payment obligations under the agreement. GSK retains the unilateral right to terminate the
agreement in its entirety upon six months prior written notice to the Company and immediately with respect to any project. Either party may also terminate the agreement, on a
project-by-project basis or in its entirety for any uncured material breach of the agreement by the other party. Either party may also terminate the agreement upon specified
actions relating to insolvency of the other party. In the event of unilateral termination by GSK, all rights granted by the Company to GSK with respect to the project to which such termination applies
would terminate and the Company would retain the rights to any compounds relating to such project. In the event of termination by GSK for cause, GSK would have a perpetual exclusive license under the
Company's intellectual property to develop and commercialize any project compounds to which such termination applies, subject to GSK's payment to the Company of specified royalties on sales of such
compounds. In the event of termination by the Company for cause, the Company would have a perpetual exclusive license under GSK's intellectual property to develop and commercialize any project
compound to which such termination applies, subject to payment by the Company to GSK of specified royalties on sales of such compounds.

Pursuant
to the agreement, GSK paid the Company a $12.0 million non-refundable, non-creditable upfront fee in October 2007, which is being recognized over
the six-year research term on a straight-line basis. GSK '052 is the Company's most advanced product candidate under the collaboration. In July 2010, GSK notified the Company
that the Company's GSK '052 product candidate had achieved proof-of-concept criteria and that GSK was exercising its option to obtain an exclusive license to develop,
commercialize and market worldwide the GSK '052 compound. In connection with the exercise of this option, GSK paid the Company $15.0 million in August 2010 and will assume sole responsibility
for the further development and commercialization of GSK '052. In addition, GSK is obligated to make payments to the Company if GSK '052 meets certain development, regulatory and commercial milestones
and to pay royalties on any future product sales of GSK '052.

98

---



Table of Contents

Anacor Pharmaceuticals, Inc.

Notes to Financial Statements (Continued)

8. License, Research, Development and Commercialization Agreements (Continued)

The Company also had the right to require GSK to purchase $10.0 million of the Company's capital stock. In December 2008, GSK purchased $30.0 million of the Company's
Series E convertible preferred stock and became a related party. Upon closing of the IPO in November 2010, all of the outstanding shares of the Company's convertible preferred stock owned by
GSK were automatically converted into 1,771,374 shares of its common stock (see Note 9). In connection with the IPO in November 2010, GSK purchased an additional 1,000,000 shares of common
stock of the Company at $5.00 per share.

Revenues
recognized under this agreement in 2008, 2009 and 2010 were as follows (in thousands):

Year Ended December 312008

2009

2010Contract revenuerelated party:Amortization of upfront fee

$
2,000

$
2,000

$
2,000Milestone fees


3,300


6,825


15,000Reimbursement for patent costs, clinical trial costs and procurement of drug material





25


909Total contract revenuerelated party

$
5,300

$
8,850

$
17,909


Lilly

In August 2010, the Company entered into a research agreement with Lilly under which the companies will collaborate to discover
products for a variety of animal health applications. Lilly will be responsible for worldwide development and commercialization of compounds
advancing from these efforts. The Company received an upfront payment of $3.5 million in September 2010, which is being recognized over a four-year research term on a
straight-line basis, and the Company will receive a minimum of $6.0 million in research funding with the potential of up to $12.0 million in research funding, if successful.
In addition, the Company will be eligible to receive payments upon the achievement of specified development and regulatory milestones, as well as tiered royalties escalating from high single digit to
in the tens royalties on sales, depending in part upon the mix of products sold. Such royalties continue through the later of expiration of the Company's patent rights or six years from the first
commercial sale on a product-by-product and country-by-country basis.

Unless
earlier terminated, the agreement continues in effect until the termination of royalty payment obligations. The agreement allows for termination by Lilly upon written notice, with
certain additional payments to the Company and a notice period that has a duration dependent on whether the notice is delivered prior to the first regulatory approval of a product under the agreement
or thereafter. In addition, either party may terminate for the other party's uncured material breach of the agreement. In the event of termination by the Company for material breach by Lilly or
termination upon written notice by Lilly, Lilly would assign to the Company certain trademarks and regulatory materials used in connection with the products under the agreement and grant to the
Company an exclusive license under Lilly's patent rights covering such products, and the Company would pay to Lilly a reasonable royalty on sales of such products should the Company desire an
exclusive license. In the event of termination for material breach by the Company, Lilly will be entitled to a return of all research funding payments for expenses the Company has not incurred or
irrevocably committed.

99

---



Table of Contents

Anacor Pharmaceuticals, Inc.

Notes to Financial Statements (Continued)

8. License, Research, Development and Commercialization Agreements (Continued)

Revenues
recognized under this 2010 agreement were as follows (in thousands):

2010Contract revenue:Amortization of upfront fee

$
308Research funding


1,057Total contract revenue

$
1,365


Schering

In February 2007, the Company entered into an exclusive license, development and commercialization agreement with Schering for the
development and worldwide commercialization of AN2690. Under the agreement, Schering assumed sole responsibility for development and commercialization of AN2690.

Pursuant
to the agreement, in March 2007, Schering paid the Company a $40.0 million non-refundable, non-creditable upfront fee, which was recognized on a
straight-line basis over the estimated 27.5 month period ended in June 2009 during which the Company performed development-related activities under its transitional responsibilities
(the Transition Period). During the Transition Period, Schering reimbursed the Company for costs incurred by the Company to perform specified development-related activities. No milestones or royalty
fees were earned under this agreement.

In
November 2009, Schering merged with Merck. In May 2010, the Company entered into a mutual termination and release agreement with Merck pursuant to which the 2007 agreement was
terminated. Under the May 2010 agreement, the Company regained the exclusive worldwide rights to AN2690, Merck provided for the transfer to the Company of all material and information related to
AN2690, Merck paid $5.8 million to the Company, and the parties released each other from any and all claims, liabilities or other types of obligations relating to the 2007 agreement. Merck did
not retain any rights to this compound.

Revenues
recognized in 2008, 2009 and 2010 under the agreement with Schering and the related mutual termination and release agreement with Merck were as follows (in thousands):

Year Ended December 312008

2009

2010Contract revenue:Amortization of upfront fee

$
17,454

$
8,728

$
Payment from Merck in connection with termination and release agreement








5,750Reimbursement for development-related activities


2,257


277


29Total contract revenue

$
19,711

$
9,005

$
5,779


100

---



Table of Contents

Anacor Pharmaceuticals, Inc.

Notes to Financial Statements (Continued)

9. Convertible Preferred Stock

The authorized, issued and outstanding shares of convertible preferred stock at December 31, 2009 were as follows (in thousands, except share data):

Shares
Authorized

Shares
Issued and
Outstanding

Aggregate
Liquidation
Preference

Carrying
Amounts (net of
Financing Costs)Series A-1


4,228,329


845,663

$
3,000

$
2,943Series A-2


1,198,046


239,608


850


850Series B


3,339,341


667,866


4,000


3,972Series C


28,089,885


5,617,968


25,000


24,837Series D


3,716,626


586,090


5,070


5,035Series E


15,100,000


2,952,283


50,000


49,83655,672,227


10,909,478

$
87,920

$
87,473


The
Company recorded the convertible preferred stock at fair value on the dates of issuance, net of issuance costs. The Company had classified the convertible preferred stock outside of
stockholders' equity (deficit) because the shares contained redemption features that were not solely within its control. Upon closing of the IPO in November 2010, 10,909,478 outstanding shares of
convertible preferred stock were automatically converted into 11,120,725 shares of common stock, and the related carrying value of $87.5 million was reclassified to additional
paid-in capital. At December 31, 2010, no convertible preferred shares were authorized, issued or outstanding.

10. Preferred Stock Warrants Liability and Common Stock Warrants

In connection with the debt financing entered into in June 2006 (see Note 6), the Company issued a warrant to purchase Series D convertible preferred stock for $8.65 per
share (Warrant #1). Under Warrant #1, 30,058 shares were initially available for purchase upon execution of the loan agreement in June 2006. In connection with the July and December 2006 borrowings,
the number of shares available for purchase under Warrant #1 was increased by an additional 30,057 shares. The Company assigned an initial fair value of $0.4 million to the warrant, of which
$0.2 million related to the June 2006 issuance, which was accounted for as capitalized debt financing cost, and $0.2 million related to the July and December 2006 share increases, which
were accounted for as discounts on the related borrowings. The Company is amortizing the capitalized debt financing costs and the debt discounts over the amended term of the note (see Note 6).
This warrant expires in 2013.

In
connection with the additional $7.0 million borrowing in May 2008, the Company issued a second warrant to purchase up to 97,109 shares of the Series D convertible
preferred stock for $8.65 per share (Warrant #2). Upon funding of the additional loan proceeds, there were 64,739 shares available for purchase under Warrant #2, all of which were immediately
exercisable. On January 1, 2009, the number of shares available for purchase under Warrant #2 increased by 32,370, and these shares were immediately exercisable. The Company assigned an initial
fair value of $1.2 million to Warrant #2 for the 64,739 shares that were available for purchase when the warrant was issued in May 2008 and a fair value of $0.3 million for the January
2009 increase in shares available for purchase under Warrant #2, both of which were accounted for as discounts on the related borrowings. The Company is amortizing the debt discounts over the amended
term of the note (see Note 6). Warrant #2 expires in 2015.

101

---



Table of Contents

Anacor Pharmaceuticals, Inc.

Notes to Financial Statements (Continued)

10. Preferred Stock Warrants Liability and Common Stock Warrants (Continued)

In
conjunction with the restructuring of the Company's debt in January 2010, the Company issued a warrant to purchase 40,623 shares of the Company's Series E convertible preferred
stock for $16.936 per share (Warrant #3). The Company assigned an initial fair value of $0.6 million to Warrant #3, which was accounted for as a discount on the related borrowings. The debt
discount is being amortized over the amended term of the note (see Note 6). Warrant #3 expires in 2017.

The
initial values of the three warrants were determined using the Black-Scholes model and the following assumptions:

Warrant #1

Warrant #2

Warrant #2

Warrant #32006

2008

2009

2010Dividend yield


0
%

0
%

0
%

0
%Volatility


73
%

74
%

75
%

70
%Weighted-average expected life (in years)


6.5 - 7.0


7.0


6.3


7.0Risk-free interest rate


4.7 - 5.1
%

3.4
%

1.87
%

3.4
%


During
2008, 2009 and 2010, the Company's interest expense included $0.5 million, $0.8 million and $0.7 million, respectively, for the amortization of the financing
costs and debt discounts.

The
preferred stock warrants liability was adjusted to its fair value at the end of each reporting period using the Black-Scholes option-pricing model to determine such fair value.
During 2008, 2009 and 2010, the Company recorded other expense (income) for the increase (decrease) in the fair value of the warrants of $(1.4) million, $0.1 million and $(1.4) million,
respectively. The fair value of the warrants was estimated to be $1.3 million at December 31, 2009. In connection with the closing of the IPO in November 2010, all three of the preferred
stock warrants automatically converted into common stock warrants and the preferred stock warrants liability, $0.4 million as of the conversion date, was reclassified to additional
paid-in capital. Accordingly, there was no preferred stock warrants liability at December 31, 2010.

At
December 31, 2010, the following common stock warrants were issued and outstanding:

Warrant

Shares Subject
to Warrants

Exercise Price
per Share

ExpirationWarrant #1


60,115

$
8.65

June 2013Warrant #2


97,109

$
8.65

May 2015Warrant #3


40,623

$
16.936

January 2017Total warrants


197,847


11. Stockholders' Equity (Deficit)

Initial Public Offering

In November 2010, the Company completed its IPO of common stock pursuant to a registration statement that was declared effective on
November 23, 2010. The Company sold 13,382,651 shares of its common stock, which included 1,382,651 shares of the Company's common stock sold pursuant to an over-allotment option
granted to the underwriters, at a price to the public of $5.00 per share. As a

102

---



Table of Contents

Anacor Pharmaceuticals, Inc.

Notes to Financial Statements (Continued)

11. Stockholders' Equity (Deficit) (Continued)

result
of the IPO, the Company raised a total of $66.9 million in gross proceeds, and approximately $61.0 million in net proceeds after deducting underwriting discounts and commissions
of $3.2 million and estimated offering expenses of $2.7 million. Costs directly associated with the Company's IPO were capitalized and recorded as deferred offering costs prior to the
closing of the IPO. These costs have been recorded as a reduction of the proceeds received to determine the amount to be recorded in additional paid-in capital. Upon the closing of the
IPO, 10,909,478 shares outstanding of the Company's convertible preferred stock automatically converted into 11,120,725 shares of its common stock.

Concurrent
with the closing of the IPO, the Company sold 2,000,000 shares of its common stock through a private placement offering at a price of $5.00 per share. Gross proceeds raised in
the private placement were $10.0 million with estimated issuance costs of $16,000.

Reverse Stock Split

In November 2010, the Company filed a certificate of amendment of amended and restated certificate of incorporation effecting a
1-for-5 reverse stock split of the Company's issued and outstanding shares of common stock and convertible preferred stock. The par value of the common and convertible
preferred stock was not adjusted as a result of the reverse stock split. All issued and outstanding common stock, convertible preferred stock, warrants for common stock, warrants for preferred stock,
and per share amounts contained in the Company's financial statements have been retroactively adjusted to reflect this reverse stock split for all periods presented.

Preferred Stock

In November 2010, the Company amended and restated its certificate of incorporation to authorize 10,000,000 shares of preferred stock
upon the completion of the IPO of its common stock. At December 31, 2010, there was no preferred stock outstanding.

Common Stock

In November 2010, the Company amended and restated its certificate of incorporation to increase the authorized common stock to
100,000,000 shares upon the completion of the IPO of its common stock.

The
following table presents common stock reserved for future issuance for the following equity instruments as of December 31, 2010:

Warrants to purchase common stock


197,847Options:Outstanding under the 2001 Equity Incentive Plan


1,943,252Reserved for future grants under the 2010 Equity Incentive Plan


932,670Reserved for future issuance under the 2010 Employee Stock Purchase Plan


250,000Total common stock reserved for future issuance


3,323,769


103

---



Table of Contents

Anacor Pharmaceuticals, Inc.

Notes to Financial Statements (Continued)

11. Stockholders' Equity (Deficit) (Continued)

2010 Equity Incentive Plan

In November 2010, the Company's board of directors approved the Company's 2010 Equity Incentive Plan (2010 Plan), which became
effective on the date of the IPO of the Company's common stock. A total of 929,832 shares of common stock were initially reserved for future issuance under the 2010 Plan; and shares subject to
outstanding stock awards granted under the Company's 2001 Equity Incentive Plan (2001 Plan) that expire or terminate for any reason prior to their exercise or settlement and would otherwise return to
the 2001 Plan reserve will be added to the shares reserved under the 2010 Plan. In addition, the number of shares of common stock available for issuance under the 2010 Plan will automatically increase
on January 1st of each year for ten years commencing on January 1, 2012 by an amount equal to 4% of the total number of shares outstanding on
December 31st of the preceding calendar year, or a lesser number of shares of common stock as determined by the Company's board of directors. The maximum number of all
shares that may be issued under the 2010 Plan is 2,875,922 shares. At December 31, 2010, the Company had 932,670 shares of common stock reserved for issuance under the 2010 Plan.

The
2010 Plan provides for the grant of awards to employees, directors and consultants in the form of incentive stock options, nonstatutory stock options, stock appreciation rights,
restricted stock awards, restricted stock unit awards, performance awards and other awards. Incentive stock options may be granted to employees and nonstatutory options may be granted to employees,
directors or consultants at exercise prices of no less than 100% of the fair value of the common stock on the grant date as determined by the board of directors. Incentive stock options may only be
granted for ten years from the date the 2010 Plan was approved by the board of directors. Options typically vest as determined by the board of directors, at the rate of 25% at the end of the first
year with the remaining balance vesting monthly over the next three years, but may be granted with different vesting terms. Options granted under the 2010 Plan expire no later than ten years after the
date of grant. The stock issuable under the 2010 Plan may be shares of authorized but unissued or reacquired common stock of the Company, including shares repurchased by the Company on the open market
or otherwise.

2010 Employee Stock Purchase Plan

The Company's board of directors adopted the 2010 Employee Stock Purchase Plan (ESPP) in November 2010, and the Company's stockholders
approved the ESPP in November 2010. The ESPP became effective upon the IPO of the Company's common stock. A total of 250,000 shares of common stock were initially reserved for future issuance under
the ESPP and are pursuant to purchase rights granted to the Company's employees or to employees of any of the Company's designated affiliates. The number of shares of common stock reserved for
issuance under the ESPP will automatically increase on January 1st of each year for ten years commencing on January 1, 2012 by the least of (i) 1% of the
total number of shares outstanding on December 31st of the preceding calendar year, (ii) 80,000 shares or (iii) the number of shares of common stock as
determined by the Company's board of directors. The ESPP permits eligible employees to purchase common stock at a discount by contributing, normally through payroll deductions, up to 10% of their base
compensation during defined offering periods. The price at which the stock is purchased is equal to the lower of 85% of the fair market value of the common stock at the first date of an offering
period, or 85% of the fair value of the common stock on the date of purchase. No shares were purchased under the ESPP in 2010. At December 31, 2010, all 250,000 shares remain available for
future issuance under the ESPP.

104

---



Table of Contents

Anacor Pharmaceuticals, Inc.

Notes to Financial Statements (Continued)

11. Stockholders' Equity (Deficit) (Continued)

2001 Equity Incentive Plan

In connection with the Company's IPO, no further options or stock purchase rights will be granted under the 2001 Plan. Any shares
remaining for issuance under the 2001 Plan as of the IPO date became available for issuance under the 2010 Plan. All outstanding stock awards granted under the 2001 Plan will remain subject to the
terms of the 2001 Plan; however, shares that expire, terminate or are forfeited prior to exercise or settlement of such shares become available for issuance under the 2010 Plan. At December 31,
2010, there were 1,943,252 shares of common stock reserved for future issuance under the 2001 Plan.

Under
the 2001 Plan, the board of directors was authorized to grant options or stock purchase rights to employees, directors and consultants. Options granted were either incentive stock
options or nonstatutory stock options. Incentive stock options were granted to employees with exercise prices of no less than the fair value, and nonstatutory options were granted to employees or
consultants at exercise prices of no less than 85% of the fair value of the common stock on the grant date as determined by the board of directors. Options vest as determined by the board of
directors, generally at the rate of 25% at the end of the first year, with the remaining balance vesting monthly over the next three years. Options granted under the Plan expire no later than ten
years after the date of grant. The Plan provides for the new issuance of common stock of the Company upon the exercise of stock options. At December 31, 2009 and 2010, there were no shares
subject to repurchase by the Company.

Stock Option Repricing

Effective April 1, 2009, the Company's board of directors approved the reduction of the exercise prices of certain outstanding
stock options previously granted to employees and nonemployees of the Company who were still providing services to the Company as of that date. The Company repriced options to purchase 664,371 shares
of the Company's common stock that included both vested and unvested stock options granted from June 2007 through August 2008 with original exercise prices ranging from $12.75 to $22.25 per share. The
Company's board of directors adjusted all of the original exercise prices for the repriced options to $7.25 per share and determined the fair value of the underlying shares of common stock to be $5.00
per share on the date of the repricing. No other terms of the repriced options were modified and these repriced stock options will continue to vest according to their original vesting schedules and
will retain their original expiration dates.

The
modification was treated as a one-for-one exchange of the previously issued stock options for new stock options with an exercise price of $7.25. The Company
recorded a one-time stock-based compensation charge of $0.2 million for the incremental value of the vested options. In addition, the Company will record additional stock-based
compensation charges of $0.5 million for the incremental value of the unvested repriced options, which will be recognized over
the remaining vesting period of the new stock options. The 2009 share numbers for options granted and options canceled in the table below include the 664,371 option shares that were exchanged in
connection with the April 2009 repricing.

105

---



Table of Contents

Anacor Pharmaceuticals, Inc.

Notes to Financial Statements (Continued)

11. Stockholders' Equity (Deficit) (Continued)

Stock Option Activity

The following table summarizes stock option activity:

Shares
Available
for Grant

Outstanding
Options
Number of
Shares

Weighted-
Average
Exercise
Price

Weighted-
Average
Remaining
Contractual
Term (Years)

Aggregate
Intrinsic
Value
(in thousands)Balance at December 31, 2007


234,642


1,056,816

$
5.30Additional shares authorized for grant


400,000





Options granted


(494,296
)

494,296

$
21.42Options exercised





(5,921
)
$
2.55




$
96Options canceled


164,075


(164,075
)
$
14.10Balance at December 31, 2008


304,421


1,381,116

$
10.00Options granted


(909,661
)

909,661

$
6.64Options exercised





(35,180
)
$
0.40




$
162Options canceled


672,481


(672,481
)
$
19.95Balance at December 31, 2009


67,241


1,583,116

$
4.07


7.1

$
2,495Additional shares authorized for grant


1,275,400





Options granted


(480,761
)

480,761

$
6.59Options exercised





(49,806
)
$
1.12




$
203Options canceled


70,790


(70,819
)
$
6.21Balance at December 31, 2010


932,670


1,943,252

$
4.69


6.7

$
3,111At December 31, 2010:Options vested and expected to vest





1,908,614

$
4.66


6.7

$
3,104Exercisable





1,275,609

$
3.82


5.6

$
3,001


The
aggregate intrinsic value of options outstanding at December 31, 2010 is calculated as the difference between the exercise price of the underlying options and the Company's
common stock closing price for the 1,038,981 shares that had exercise prices that were lower than the closing stock price of $5.37 at December 31, 2010. The weighted-average fair values of
options granted to employees in 2008, 2009 and 2010 were $14.22, $1.49 and $4.13 per share, respectively. Total options granted to employees during 2009 were 844,861 shares, including 614,571 shares
underlying options that were exchanged in connection with the April 2009 repricing.

106

---



Table of Contents

Anacor Pharmaceuticals, Inc.

Notes to Financial Statements (Continued)

11. Stockholders' Equity (Deficit) (Continued)

Stock options by exercise price at December 31, 2010 are as follows:

Options Outstanding

Options ExercisableExercise Price

Number

Weighted-
Average
Remaining
Contractual
Term (Years)

Weighted-
Average
Exercise
Price

Number

Weighted-
Average
Exercise
Price$0.35


27,020


1.7

$
0.35


27,020

$
0.35$0.60


587,745


4.5

$
0.60


587,745

$
0.60$1.90


4,813


5.6

$
1.90


4,813

$
1.90$5.00


419,403


8.9

$
5.00


121,621

$
5.00$7.25


606,889


6.2

$
7.25


470,475

$
7.25$7.55


297,382


9.6

$
7.55


63,935

$
7.551,943,252


6.7

$
4.69


1,275,609

$
3.82


Stock-Based Compensation

The Company estimates the fair value of stock options granted on the date of grant using the Black-Scholes option-pricing model, which
requires the use of highly subjective and complex assumptions to determine the fair value of stock-based awards. As a newly public company, sufficient relevant historical data does not exist to
support the volatility of the Company's common stock prices or the expected term of its stock options. Therefore, the Company has used the average historical volatilities of a peer group of
publicly-traded companies within its industry to determine a reasonable estimate of its expected volatility. In addition, the Company has opted to use the simplified method for estimating the expected
term of options granted to employees.

The
risk-free interest rate assumptions are based on the yield of U.S. Treasury Constant Maturity rate with durations similar to the expected term of the related awards. The
expected dividend yield assumption is based on the Company's historic and expected absence of dividend payouts.

For
options granted prior to January 1, 2006, the graded-vested (multiple-option) method continues to be used for expense attribution related to the portion of those options that
were unvested as of January 1, 2006. The straight-line (single-option) method is being used for expense attribution of all awards granted on or after January 1, 2006.

The
fair values of employee stock options granted under the Plan were estimated at the date of grant using the Black-Scholes model with the following assumptions:

Year Ended December 312008

2009

2010Dividend yield


0
%

0
%

0
%Volatility


73
%

70 - 76
%

71 - 73
%Weighted-average expected life (in years)


6.1


4.9 - 6.1


6.1Risk-free interest rate


2.8
%

1.7 - 2.1
%

1.8 - 1.9
%


Prior
to its IPO, the Company had historically granted stock options at exercise prices not less than the fair market value of its common stock as determined by the board of directors
based on input

107

---



Table of Contents

Anacor Pharmaceuticals, Inc.

Notes to Financial Statements (Continued)

11. Stockholders' Equity (Deficit) (Continued)

from
management. The determination of estimated fair value of its common stock on the date of grant had been based on a number of objective and subjective factors including: recent sales of
convertible preferred stock to investors; comparable rights and preferences of other outstanding equity securities; progress of research and development efforts and milestones attained; results of
operations, financial position and levels of debt and available capital resources of the Company; perspective provided by valuation analyses of the Company's stock performed by management; and the
likelihood of a liquidity event such as an IPO or the sale of the Company given prevailing market and biotechnology sector conditions.

Employee
stock-based compensation expense recognized in 2008, 2009 and 2010 was calculated based on awards ultimately expected to vest and has been reduced for estimated forfeitures.
Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.

Employee
stock-based compensation expense was as follows (in thousands):

Year Ended December 312008

2009

2010Research and development

$
1,002

$
1,451

$
1,530General and administrative


707


806


760Total

$
1,709

$
2,257

$
2,290


At
December 31, 2010, the Company had $3.6 million of total unrecognized compensation expense, net of estimated forfeitures, related to outstanding stock options that will
be recognized over a weighted-average period of 1.9 years.

Stock Options Granted to Nonemployees

During 2008, 2009 and 2010, the Company granted nonemployees 25,000, 64,800, and 67,500 option shares, respectively, to purchase common
stock. Included in the 2009 grants to nonemployees were 49,800 option shares that were exchanged in connection with the April 2009 repricing.

In
connection with grants of stock options to nonemployees, the Company recorded stock-based compensation expense as follows (in thousands):

Year Ended
December 312008

2009

2010Research and development

$
261

$
106

$
101General and administrative


21


87


395Total

$
282

$
193

$
496


Stock-based
compensation expense related to stock options granted to nonemployees is recognized as the stock options vest. The stock-based compensation expense related to nonemployees
will fluctuate as the fair value of the Company's common stock fluctuates. The Company believes that the fair values of the stock options are more reliably measurable than the fair values of the
services received. The fair value of nonemployee options in 2008, 2009 and 2010 was estimated using the Black-Scholes method

108

---



Table of Contents

Anacor Pharmaceuticals, Inc.

Notes to Financial Statements (Continued)

11. Stockholders' Equity (Deficit) (Continued)

with
the following weighted-average assumptions: expected life is equal to the remaining contractual term of the award as of the measurement date; risk-free rate is based on the U.S.
Treasury Constant Maturity rate with a term similar to the expected life of the option at the measurement date; expected dividend yield of 0%; and an average volatility ranging from 70% to 80%. The
Company has used the average historical volatilities of a peer group of publicly-traded companies within its industry to estimate volatility.

12. 401(k) Plan

The Company sponsors a 401(k) Plan to which eligible employees may elect to contribute, on a pretax basis, subject to certain limitations. The Company does not match any employee
contributions.

13. Income Taxes

The income tax benefits for 2008 and 2009 were federal refundable credits of $44,000 and $15,000, respectively. The American Recovery and Reinvestment Act of 2009 allowed corporations
without current tax liabilities to obtain refunds for certain research tax credit and alternative minimum tax credit carryforwards by electing to forego the 50% additional first year depreciation for
new property acquired after June 30, 2008 and placed in service before January 1, 2010. This Act extended the provisions of the Housing Assistance Tax Act of 2008 (H.R. 3221) which was
set to expire for assets
placed in service before January 1, 2009. For tax years 2008 and 2009, the Company elected to obtain refunds for a portion of its research and development tax credit carryforwards from taxable
years before January 1, 2006.

A
reconciliation of the expected income tax benefit computed using the federal statutory income tax rate to the Company's effective income tax rate is as follows:

Year Ended December 312008

2009

2010Income tax computed at federal statutory tax rate


34.0
%

34.0
%

34.0
%State taxes, net of federal benefit


7.8
%

7.0
%

9.0
%Stock-based compensation


(1.5
)%

(1.5
)%

(4.2
)%Research and development credits


3.9
%

3.4
%

6.3
%Change in valuation allowance


(46.0
)%

(42.6
)%

(49.7
)%Government grant credit



%


%

4.5
%Other


2.0
%

(0.2
)%

0.1
%Total


0.2
%

0.1
%

0.0
%


109

---



Table of Contents

Anacor Pharmaceuticals, Inc.

Notes to Financial Statements (Continued)

13. Income Taxes (Continued)

Significant
components of the Company's deferred tax assets for federal and state income taxes were as follows (in thousands):

December 312009

2010Deferred tax assets:Federal and state net operating losses

$
34,026

$
38,046Federal and state research and development credit carryforwards


4,353


5,290Deferred revenues


2,988


2,191Stock-based compensation


1,141


1,777Other


1,331


1,593Total deferred tax assets


43,839


48,897Valuation allowance


(43,839
)

(48,897
)Net deferred tax assets

$


$



Due
to the Company's lack of earnings history, the deferred assets have been fully offset by a valuation allowance at December 31, 2009 and 2010. The increase in the valuation
allowance on the deferred tax assets was $10.0 million, $10.6 million and $5.1 million for 2008, 2009 and 2010, respectively.

At
December 31, 2010, the Company had net operating loss carryforwards for federal and state income tax purposes of approximately $95.5 million and $95.6 million,
respectively. These federal and state carryforwards will begin to expire in the years 2021 and 2013, respectively. The Company also had federal research and development tax credit carryforwards of
approximately $4.6 million, which expire beginning in 2024 if not utilized. In addition, state research and development tax credit carryforwards of approximately $3.0 million will carry
over indefinitely.

Internal
Revenue Code Section 382 places a limitation (the Section 382 Limitation) on the amount of taxable income, that can be offset by net operating loss carryforwards
after a change in control (generally, a greater than 50% change in ownership). Typically, after a control change, a company cannot deduct operating loss carryforwards in excess of the
Section 382 Limitation. Due to these changes in ownership provisions, utilization of the net operating loss and tax credit carryforwards may be subject to an annual limitation regarding their
utilization against taxable income in future periods.

The
Company adopted the provisions of the standard for accounting for uncertainties in income taxes on January 1, 2007. Upon adoption, the Company recognized no material
adjustment in the liability for unrecognized tax benefits. At December 31, 2009 and 2010, the Company had approximately $1.3 million and $1.5 million, respectively, of
unrecognized tax benefits, none of which would currently affect the Company's effective tax rate if recognized due to the Company's deferred tax assets being fully offset by a valuation allowance. The
Company does not believe there will be any material changes in its unrecognized tax positions over the next twelve months.

110

---



Table of Contents

Anacor Pharmaceuticals, Inc.

Notes to Financial Statements (Continued)

13. Income Taxes (Continued)

The
activity related to unrecognized tax benefits was as follows (in thousands):

Year Ended
December 312009

2010Balance at the beginning of the year

$
932

$
1,254Additions based on tax positions related to current year


345


273Additions for tax positions of prior years





Reductions for tax positions of prior years


(23
)

(2
)Settlements





Balance at the end of the year

$
1,254

$
1,525


If
applicable, the Company would classify interest and penalties related to uncertain tax positions in income tax expense. Through December 31, 2010, there has been no interest
expense or penalties related to unrecognized tax benefits. The tax years 2001 through 2010 remain open to examination by one or more major taxing jurisdictions to which the Company is subject. There
are no income tax examinations currently in progress.

14. U.S. Government Grant

In October 2010, the Company was awarded $1.5 million in grant funds by the United States Department of the Treasury under the Qualifying Therapeutic Discovery Project program to
support research for six projects with the potential to produce new therapies. The qualifying expenses under this program were incurred by the Company during 2009 and 2010. The Company recognized
$1.5 million as government grant revenue for the year ended December 31, 2010. At December 31, 2010, $0.1 million is due to the Company and is included in government grant
receivable.

15. Quarterly Financial Data (Unaudited)

The following table summarizes the unaudited quarterly financial data for the last two fiscal years (in thousands, except per share data):

Selected Quarterly Data:

Quarter EndedMarch 31,
2009

June 30,
2009

September 30,
2009

December 31,
2009Total revenues

$
5,454

$
5,585

$
829

$
6,775Net income (loss)

$
(5,935
)
$
(5,496
)
$
(9,484
)
$
(3,924
)Basic net income (loss) per share

$
(4.21
)
$
(3.90
)
$
(6.72
)
$
(2.74
)Diluted net income (loss) per share

$
(4.21
)
$
(3.90
)
$
(6.72
)
$
(2.74
)


111

---



Table of Contents

Anacor Pharmaceuticals, Inc.

Notes to Financial Statements (Continued)

15. Quarterly Financial Data (Unaudited) (Continued)



Quarter EndedMarch 31,
2010

June 30,
2010

September 30,
2010

December 31,
2010Total revenues

$
710

$
6,674

$
16,897

$
3,543Net income (loss)

$
(8,154
)
$
(1,471
)
$
7,062

$
(7,495
)Basic net income (loss) per share

$
(5.53
)
$
(0.99
)
$
4.73

$
(0.73
)Diluted net income (loss) per share

$
(5.53
)
$
(0.99
)
$
0.49

$
(0.73
)


Income
(loss) per share amounts for the 2009 and 2010 quarters and full years have been computed separately. Accordingly, quarterly amounts may not add to the annual amounts because of
differences in the weighted average shares outstanding during each quarter.

16. Subsequent Events

New Agreements

Medicis

On February 10, 2011, the Company entered into a research and development agreement with Medicis Pharmaceutical Corporation
(Medicis) to discover and develop boron-based small molecule compounds directed against a target for the potential treatment of acne.

Under
the terms of the agreement, the Company received a $7.0 million upfront payment from Medicis in February 2011 and will be primarily responsible for discovering and
conducting early development of product candidates which utilize the Company's proprietary boron chemistry platform. Medicis will have an option to obtain an exclusive license for products covered by
the agreement. The Company will be eligible to receive payments upon the achievement of specified development, regulatory and sales milestones, as well as high single-digit to in the tens royalties on
sales by Medicis. Medicis will be responsible for further development and commercialization of the licensed products on a worldwide basis.

Medicines for Malaria Venture

On March 17, 2011, the Company entered into a development agreement with Medicines for Malaria Ventures (MMV) to develop
Anacor's compound AN3661 for the treatment of malaria. Under the agreement, Anacor and MMV will work together on the development of AN3661 through human proof-of-concept
studies. AN3661 was developed as part of a research agreement signed by the two parties in April 2010 to identify new compounds for the treatment of malaria using Anacor's boron chemistry. AN3661 is
the first candidate arising out of the research agreement to move into preclinical development. The Company expects to receive upfront funding associated with this preclinical development under this
agreement of approximately $1.8 million in the second quarter of 2011. In addition, the Company received approximately $0.6 million in funding in February 2011 under the original
research agreement.

Notes Payable

On March 18, 2011, the Company entered into a loan and security agreement with new lenders to provide up to $30.0 million
available in three tranches of $10.0 million each. The first $10.0 million

112

---



Table of Contents

Anacor Pharmaceuticals, Inc.

Notes to Financial Statements (Continued)

16. Subsequent Events (Continued)

tranche
was drawn at the closing of the transaction, at which time the Company repaid $6.6 million of the remaining obligations under its existing loan. The second and third tranches of
$10.0 million each are available upon the achievement of either the full enrollment of the Phase 3 trials for AN2690 or the initiation of a Phase 3 trial for AN2728. Upon
achievement of either of these development milestones, the second tranche of $10.0 million is available for drawdown through March 31, 2012 and the third tranche of $10.0 million
is available for drawdown through September 30, 2012. The interest rate for each tranche will be fixed upon drawdown at a rate equal to the greater of 9.4% or 9.1% plus the 3-month
U.S. LIBOR rate. Payments under the loan agreement are interest only until April 30, 2012 followed by equal monthly payments of interest and principal through April 1, 2015. In addition,
a final payment equal to 5.5% of the amounts drawn ($550,000 as of the first tranche) will be due on the earlier of April 1, 2015, or termination. The Company paid a financing fee of
$0.3 million associated with the new loan. Future payments related to the first $10.0 million tranche of the new loan are $0.7 million, $2.9 million, $3.8 million,
$3.8 million and $1.8 million in 2011, 2012, 2013, 2014 and 2015, respectively.

The
loan agreement includes standard affirmative and restrictive covenants, but does not include any covenants to attain or maintain certain financial metrics, and also included standard
events of default, including payment defaults, breaches of covenants following any applicable cure period, a material impairment in the perfection or priority of the lenders' security interest or in
the value of the collateral,
and a material impairment of the prospect of repayment of the loans. Upon the occurrence of an event of default and following any applicable cure periods, a default interest rate of an additional 5%
may be applied to the outstanding loan balances, and the lenders may declare all outstanding obligations immediately due and payable and take such other actions as set forth in the loan agreement.

The
loan is secured by all assets of the Company except intellectual property. Under the loan agreement, the Company also agreed to certain restrictions regarding the pledging or
encumbrance of its intellectual property.

In
connection with the new loan agreement and the first tranche drawdown of $10.0 million, the Company issued initial warrants to the lenders to purchase 80,527 shares of its
common stock (equal to 5.5% of the amount drawn) at an exercise price of $6.83 per share. The warrants are immediately exercisable, may be exercised on a cashless basis and will expire on
March 18, 2018. The number of shares subject to the warrants will increase by an amount equal to 5.5% of the amount drawn at each subsequent tranche, divided by the exercise price per share for
that tranche (the lower of the 10-day average share price prior to the drawdown or the price per share on the day prior to the drawdown), up to a maximum aggregate exercise price of
$1.65 million.

The
Company granted certain piggyback registration rights pursuant to which, under certain conditions, the Company will register its shares of common stock issuable upon exercise of the
warrants held by the lenders.

113

---





Table of Contents

ITEM 9.    CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

None.

ITEM 9A.    CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Exchange
Act reports is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms and that such information is accumulated and
communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow for timely decisions regarding required disclosure. In designing and
evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving
the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

As
required by SEC Rule 13a-15(b), we carried out an evaluation, under the supervision and with the participation of our management, including our principal executive
officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Annual Report on
Form 10-K. Based on the foregoing, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective at the
reasonable assurance level.

Exemption from Management's Report on Internal Control Over Financial Reporting for the Fiscal Year Ended December 31, 2010

As a newly public company and under the applicable rules of the Securities and Exchange Commission, we are not required to include a
report of management's assessment regarding internal control over financial reporting or an attestation report of an Independent Registered Public Accounting Firm in this Annual Report on
Form 10-K.

Changes in Internal Control Over Financial Reporting

None.

ITEM 9B.    OTHER INFORMATION

None.

114

---



Table of Contents

PART III

Certain information required by Part III is omitted from this Report on Form 10-K and is incorporated herein
by reference to our definitive Proxy Statement for our 2011 Annual Meeting of Stockholders (the "Proxy Statement"), which we intend to file pursuant to Regulation 14A of the Securities Exchange
Act of 1934, as amended, within 120 days after December 31, 2010.

ITEM 10.    DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

The information required by this item concerning our directors is incorporated by reference to the information set forth in the section
titled "Directors and Corporate Governance" in our Proxy Statement. Information required by this item concerning our executive officers is incorporated by reference to the information set forth in the
section entitled "Executive Officers of the Company" in our Proxy Statement. Information regarding Section 16 reporting compliance is incorporated by reference to the information set forth in
the section entitled "Section 16(a) Beneficial Ownership Reporting Compliance" in our Proxy Statement.

ITEM 11.    EXECUTIVE COMPENSATION

The information required by this item regarding executive compensation is incorporated by reference to the information set forth in the
sections titled "Executive Compensation" in our Proxy Statement.

ITEM 12.    SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

The information required by this item regarding security ownership of certain beneficial owners and management is incorporated by
reference to the information set forth in the section titled "Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters" and "Equity Compensation Plan Information"
in our Proxy Statement.

ITEM 13.    CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

The information required by this item regarding certain relationships and related transactions and director independence is
incorporated by reference to the information set forth in the sections titled "Certain Relationships and Related Transactions" and "Election of Directors", respectively, in our Proxy Statement.

ITEM 14.    PRINCIPAL ACCOUNTANT FEES AND SERVICES

The information required by this item regarding principal accountant fees and services is incorporated by reference to the information
set forth in the section titled "Principal Accountant Fees and Services" in our Proxy Statement.

115

---



Table of Contents

PART IV

Item 15.    EXHIBITS AND FINANCIAL STATEMENT SCHEDULES



116

---





Table of Contents

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly
caused this report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Palo Alto, State of California, on the 29th day of March
2011.

ANACOR PHARMACEUTICALS, INC.By:

/s/ DAVID P. PERRY David P. Perry President and Chief Executive Officer


POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints David P. Perry and Geoffrey
M. Parker, jointly and severally, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her, and in his or
her name, place and stead, in any and all capacities, to sign any and all amendments to this report on Form 10-K, and to file the same, with all exhibits thereto, and other
documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each
and every act and thing requisite or necessary to be done in and about the premises hereby ratifying and confirming all that said attorneys-in-fact and agents, or his
substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, this report on Form 10-K has been signed below by the following persons on behalf of
the registrant and in the capacities and on the dates indicated.

Signature

Title

Date/s/ DAVID P. PERRY David P. Perry

President, Chief Executive Officer and Director (Principal Executive Officer)

March 29, 2011/s/ GEOFFREY M. PARKER Geoffrey M. Parker

Senior Vice President, Chief Financial Officer (Principal Financial and Accounting Officer)

March 29, 2011/s/ MARK LESCHLY Mark Leschly

Chairman of the Board of Directors

March 29, 2011/s/ ZHI HONG, PH.D. Zhi Hong, Ph.D.

Director

March 29, 2011


117

---



Table of Contents

Signature

Title

Date/s/ ANDERS D. HOVE, M.D. Anders D. Hove, M.D.

Director

March 29, 2011/s/ PAUL H. KLINGENSTEIN Paul H. Klingenstein

Director

March 29, 2011/s/ RICHARD J. MARKHAM Richard J. Markham

Director

March 29, 2011/s/ LUCY SHAPIRO, PH.D. Lucy Shapiro, Ph.D.

Director

March 29, 2011


118

---





Table of Contents

Exhibit Index

Exhibit
Number

Description3.1(1)

Amended and Restated Certificate of Incorporation of the Registrant.3.2(1)

Amended and Restated Bylaws of the Registrant.4.1

Reference is made to Exhibits 3.1 through 3.2.4.2(2)

Form of the Registrant's Common Stock Certificate.4.3(2)

Amended and Restated Investors' Rights Agreement among the Registrant and certain of its security holders, dated as of December 24, 2008, and amendment thereto, dated July 22, 2010.4.4(2)

Amended and Restated Preferred Stock Purchase Warrant to purchase shares of Series D convertible preferred stock issued to Lighthouse Capital Partners V, L.P., dated as of May 1, 2008.4.5(2)

Preferred Stock Purchase Warrant to purchase shares of Series D convertible preferred stock issued to Lighthouse Capital Partners V, L.P., dated as of May 1, 2008.4.6(2)

Preferred Stock Purchase Warrant to purchase shares of Series E convertible preferred stock issued to Lighthouse Capital Partners V, L.P., dated as of January 1, 2010.4.7

Common Stock Purchase Agreement among the Registrant and certain of its security holders, dated as of November 23, 2010.4.8

Registration Rights Agreement among the Registrant and certain of its security holders, dated as of November 23, 2010.10.1(2)+

Form of Amended and Restated Indemnification Agreement between the Registrant and each of its directors and executive officers.10.2(2)+

Anacor Pharmaceuticals, Inc. 2001 Equity Incentive Plan, as amended, and forms of agreement thereunder.10.3(2)+

Anacor Pharmaceuticals, Inc. 2010 Equity Incentive Plan, and forms of agreement thereunder.10.4(2)+

Anacor Pharmaceuticals, Inc. 2010 Employee Stock Purchase Plan.10.5(2)+

Anacor Pharmaceuticals, Inc. Employee Bonus Plan.10.6(2)+

Letter Agreement between the Registrant and Kirk R. Maples, Ph.D., dated as of August 1, 2002.10.7(2)+

Letter Agreement between the Registrant and David P. Perry, dated as of November 21, 2002, and amendment thereto, dated as of August 30, 2005.10.8(2)+

Letter Agreement between the Registrant and Jacob J. Plattner, Ph.D., dated as of October 21, 2003.10.9(2)+

Letter Agreement between the Registrant and Irwin Heyman, Ph.D., dated as of December 16, 2005.10.10(2)+

Letter Agreement between the Registrant and James Marconi, dated as of October 29, 2007.10.11(2)+

Letter Agreement between the Registrant and Lee Zane, dated as of November 30, 2007.


119

---



Table of Contents

Exhibit
Number

Description10.12(2)

Letter Agreement between the Registrant and Stephen J. Benkovic, Ph.D., dated as of May 24, 2009.10.13(2)+

Letter Agreement between the Registrant and Geoffrey M. Parker, dated as of September 10, 2010.10.14(2)

Consulting Agreement between the Registrant and Stephen J. Benkovic, Ph.D., dated as of May 24, 2007, and amendments thereto, dated effective as of April 1, 2008, January 1, 2009 and
January 1, 2010.10.15(2)+

Consulting Agreement between the Registrant and Geoffrey M. Parker, dated as of December 8, 2009 and amendments thereto, dated effective as of April 9, 2010 and July 10, 2010.10.16(2)

Advisory Board Agreement between the Registrant and Lucy Shapiro, Ph.D., dated effective as of October 1, 2005, and amendments thereto, dated effective as of October 1, 2007 and January 1,
2010.10.17(2)+

Form of Change of Control and Severance Agreement for Senior Vice Presidents of the Registrant, and amendment thereto.10.18(2)+

Form of Change of Control and Severance Agreement for Vice Presidents of the Registrant, and amendment thereto.10.19(2)

Change of Control Agreement between the Registrant and Stephen J. Benkovic, Ph.D., dated as of September 28, 2006.10.20(2)

Change of Control Agreement between the Registrant and Lucy Shapiro, Ph.D., dated as of October 25, 2006.10.21(2)+

Change of Control and Severance Agreement between the Registrant and David P. Perry, dated as of August 21, 2007, and amendment thereto, dated as of December 30, 2008.10.22(2)

Lease between Balzer Family Investments, L.P. (formerly HDP Associates, LLC) and the Registrant, dated as of October 16, 2002, and amendments thereto, dated as of January 21, 2003, August 1,
2005, September 23, 2008, March 31, 2009 and September 30, 2010.10.23(2)

Lease between California Pacific Commercial Corporation and the Registrant, dated as of October 5, 2007.10.24(2)

Loan and Security Agreement No. 5251 between Lighthouse Capital Partners V, L.P. and the Registrant, dated as of June 30, 2006, and amendments thereto dated as of February 26, 2008, May 1,
 2008 and January 23, 2010.10.25(2)

Research and Development Collaboration, Option and License Agreement between GlaxoSmithKline LLC and the Registrant, dated as of October 5, 2007, and amendments thereto, dated as of December 15, 2008,
May 20, 2009 and July 21, 2009.10.26(2)

Collaborative Research, License & Commercialization Agreement between Eli Lilly and Company and Registrant, dated as of August 25, 2010.23.1

Consent of Independent Registered Public Accounting Firm.24.1

Power of Attorney (see signature page).31.1

Certification of Principal Executive Officer required by Rule 13a-14(a) or Rule 15d-14(a).31.2

Certification of Principal Financial Officer required by Rule 13a-14(a) or Rule 15d-14(a).


120

---



Table of Contents

Exhibit
Number

Description32.1

Certifications required by Rule 13a-14(b) or Rule 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. 1350).


+Indicates
management contract or compensatory plan.Confidential
treatment has been received with respect to certain portions of this exhibit. Omitted portions have been filed separately with the
Securities and Exchange Commission.Confidential
treatment has been requested with respect to certain portions of this exhibit. Omitted portions have been filed
separately with the Securities and Exchange Commission.(1)Filed
as an exhibit to the Registrant's Current Report on Form 8-K filed on December 6, 2010, and incorporated herein by
reference.(2)Filed
as an exhibit to the Registrant's Registration Statement on Form S-1 (File No. 333-169322), effective
November 23, 2010, and incorporated herein by reference.


121

---